Tay-Sachs Disease

Genetic MONDO:0010100 Pathograph 53 Show in embeddings browser Lysosomal Storage Disorder Neurodegenerative Disease

Tay-Sachs disease is an autosomal recessive GM2 gangliosidosis caused by biallelic pathogenic variants in HEXA, which encodes the alpha subunit of the lysosomal enzyme beta-hexosaminidase A. Deficient hexosaminidase A activity blocks degradation of GM2 ganglioside, which accumulates progressively within neurons and triggers neuroinflammation and neuronal death. The classic infantile form presents with developmental regression, hypotonia, an exaggerated startle response, a macular cherry-red spot, seizures, and blindness, while juvenile and late-onset forms with residual enzyme activity follow a more protracted course dominated by ataxia and motor neuron involvement.

Ask OpenScientist

Ask a research question about Tay-Sachs Disease. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Mappings
1
Inheritance
15
Pathophys.
30
Phenotypes
4
Hypotheses
6
Gaps
53
Pathograph
1
Genes
1
Variants
9
Medical Actions
3
Subtypes
4
Differentials
3
Datasets
9
Trials
7
Models
1
References
1
Deep Research
1
Hyp. Reports
🔗

Mappings

MONDO
MONDO:0010100 Tay-Sachs disease
skos:exactMatch ORPHA:845 ORPHA:845: CONSISTENT
Orphanet lists MONDO:0010100 as an exact cross-reference for Tay-Sachs disease.
👪

Inheritance

1
Autosomal recessive inheritance HP:0000007
When both parents carry a pathogenic HEXA variant, each conception has a 25% affected, 50% carrier and 25% unaffected noncarrier probability. Heterozygous carriers are asymptomatic.
Autosomal recessive inheritance
Show evidence (2 references)
ORPHA:845 SUPPORT Other
"Autosomal recessive"
Orphanet directly lists autosomal recessive inheritance for ORPHA:845.
PMID:20301397 SUPPORT Other
"At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier."
Mendelian recurrence applies when both parents are confirmed carriers.
◆

Subtypes

3
Infantile Tay-Sachs
Onset usually at 3–6 months; rapid progression with survival influenced by airway and nutritional support, sometimes to 5–7 years.
Show evidence (1 reference)
PMID:20301397 SUPPORT Other
"Seizures are common by 12 months with further deterioration in the second year of life and death occurring between ages two and three years with some survival to five to seven years."
Infantile progression and survival vary with stage and supportive care; a fixed death-by-four rule is inaccurate.
Juvenile Tay-Sachs
Childhood onset with variable progression, often fatal in the second decade; subtype boundaries are approximate.
Show evidence (1 reference)
PMID:20301397 SUPPORT Other
"Spasticity, dysphagia, and seizures are present by the end of the first decade of life, with death within the second decade of life, usually by aspiration."
GeneReviews supports juvenile motor/bulbar progression and aspiration complications.
Late-Onset Tay-Sachs
Onset in older teens or adulthood with variable neurologic and psychiatric progression over decades.
Show evidence (1 reference)
PMID:20301397 SUPPORT Other
"Late-onset TSD presents in older teens or young adults with a slowly progressive spectrum of neurologic symptoms including lower-extremity weakness with muscle atrophy, dysarthria, incoordination, tremor, mild spasticity and/or dystonia, and psychiatric manifestations including acute psychosis."
The late-onset spectrum spans cerebellar, motor, and neuropsychiatric dysfunction.
◈

Mechanistic Hypotheses

4
Canonical HEXA Deficiency / GM2 Ganglioside Neuronal Storage Model
canonical_hexa_gm2_ganglioside_neuronal_storage_model CANONICAL
Evidence balance 2 support
Biallelic pathogenic HEXA variants impair the alpha subunit of lysosomal HexA, an alpha/beta heterodimer requiring the GM2 activator protein for membrane GM2 hydrolysis. Deficient catabolism causes neuronal GM2 storage, followed by neuronal dysfunction and loss, glial inflammation and variable myelin abnormalities. Residual activity shapes a continuum from infantile to juvenile and late-onset disease. The downstream contributions of ER stress, autophagy and neurodevelopmental perturbation require context-specific interpretation. Mouse neuraminidase bypass metabolism limits translation from Hexa-null animals.
The core mechanism remains canonical. OpenScientist correctly identified the Hexa/Neu3 mouse-model correction and several experimental downstream mechanisms, but overstated HSCT causal inference and missed published human AAV results and fetal-brain transcriptomics. Human biochemical target engagement does not ensure clinical benefit; the report is assessed separately against primary studies.
Deep research
OpenScientist citations 33 citations 2026-05-25T13:40:32.505382
Show evidence (2 references)
PMID:20301397 SUPPORT Other
"HEXA disorders are best considered as a disease continuum based on the amount of residual beta-hexosaminidase A (HEX A) enzyme activity."
GeneReviews supports a residual-activity continuum rather than fixed activity thresholds or survival cutoffs.
PMID:16698036 SUPPORT In Vitro
"Only the alpha-subunit active site can hydrolyze GM2 gangliosides due to a flexible loop structure that is removed post-translationally from beta, and to the presence of alphaAsn423 and alphaArg424."
Crystallography identifies alpha-subunit-specific substrate and activator interactions.
GM2-associated ER stress and neuronal injury
gm2_er_stress EMERGING
Evidence balance 2 support
GM2 loading in neuronal cultures activates a biphasic PERK response, progressing from adaptation to CHOP-associated injury. Trafficking from lysosomal storage to ER membranes and the contribution in human disease remain unresolved.
Pathograph links
GM2-associated PERK activation -> CHOP-associated neuronal injury INDIRECT KNOWN INTERMEDIATES Prolonged experimental ER stress engages CHOP-associated neurite atrophy and apoptosis. Intermediates: prolonged PERK signaling and CHOP induction
CHOP-associated neuronal injury -> Neuronal injury INDIRECT UNKNOWN INTERMEDIATES This experimentally supported injury pathway may contribute to GM2-associated neurodegeneration; its in vivo importance in Tay-Sachs remains unquantified.
Show evidence (2 references)
PMID:30389374 SUPPORT In Vitro
"We found that ER GM2 accumulation in cultured neurons induces luminal Ca2+ depletion, which in turn activates PERK (protein kinase RNA [PKR]-like ER kinase), one of three UPR sensors."
Cultured-neuron GM2 loading supports an ER calcium/PERK mechanism; lysosomal-to-ER trafficking and necessity in human Tay-Sachs are unresolved.
PMID:30389374 SUPPORT In Vitro
"Both processes were effectively modulated by treatment with the selective PERK inhibitor GSK2606414, by CN knockdown, and by CHOP knockdown."
PERK inhibition and calcineurin/CHOP knockdown provide direct cellular perturbation evidence for neurite atrophy/apoptosis.
Autophagic flux and lysosomal integrity impairment
autophagy_lysosomal_integrity EMERGING
Evidence balance 2 support
GM2 patient fibroblasts show reduced basal mTOR signaling, impaired flux and lysosomal permeability; L-arginine partly rescues these cellular abnormalities. This is not a demonstrated neuronal or clinical treatment mechanism.
Show evidence (2 references)
PMID:34831346 SUPPORT In Vitro
"GM2 fibroblasts showed diminished mTOR signalling with reduced basal mTOR activity."
Patient-derived Tay-Sachs and Sandhoff fibroblasts reveal an autophagy/lysosomal phenotype; neuronal in vivo generalization is unproven.
PMID:34831346 SUPPORT In Vitro
"Pathological autophagosomes with impaired autophagic flux, an abnormality confirmed by electron microscopy and biochemical studies revealing the accelerated release of mature cathepsins and HexA into the cytosol, indicating increased lysosomal permeability."
Patient fibroblast assays document impaired flux and lysosomal leakage, not the full human neurodegenerative sequence.
Prenatal developmental perturbation
prenatal_developmental_perturbation EMERGING
Evidence balance 1 support
Fetal Tay-Sachs brain RNA-seq and Sandhoff organoids suggest a developmental component preceding end-stage neurodegeneration. Genotype, family, brain region and model differences limit generalization.
Pathograph links
HEXA mutations -> Prenatal neurodevelopmental perturbation INDIRECT UNKNOWN INTERMEDIATES A juvenile-associated biallelic HEXA genotype was associated with early fetal storage and developmental transcriptomic changes; causal intermediates and clinical consequences remain unresolved.
Show evidence (1 reference)
PMID:36700853 SUPPORT Human Clinical
"We find that the transcriptomes are perturbed by 17 week’s gestation, suggesting abnormal neurodevelopment, which has implications for therapeutic intervention for TSD."
Two affected sibling fetuses with a juvenile-associated genotype and two controls were sampled across brain regions; 19 GEO libraries are not 19 independent fetuses.
?

Discussions and Knowledge Gaps

6
How do lysosomal storage, ER stress, autophagy and inflammation interact in human neurons?
KNOWLEDGE GAP experimental_routes
Attached to
pathophysiology#GM2-associated PERK activation pathophysiology#Impaired autophagic flux and lysosomal integrity pathophysiology#Neuroinflammation and Astrogliosis
ER stress and autophagy nodes have primary experimental support but are not joined to the neuronal-storage node by invented transport or death edges. GM2 loading does not establish lysosomal-to-ER trafficking, fibroblast abnormalities do not establish neuronal injury, and reduced inflammatory markers do not identify a dominant pathway. PERK/CHOP perturbation is causal in its cellular model, contrary to the report’s blanket statement that downstream links have only temporal evidence.
Show evidence (4 references)
PMID:30389374 SUPPORT In Vitro
"We found that ER GM2 accumulation in cultured neurons induces luminal Ca2+ depletion, which in turn activates PERK (protein kinase RNA [PKR]-like ER kinase), one of three UPR sensors."
Cultured-neuron GM2 loading supports an ER calcium/PERK mechanism; lysosomal-to-ER trafficking and necessity in human Tay-Sachs are unresolved.
PMID:30389374 SUPPORT In Vitro
"Both processes were effectively modulated by treatment with the selective PERK inhibitor GSK2606414, by CN knockdown, and by CHOP knockdown."
PERK inhibition and calcineurin/CHOP knockdown provide direct cellular perturbation evidence for neurite atrophy/apoptosis.
PMID:34831346 SUPPORT In Vitro
"Pathological autophagosomes with impaired autophagic flux, an abnormality confirmed by electron microscopy and biochemical studies revealing the accelerated release of mature cathepsins and HexA into the cytosol, indicating increased lysosomal permeability."
Patient fibroblast assays document impaired flux and lysosomal leakage, not the full human neurodegenerative sequence.
+ 1 more reference
What determines subtype, circuit and neuronal population vulnerability?
KNOWLEDGE GAP selective_vulnerability
Attached to
pathophysiology#Late-onset multifocal neuronal dysfunction phenotypes#Depression phenotypes#Sleep disturbance phenotypes#Axonal polyneuropathy phenotypes#Macrocephaly phenotypes#Abnormal saccadic eye movements phenotypes#Sphincter incontinence
Clinical cohorts identify different cerebellar, motor, peripheral nerve and psychiatric manifestations without resolving all substrate-to-circuit mechanisms. The Czech 1.8–4.1% enzyme range is assay/cohort-specific, not a universal threshold. Peripheral axon loss, sleep and mood findings are retained without speculative circuit arrows. Quantitative saccadic abnormalities localize cerebellar dysfunction, but correlation with ataxia severity does not isolate the substrate-to-circuit sequence. Juvenile sphincter incontinence is clinically documented without a resolved autonomic or motor pathway. The macrocephaly case establishes the finding without separating storage, gliosis and ventricular contributions; these three phenotypes remain explicitly unwired.
Show evidence (5 references)
PMID:31076878 SUPPORT Human Clinical
"Residual enzyme activity was 1.8-4.1% of controls."
Fourteen Czech LOTS cases define a study-specific assay range, not a universal disease threshold.
PMID:9073025 SUPPORT Human Clinical
"The phenotypical expression was remarkably homogeneous, consisting in a combination of slowly progressive motor neuron disease, ataxia and ocular motor disturbances. None of the patients were demented at this stage of their illness."
Four adult siblings carrying the same compound-heterozygous genotype expressed the same narrow motor-neuron, cerebellar and oculomotor pattern, so the population selectivity is reproducible within one genotype and family. The study reports clinical and imaging phenotype, not regional GM2 load, so it does not establish that cortical neurons are spared.
PMID:31964693 SUPPORT Human Clinical
"Cerebellar oculomotor abnormalities were present in all patients with LOGG, including those with normal clinical oculomotor examinations."
The ten-person mixed late-onset GM2 cohort supports an oculomotor association, not a directly isolated storage-to-circuit mechanism.
+ 2 more references
Do prenatal abnormalities constrain the window for treatment?
KNOWLEDGE GAP developmental_window
Attached to
pathophysiology#Prenatal neurodevelopmental perturbation
Human fetal transcriptomics existed before the OpenScientist report: two affected sibling fetuses and two controls, with multiple regional samples. These observations complement Sandhoff organoids but do not prove irreversible prenatal clinical damage or that prenatal treatment is necessary.
Show evidence (1 reference)
PMID:36700853 SUPPORT Human Clinical
"We find that the transcriptomes are perturbed by 17 week’s gestation, suggesting abnormal neurodevelopment, which has implications for therapeutic intervention for TSD."
Two affected sibling fetuses with a juvenile-associated genotype and two controls were sampled across brain regions; 19 GEO libraries are not 19 independent fetuses.
Which biomarkers predict meaningful clinical benefit?
KNOWLEDGE GAP biomarker_clinical_dissociation
Attached to
biochemical#CSF GM2 concentration biochemical#Plasma GM2 34:1 and GM2/GM3 ratio treatments#Venglustat substrate reduction investigation
AMETHIST reduced CSF GM2 without clinical improvement or biomarker-outcome correlation. CSF target engagement does not directly establish clearance of intraneuronal lysosomal GM2, so the human trial alone is not used to assert a treatment-effect edge to neuronal storage. Plasma diagnostic discrimination in a selected cohort is not a therapeutic surrogate. Randomized treatment, timing, tissue exposure and clinical outcome studies are needed.
Show evidence (1 reference)
PMID:41108138 SUPPORT Human Clinical
"Decreased CSF GM2 concentrations did not correlate with clinical endpoints."
Direct trial evidence prevents equating substrate reduction with clinical efficacy.
Which secondary lipid changes contribute specifically to Tay-Sachs pathology?
KNOWLEDGE GAP cross_disorder_lipid_cascades
Attached to
pathophysiology#GM2 ganglioside accumulation in neurons
The report’s secondary-lipid cascade discussion relies mainly on Niemann-Pick and mucopolysaccharidosis biochemistry. Secondary GM2 storage in those disorders supports convergence but does not prove that GM2 drives the same cholesterol/glucosylceramide cascade in Tay-Sachs.
Show evidence (2 references)
PMID:32272755 SUPPORT Other
"they trigger a secondary accumulation of ganglioside GM2, glucosylceramide and cholesterol in Niemann-Pick disease type A and B, and of GM2 and glucosylceramide in Niemann-Pick disease type C."
Review/reconstitution evidence describes different primary lysosomal disorders.
PMID:8896570 SUPPORT Model Organism
"The mucopolysaccharidosis phenotype is not seen in the Tay-Sachs or Sandhoff disease model mice or in the corresponding human patients."
Glycosaminoglycan storage appears only when both hexosaminidase subunits are removed, and is absent from Tay-Sachs model mice and from patients. This is direct evidence against carrying mucopolysaccharidosis storage biochemistry into the Tay-Sachs cascade, which is the caution this gap records.
How much visual impairment arises from retinal versus central visual pathway dysfunction?
KNOWLEDGE GAP visual-loss-localization
Attached to
pathophysiology#Retinal ganglion cell lipid storage phenotypes#Blindness phenotypes#Visual Impairment
The retinal-storage source directly explains the cherry-red macula but does not establish the causal partition of visual loss. Clinical visual impairment is retained without forcing a retinal-storage-to-blindness edge from a phenotype-frequency annotation.
Show evidence (1 reference)
PMID:19820796 SUPPORT Human Clinical
"The accumulation of lipid in retinal ganglion cells that leads to a chalk-white appearance of the fundus called 'cherry red spot' is the hallmark of Tay-Sachs disease."
This supports the visible macular sign, not attribution of all blindness to retinal storage.
⚙

Pathophysiology

15
HEXA mutations
Biallelic pathogenic variants in HEXA disrupt the alpha subunit of hexosaminidase A. Severe alleles cause the classic infantile enzyme deficiency, while residual-activity alleles can produce later-onset disease.
Prenatal developmental perturbation
HEXA hgnc:4878 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves HEXA (hgnc:4878). hgnc:4878 is a gene from the HUGO Gene Nomenclature Committee.
beta-N-acetylhexosaminidase activity GO:0004563 ↓ DECREASED Gene Ontology (GO) Relation: this pathophysiological event involves this molecular function This pathophysiological event involves decreased beta-N-acetylhexosaminidase activity (GO:0004563). GO:0004563 is a molecular function from the Gene Ontology.
Downstream
Hexosaminidase A deficiency Loss of functional alpha subunit reduces enzyme activity.
Residual but insufficient HexA activity in late-onset disease Some pathogenic HEXA alleles, especially G269S, retain residual enzyme activity and shift expression toward late-onset disease.
Prenatal neurodevelopmental perturbation A juvenile-associated biallelic HEXA genotype was associated with early fetal storage and developmental transcriptomic changes; causal intermediates and clinical consequences remain unresolved. Prenatal developmental perturbation
Show evidence (2 references)
PMID:40710901 SUPPORT Other
"Mechanistically, TSD is caused by mutations in the HEXA gene, which encodes the alpha subunit of hexosaminidase A."
Review states Tay-Sachs disease is caused by HEXA mutations affecting hexosaminidase A.
PMID:15714079 SUPPORT Human Clinical
"Analysis of the beta-hex A gene revealed the G269S mutation as the most common disease allele; found in homozygosity (N = 1) or heterozygosity (N = 18; including 2 sib pairs)."
Late-onset cohort identifies G269S as the major HEXA allele associated with residual-activity late-onset Tay-Sachs disease.
Hexosaminidase A deficiency
Loss or reduction of the alpha subunit impairs the HexA heterodimer and GM2 hydrolysis; HexB activity is normally preserved or elevated. Synthetic-substrate assays require distinction from pseudodeficiency and B1 alleles.
ganglioside catabolic process GO:0006689 ↓ DECREASED Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased ganglioside catabolic process (GO:0006689). GO:0006689 is a biological process from the Gene Ontology.
Downstream
Failure of lysosomal GM2 hydrolysis HexA deficiency prevents alpha-subunit-specific cleavage of membrane GM2 presented by GM2 activator protein.
Show evidence (4 references)
PMID:19820796 SUPPORT Human Clinical
"Tay-Sachs disease is an autosomal recessive disorder of sphingolipid metabolism, caused by enzyme hexosaminidase A deficiency that leads to an accumulation of GM2 in neurocytes which results in progressive loss of neurological function."
Supports hexosaminidase A deficiency as a core defect in Tay-Sachs disease.
PMID:36700853 SUPPORT Human Clinical
"We also observed a shift in the expression of the sphingolipid metabolic pathway away from production of the HEXA substrate, GM2 ganglioside, presumptively to compensate for dysfunction of the enzyme."
Fetal-brain transcriptomics shows compensatory remodeling of the sphingolipid metabolic pathway in HEXA-deficient brain, indicating that enzyme dysfunction perturbs sphingolipid metabolism prenatally.
PMID:36700853 SUPPORT Human Clinical
"We identified dramatic changes in the transcriptome, suggesting a perturbation of normal development."
Fetal-brain transcriptomics in HEXA-mutant samples documents dramatic transcriptomic changes consistent with perturbed neurodevelopment preceding overt neurodegeneration.
+ 1 more reference
Failure of lysosomal GM2 hydrolysis
Deficient HexA cannot remove terminal N-acetylgalactosamine from GM2 presented by GM2 activator protein, interrupting GM2-to-GM3 catabolism.
Downstream
GM2 ganglioside accumulation in neurons Failure of lysosomal GM2 degradation permits progressive substrate accumulation.
Show evidence (1 reference)
PMID:12662933 SUPPORT In Vitro
"Hex A degrades G(M2) by removing a terminal N-acetyl-D-galactosamine (beta-GalNAc) residue, and this activity requires the G(M2)-activator, a protein which solubilizes the ganglioside for presentation to Hex A."
Structural and biochemical analysis specifies the hydrolytic step.
Residual but insufficient HexA activity in late-onset disease
Late-onset Tay-Sachs disease is usually associated with at least one HEXA allele that preserves residual beta-hexosaminidase A activity. Partial enzyme activity delays onset but does not prevent progressive neurologic and neuropsychiatric disease.
HEXA hgnc:4878 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves HEXA (hgnc:4878). hgnc:4878 is a gene from the HUGO Gene Nomenclature Committee.
ganglioside catabolic process GO:0006689 ↓ DECREASED Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased ganglioside catabolic process (GO:0006689). GO:0006689 is a biological process from the Gene Ontology.
beta-N-acetylhexosaminidase activity GO:0004563 ↓ DECREASED Gene Ontology (GO) Relation: this pathophysiological event involves this molecular function This pathophysiological event involves decreased beta-N-acetylhexosaminidase activity (GO:0004563). GO:0004563 is a molecular function from the Gene Ontology.
Animal models
Gly269Ser knock-in/Neu3-null mouse Mouse partially recapitulates
Downstream
GM2 ganglioside accumulation in neurons Residual enzyme activity delays substrate accumulation and onset but remains insufficient for normal neuronal GM2 turnover.
Show evidence (1 reference)
PMID:15714079 SUPPORT Human Clinical
"In most cases, the later-onset of expression results from the presence of at least one allele (usually the G269S mutation), associated with residual enzyme (beta-hexosaminidase A) activity."
Directly links late-onset disease expression to residual beta-hexosaminidase A activity from alleles such as G269S.
GM2 ganglioside accumulation in neurons
GM2 ganglioside accumulates in neuronal lysosomes, particularly in the brain.
Neuron CL:0000540 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Neuron (CL:0000540). CL:0000540 is a cell type from the Cell Ontology.
Animal models
Hexa knockout mouse Mouse partially recapitulates
Hexa/Neu3 double-knockout mouse Mouse partially recapitulates
Naturally occurring Jacob sheep Tay-Sachs disease Sheep partially recapitulates
Downstream
GM2 Ganglioside Accumulation Neuronal lysosomal storage manifests clinically as GM2-ganglioside accumulation.
Neuroinflammation and Astrogliosis GM2 storage activates microglia and astrocytes, amplifying inflammatory neuronal injury.
Oligodendrocyte and myelin abnormalities Storage and glial inflammation accompany oligodendrocyte and myelin abnormalities in Tay-Sachs sheep; the complete causal sequence has not been isolated.
Neuronal injury Storage-related toxicity contributes to neuronal loss.
Retinal ganglion cell lipid storage GM2/lipid storage also occurs in retinal ganglion cells, producing the characteristic fundus change.
Late-onset multifocal neuronal dysfunction Slow storage-associated neuronal dysfunction in residual-activity disease produces a variable late-onset syndrome.
Show evidence (1 reference)
PMID:22025593 SUPPORT Human Clinical
"G(M2) gangliosidoses are caused by an inherited deficiency of lysosomal β-hexosaminidase and result in ganglioside accumulation in the brain."
GM2 gangliosidosis (includes Tay-Sachs) shows ganglioside accumulation in brain.
Neuroinflammation and Astrogliosis
GM2 ganglioside storage is accompanied by activated microglia, astrocyte activation, and inflammatory mediator production that can worsen neuronal injury.
Microglia CL:0000129 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Microglia, annotated with microglial cell (CL:0000129). CL:0000129 is a cell type from the Cell Ontology. Astrocyte CL:0000127 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Astrocyte (CL:0000127). CL:0000127 is a cell type from the Cell Ontology.
microglial cell activation GO:0001774 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves microglial cell activation (GO:0001774). GO:0001774 is a biological process from the Gene Ontology. astrocyte activation GO:0048143 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves astrocyte activation (GO:0048143). GO:0048143 is a biological process from the Gene Ontology. neuroinflammatory response GO:0150076 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves neuroinflammatory response (GO:0150076). GO:0150076 is a biological process from the Gene Ontology.
Animal models
Hexa/Neu3 double-knockout mouse Mouse partially recapitulates
Downstream
Neuronal injury Inflammatory glial responses may amplify neuronal injury; timing and marker-reduction studies do not prove a dominant mechanism in human disease.
Show evidence (2 references)
PMID:32951593 SUPPORT Model Organism
"We found elevated levels of pro-inflammatory cytokine and chemokine transcripts, such as Ccl2, Ccl3, Ccl4, and Cxcl10 and also extensive microglial and astrocyte activation and proliferation, accompanied by peripheral blood mononuclear cell infiltration in the vicinity of neurons and oligodendrocytes."
Hexa/Neu3 double-knockout mice demonstrate the inflammatory branch; this is not direct human causal evidence.
PMID:12615653 SUPPORT Model Organism
"Substrate reduction therapy in the Sandhoff mouse model slowed the rate of accumulation of glycosphingolipids in the CNS, thus delaying the onset of the inflammatory process and disease pathogenesis."
Substrate intervention supports storage-dependent inflammation in Sandhoff mice, providing indirect support for Tay-Sachs.
Oligodendrocyte and myelin abnormalities
Tay-Sachs sheep have reduced oligodendrocyte density and forebrain myelination alongside glial activation. Cross-sectional observations do not fully separate failure of myelin formation from later myelin loss, and species-specific results require qualified human interpretation.
Oligodendrocyte CL:0000128 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Oligodendrocyte (CL:0000128). CL:0000128 is a cell type from the Cell Ontology.
myelination GO:0042552 ↓ DECREASED Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased myelination (GO:0042552). GO:0042552 is a biological process from the Gene Ontology.
Downstream
Hypomyelination Reduced myelination is observed in the sheep model; human pediatric GM2 imaging also documents hypomyelination, but does not isolate oligodendrocyte loss as its sole cause.
Show evidence (2 references)
PMID:34456134 SUPPORT Model Organism
"Microglial activation and reactive astrocytes were observed globally on histopathology in TSD sheep with a widespread reduction in oligodendrocyte density."
Sheep Tay-Sachs natural-history study directly documents widespread reduction in oligodendrocyte density alongside microglial and astrocyte activation.
PMID:34456134 SUPPORT Model Organism
"Myelination is reduced primarily in the forebrain illustrated by loss of white matter on MRI."
Sheep data document reduced forebrain myelination without resolving impaired formation versus later myelin loss.
Retinal ganglion cell lipid storage
Lipid-filled retinal ganglion cells make the surrounding fundus appear pale, leaving the fovea as a cherry-red macular spot. This finding does not by itself establish the mechanism or severity of visual loss.
Retinal ganglion cell CL:0000740 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Retinal ganglion cell (CL:0000740). CL:0000740 is a cell type from the Cell Ontology.
lysosome GO:0005764 Gene Ontology (GO) Relation: this pathophysiological event involves this cellular component This pathophysiological event involves lysosome (GO:0005764). GO:0005764 is a cellular component from the Gene Ontology.
Downstream
Cherry-Red Spot Retinal ganglion cell lipid storage creates the chalk-white fundus around the fovea.
Show evidence (1 reference)
PMID:19820796 SUPPORT Human Clinical
"The accumulation of lipid in retinal ganglion cells that leads to a chalk-white appearance of the fundus called 'cherry red spot' is the hallmark of Tay-Sachs disease."
Directly supports the retinal-ganglion-cell storage mechanism leading to cherry-red spot.
Neuronal injury
Storage-associated neuronal dysfunction can precede progressive loss. Diverse affected circuits account for developmental, motor, sensory and epileptic manifestations; apoptosis is one experimentally studied route, not the definition of all injury.
Neuron CL:0000540 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Neuron (CL:0000540). CL:0000540 is a cell type from the Cell Ontology.
Downstream
Developmental Regression Rapid infantile neurodegeneration causes developmental arrest and loss of attained milestones.
Hypotonia Early neuronal dysfunction presents with hypotonia in infantile GM2 gangliosidosis.
Exaggerated Startle Response Altered pontine reticular reflex excitability may mediate exaggerated startle; precise cell loss is not established.
Seizures Progressive cortical neurodegeneration contributes to epileptic seizures.
Spasticity Progressive upper motor neuron and corticospinal dysfunction contributes to late-stage spasticity.
Dysphagia Progressive bulbar and brainstem dysfunction contributes to swallowing impairment.
Juvenile cerebellar and bulbar involvement Slower childhood-onset neurodegeneration produces cerebellar, bulbar, and motor pathway manifestations.
Show evidence (2 references)
PMID:29618308 SUPPORT Other
"Inherited as a classical autosomal recessive disorder, this global disease of the nervous system induces developmental arrest with regression of attained milestones; neurodegeneration progresses rapidly to cause premature death in young children."
Review describes rapid neurodegeneration in infantile GM2 gangliosidosis, consistent with neuronal loss.
PMID:20301397 SUPPORT Other
"HEXA disorders are best considered as a disease continuum based on the amount of residual beta-hexosaminidase A (HEX A) enzyme activity."
GeneReviews supports a residual-activity continuum rather than fixed activity thresholds or survival cutoffs.
Juvenile cerebellar and bulbar involvement
Juvenile Tay-Sachs disease progresses through cerebellar, bulbar, and motor pathway involvement, producing gait, speech, swallowing, tone, and weakness manifestations over childhood.
Neuron CL:0000540 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Neuron (CL:0000540). CL:0000540 is a cell type from the Cell Ontology.
Downstream
Ataxia Cerebellar involvement produces incoordination and gait disturbance.
Proximal Muscle Weakness Progressive motor involvement contributes to limb weakness and muscle wasting.
Muscle Weakness Progressive motor pathway and anterior motor neuron involvement produce generalized muscle weakness across Tay-Sachs subtypes.
Skeletal Muscle Atrophy Progressive motor involvement produces muscle wasting that corresponds to skeletal muscle atrophy.
Dysarthria Bulbar and motor speech pathway involvement produces dysarthria and speech deterioration.
Dysphagia Bulbar involvement contributes to swallowing impairment in juvenile disease.
Spasticity Progressive motor pathway involvement contributes to increasing tone and spasm progression.
Progressive Spasticity Progressive motor pathway involvement manifests as increasing spasm progression and progressive spasticity.
Cerebellar Atrophy Chronic cerebellar involvement produces cerebellar atrophy on brain MRI in juvenile disease.
Show evidence (2 references)
PMID:17015493 SUPPORT Human Clinical
"The most common symptoms at onset were gait disturbances (66.7%), incoordination (52.4%), speech problems (28.6%), and developmental delay (28.6%)."
Prospective juvenile GM2 gangliosidosis cohort supports gait, coordination, and speech involvement in juvenile Tay-Sachs disease.
PMID:20301397 SUPPORT Other
"Spasticity, dysphagia, and seizures are present by the end of the first decade of life, with death within the second decade of life, usually by aspiration."
GeneReviews supports juvenile motor/bulbar progression and aspiration complications.
Late-onset multifocal neuronal dysfunction
Late-onset disease affects cerebellar and motor systems and can involve distributed neuropsychiatric networks. Regional vulnerability and the mechanism of psychiatric symptoms remain incompletely resolved.
Neuron CL:0000540 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Neuron (CL:0000540). CL:0000540 is a cell type from the Cell Ontology.
Downstream
Ataxia Cerebellar involvement causes gait and balance impairment.
Proximal Muscle Weakness Anterior motor neuron involvement contributes to progressive proximal weakness.
Cerebellar Atrophy Chronic cerebellar involvement produces marked cerebellar atrophy on neuroimaging in late-onset disease.
Tremor Cerebellar and motor pathway involvement contributes to action tremor and stimulus-sensitive myoclonus in late-onset disease.
Psychosis Psychosis occurs in late-onset disease, but the specific affected circuits and causal intermediates are unresolved.
Dystonia Multifocal neuronal dysfunction can contribute to this late-onset manifestation; the detailed circuit-specific sequence is unresolved.
Cognitive decline Multifocal neuronal dysfunction can contribute to this late-onset manifestation; the detailed circuit-specific sequence is unresolved.
Frequent falls Multifocal neuronal dysfunction can contribute to this late-onset manifestation; the detailed circuit-specific sequence is unresolved.
Myoclonus Multifocal neuronal dysfunction can contribute to this late-onset manifestation; the detailed circuit-specific sequence is unresolved.
Show evidence (2 references)
PMID:15714079 SUPPORT Human Clinical
"Early on, the majority of patients develop signs of either cerebellar or anterior motor neuron involvement."
Cohort conclusion supports cerebellar and anterior motor neuron involvement as the early late-onset phenotype mechanism.
PMID:39807213 SUPPORT Human Clinical
"We report 2 cases of adult-onset progressive weakness, ataxia, and neuropsychiatric symptoms in a 30-year-old man and 37-year-old woman."
Recent adult-onset cases confirm the weakness, ataxia, and neuropsychiatric manifestation cluster.
GM2-associated PERK activation
Mechanism confidence: Provisional
In GM2-loaded neuronal cultures, ER calcium depletion activates PERK, with early adaptive calcineurin and later CHOP-associated responses. This node represents experimental signaling; the upstream lysosomal-to-ER route in patients remains unresolved.
GM2-associated ER stress and neuronal injury
endoplasmic reticulum unfolded protein response GO:0030968 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves endoplasmic reticulum unfolded protein response (GO:0030968). GO:0030968 is a biological process from the Gene Ontology.
Experimental models
GM2-loaded neuronal cultures PRIMARY CELL CULTURE
Downstream
CHOP-associated neuronal injury Prolonged experimental ER stress engages CHOP-associated neurite atrophy and apoptosis. GM2-associated ER stress and neuronal injury
Show evidence (1 reference)
PMID:30389374 SUPPORT In Vitro
"We found that ER GM2 accumulation in cultured neurons induces luminal Ca2+ depletion, which in turn activates PERK (protein kinase RNA [PKR]-like ER kinase), one of three UPR sensors."
Cultured-neuron GM2 loading supports an ER calcium/PERK mechanism; lysosomal-to-ER trafficking and necessity in human Tay-Sachs are unresolved.
CHOP-associated neuronal injury
Mechanism confidence: Provisional
Cultured-neuron neurite atrophy and apoptosis respond to PERK inhibition and CHOP/calcineurin knockdown. A chemical chaperone acting on PERK reduces the same two readouts together in primary neuron cultures.
GM2-associated ER stress and neuronal injury
Downstream
Neuronal injury This experimentally supported injury pathway may contribute to GM2-associated neurodegeneration; its in vivo importance in Tay-Sachs remains unquantified. GM2-associated ER stress and neuronal injury
Show evidence (2 references)
PMID:30389374 SUPPORT In Vitro
"Both processes were effectively modulated by treatment with the selective PERK inhibitor GSK2606414, by CN knockdown, and by CHOP knockdown."
PERK inhibition and calcineurin/CHOP knockdown provide direct cellular perturbation evidence for neurite atrophy/apoptosis.
PMID:37108372 SUPPORT In Vitro
"Here, we found that UDCA significantly diminished the neurite atrophy induced by GM2 accumulation in primary neuron cultures. It also decreased the up-regulation of pro-apoptotic CHOP, a downstream PERK-signaling component."
A second, pharmacological perturbation from an independent study moves neurite atrophy and CHOP induction together, which is the coupling this node asserts. It remains primary-culture evidence; ursodeoxycholic acid has not been tested clinically in Tay-Sachs disease.
Impaired autophagic flux and lysosomal integrity
Mechanism confidence: Provisional
Tay-Sachs/Sandhoff skin fibroblasts show abnormal autophagosomes, reduced basal mTOR signaling and lysosomal leakage. This is an experimental cellular branch; a direct arrow to neuronal death is not established.
autophagy GO:0006914 ↕ DYSREGULATED Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves dysregulated autophagy (GO:0006914). GO:0006914 is a biological process from the Gene Ontology.
Experimental models
Patient-derived GM2 skin fibroblasts PRIMARY CELL CULTURE
Show evidence (2 references)
PMID:34831346 SUPPORT In Vitro
"GM2 fibroblasts showed diminished mTOR signalling with reduced basal mTOR activity."
Patient-derived Tay-Sachs and Sandhoff fibroblasts reveal an autophagy/lysosomal phenotype; neuronal in vivo generalization is unproven.
PMID:34831346 SUPPORT In Vitro
"Pathological autophagosomes with impaired autophagic flux, an abnormality confirmed by electron microscopy and biochemical studies revealing the accelerated release of mature cathepsins and HexA into the cytosol, indicating increased lysosomal permeability."
Patient fibroblast assays document impaired flux and lysosomal leakage, not the full human neurodegenerative sequence.
Prenatal neurodevelopmental perturbation
Mechanism confidence: Provisional
In two affected sibling fetuses at 17 weeks, GM2 storage and bulk transcriptomic changes suggest altered differentiation/proliferation before end-stage neuroinflammatory signatures. The findings are hypothesis-generating across a small number of biological donors.
Experimental models
Sandhoff cerebral organoids with isogenic correction ORGANOID
Show evidence (1 reference)
PMID:36700853 SUPPORT Human Clinical
"We find that the transcriptomes are perturbed by 17 week’s gestation, suggesting abnormal neurodevelopment, which has implications for therapeutic intervention for TSD."
Two affected sibling fetuses with a juvenile-associated genotype and two controls were sampled across brain regions; 19 GEO libraries are not 19 independent fetuses.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Tay-Sachs Disease Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

30
Cardiovascular 1
Cherry-Red Spot VERY_FREQUENT Cherry red spot of the macula HP:0010729 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Cherry-Red Spot, annotated with Cherry red spot of the macula (HP:0010729). HP:0010729 is a phenotype from the Human Phenotype Ontology.
Characteristic of infantile disease but not pathognomonic; also occurs in other storage diseases and central retinal artery occlusion. Rare in juvenile disease.
Show evidence (2 references)
PMID:19820796 SUPPORT Human Clinical
"The accumulation of lipid in retinal ganglion cells that leads to a chalk-white appearance of the fundus called 'cherry red spot' is the hallmark of Tay-Sachs disease."
Case report describes cherry-red spot as the hallmark ophthalmologic finding in Tay-Sachs disease.
PMID:19820796 SUPPORT Human Clinical
"It is also seen in others neurometabolic diseases as well as in central retinal artery occlusion."
The source explicitly rules out disease specificity of a cherry-red spot.
Digestive 1
Dysphagia FREQUENT HP:0002015 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Dysphagia (HP:0002015). HP:0002015 is a phenotype from the Human Phenotype Ontology.
Show evidence (3 references)
PMID:30524313 SUPPORT Other
"Common neurodegenerative symptoms in infants are hypotension, inability to sit or hold their head unsupported, eye movement abnormalities, dysphagia, spasms, and hypomyelination"
Review lists dysphagia among common infantile Tay-Sachs neurodegenerative symptoms.
PMID:17015493 SUPPORT Human Clinical
"However, dysphagia, sphincter incontinence, and sleep problems occurred earlier in those with the Tay-Sachs variant."
Juvenile GM2 gangliosidosis natural history documents earlier dysphagia in the Tay-Sachs variant.
ORPHA:845 SUPPORT Other
"HP:0002015 | Dysphagia | Frequent (79-30%)"
Orphanet lists dysphagia as a frequent HPO phenotype for Tay-Sachs disease.
Eye 3
Blindness OCCASIONAL HP:0000618 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Blindness (HP:0000618). HP:0000618 is a phenotype from the Human Phenotype Ontology.
Visual loss can progress to blindness in infantile disease. Aggregate Orphanet frequencies combine subtypes and stages.
Show evidence (2 references)
PMID:24011710 SUPPORT Other
"Disorders such as Tay-Sachs or Niemann-Pick disease are the most familiar examples of dysfunction in sphingolipid metabolism and are typically associated with neurodegeneration and ocular findings such as blindness."
Review establishes blindness as a characteristic ocular finding in sphingolipidoses including Tay-Sachs disease, though without quantitative frequency data.
ORPHA:845 SUPPORT Other
"HP:0000618 | Blindness | Occasional (29-5%)"
Orphanet lists blindness as occasional for Tay-Sachs disease; visual impairment (HP:0000505) is more common at FREQUENT frequency.
Visual Impairment FREQUENT HP:0000505 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Visual Impairment (HP:0000505). HP:0000505 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
ORPHA:845 SUPPORT Other
"HP:0000505 | Visual impairment | Frequent (79-30%)"
Orphanet lists visual impairment as a frequent HPO phenotype for Tay-Sachs disease.
Abnormal saccadic eye movements HP:0000570 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Abnormal saccadic eye movements (HP:0000570). HP:0000570 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:31964693 SUPPORT Human Clinical
"Oculomotor abnormalities were found in all participants, including 3/10 with clinically normal eye movements."
Cross-sectional mixed late-onset GM2 study supports sensitive oculomotor findings, not universal Tay-Sachs penetrance.
Head and Neck 1
Macrocephaly HP:0000256 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Macrocephaly (HP:0000256). HP:0000256 is a phenotype from the Human Phenotype Ontology.
Macrocephaly can occur in infantile disease; a single case does not establish frequency or distinguish the contributions of storage, gliosis and ventricular enlargement.
Show evidence (1 reference)
PMID:7732608 SUPPORT Human Clinical
"Generalized hypotonia, macrocephaly, hyperacusis and a retinal cherry red spot appearance were present."
Case report documents macrocephaly in Tay-Sachs disease.
Metabolism 1
GM2 Ganglioside Accumulation VERY_FREQUENT HP:0003495 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is GM2 Ganglioside Accumulation, annotated with GM2-ganglioside accumulation (HP:0003495). HP:0003495 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
ORPHA:845 SUPPORT Other
"HP:0003495 | GM2-ganglioside accumulation | Very frequent (99-80%)"
Orphanet lists GM2-ganglioside accumulation as a very frequent HPO phenotype for Tay-Sachs disease.
Musculoskeletal 7
Hypotonia FREQUENT HP:0001252 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hypotonia (HP:0001252). HP:0001252 is a phenotype from the Human Phenotype Ontology.
Reported at onset in 60% of the mixed infantile GM2 natural-history cohort; later tone may become spastic.
Show evidence (1 reference)
PMID:22025593 SUPPORT Human Clinical
"Common symptoms at onset were developmental arrest (83%), startling (65%), and hypotonia (60%)."
Natural history study confirms hypotonia in 60% of infantile GM2 gangliosidosis patients at disease onset.
Muscle Weakness VERY_FREQUENT HP:0001324 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Muscle Weakness (HP:0001324). HP:0001324 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
ORPHA:845 SUPPORT Other
"HP:0001324 | Muscle weakness | Very frequent (99-80%)"
Orphanet lists muscle weakness as a very frequent HPO phenotype for Tay-Sachs disease.
Skeletal Muscle Atrophy VERY_FREQUENT HP:0003202 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Skeletal Muscle Atrophy (HP:0003202). HP:0003202 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
ORPHA:845 SUPPORT Other
"HP:0003202 | Skeletal muscle atrophy | Very frequent (99-80%)"
Orphanet lists skeletal muscle atrophy as a very frequent HPO phenotype for Tay-Sachs disease.
Proximal Muscle Weakness HP:0003701 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Proximal muscle weakness (HP:0003701). HP:0003701 is a phenotype from the Human Phenotype Ontology.
Show evidence (3 references)
PMID:17015493 SUPPORT Human Clinical
"Muscle wasting (10.6 +/- 7.4 years), proximal weakness (11.1 +/- 7.7 years), and incontinence of sphincters (14.6 +/- 9.7 years) appeared later in the course of the disease."
Juvenile GM2 gangliosidosis natural-history cohort documents later proximal weakness, supporting juvenile Tay-Sachs motor weakness.
PMID:39807213 SUPPORT Human Clinical
"We report 2 cases of adult-onset progressive weakness, ataxia, and neuropsychiatric symptoms in a 30-year-old man and 37-year-old woman."
Recent adult-onset cases directly document progressive weakness.
PMID:15714079 SUPPORT Human Clinical
"Early on, the majority of patients develop signs of either cerebellar or anterior motor neuron involvement."
Anterior motor neuron involvement mechanistically supports progressive proximal weakness in late-onset disease.
Progressive Spasticity VERY_FREQUENT HP:0002191 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Progressive Spasticity (HP:0002191). HP:0002191 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
ORPHA:845 SUPPORT Other
"HP:0002191 | Progressive spasticity | Very frequent (99-80%)"
Orphanet lists progressive spasticity as a very frequent HPO phenotype for Tay-Sachs disease.
Spasticity HP:0001257 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Spasticity (HP:0001257). HP:0001257 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:20301397 SUPPORT Other
"Spasticity, dysphagia, and seizures are present by the end of the first decade of life, with death within the second decade of life, usually by aspiration."
GeneReviews supports juvenile motor/bulbar progression and aspiration complications.
PMID:20301397 SUPPORT Other
"Late-onset TSD presents in older teens or young adults with a slowly progressive spectrum of neurologic symptoms including lower-extremity weakness with muscle atrophy, dysarthria, incoordination, tremor, mild spasticity and/or dystonia, and psychiatric manifestations including acute psychosis."
The late-onset spectrum spans cerebellar, motor, and neuropsychiatric dysfunction.
Frequent falls HP:0002359 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Frequent falls (HP:0002359). HP:0002359 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301397 SUPPORT Other
"circumstances that exacerbate the risk of falls (i.e., walking on uneven or unstable surfaces)"
GeneReviews identifies fall risk requiring preventive care.
Nervous System 14
Developmental Regression HP:0002376 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Developmental Regression (HP:0002376). HP:0002376 is a phenotype from the Human Phenotype Ontology.
Infantile weakness may begin at 3–6 months, followed by developmental plateau and loss of skills, often after 8–10 months. Developmental arrest percentages are not equivalent to regression prevalence.
Show evidence (3 references)
PMID:25143775 SUPPORT Human Clinical
"All of them had a developmental disorder as a chief complaint. 38%of patients had a history of developmental delay or regression"
Case series confirms developmental regression as a key presenting feature in GM2 gangliosidosis patients.
PMID:22025593 SUPPORT Human Clinical
"Common symptoms at onset were developmental arrest (83%), startling (65%), and hypotonia (60%)."
Natural history study of 97 patients confirms developmental arrest in 83% of infantile GM2 gangliosidosis cases.
PMID:29618308 SUPPORT Other
"Inherited as a classical autosomal recessive disorder, this global disease of the nervous system induces developmental arrest with regression of attained milestones; neurodegeneration progresses rapidly to cause premature death in young children."
Review describes developmental arrest with regression of milestones as a core feature of Tay-Sachs disease.
Exaggerated Startle Response FREQUENT HP:0002267 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Exaggerated Startle Response (HP:0002267). HP:0002267 is a phenotype from the Human Phenotype Ontology.
65% at presentation in a mixed infantile GM2 cohort; this is not a prevalence estimate across all Tay-Sachs subtypes.
Show evidence (3 references)
PMID:22025593 SUPPORT Human Clinical
"Common symptoms at onset were developmental arrest (83%), startling (65%), and hypotonia (60%)."
Natural history study of 97 infantile GM2 gangliosidosis patients confirms exaggerated startle response in 65%, consistent with FREQUENT frequency in the infantile subtype.
PMID:24534057 SUPPORT Human Clinical
"The augmented startle reflex appeared between the age of 3 and 17 months and disappeared between the age of 4 and 6 years."
Electrophysiological study documents the temporal evolution of the augmented startle reflex in Tay-Sachs disease.
ORPHA:845 SUPPORT Other
"HP:0002267 | Exaggerated startle response | Occasional (29-5%)"
Orphanet reports occasional frequency across all subtypes in aggregate; the infantile-specific cohort literature (65%) supports FREQUENT as the appropriate designation for infantile-onset disease.
Seizures HP:0001250 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Seizures, annotated with Seizure (HP:0001250). HP:0001250 is a phenotype from the Human Phenotype Ontology.
Seizures become common during infantile progression and occur in juvenile disease. The 22% mixed-series presentation figure and aggregate Orphanet band do not describe lifetime infantile frequency.
Show evidence (3 references)
PMID:25143775 SUPPORT Human Clinical
"38%of patients had a history of developmental delay or regression and 22% had seizures."
Case series documents seizures in 22% of GM2 gangliosidosis patients, consistent with the OCCASIONAL frequency band.
ORPHA:845 SUPPORT Other
"HP:0001250 | Seizure | Occasional (29-5%)"
Orphanet lists seizure as an occasional HPO phenotype for Tay-Sachs disease, consistent with the 22% frequency reported in cohort studies.
PMID:20301397 SUPPORT Other
"Seizures are common by 12 months with further deterioration in the second year of life and death occurring between ages two and three years with some survival to five to seven years."
Infantile progression and survival vary with stage and supportive care; a fixed death-by-four rule is inaccurate.
Ataxia HP:0001251 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Ataxia (HP:0001251). HP:0001251 is a phenotype from the Human Phenotype Ontology.
Show evidence (3 references)
PMID:17015493 SUPPORT Human Clinical
"The most common symptoms at onset were gait disturbances (66.7%), incoordination (52.4%), speech problems (28.6%), and developmental delay (28.6%)."
Juvenile GM2 gangliosidosis cohort documents gait disturbance and incoordination at onset, supporting juvenile Tay-Sachs ataxia.
PMID:15714079 SUPPORT Human Clinical
"Mean age at onset was 18.1 years; balance problems and difficulty climbing stairs were the most frequent presenting complaints."
Late-onset cohort identifies balance problems as a leading presenting complaint, supporting ataxia as a subtype-specific phenotype.
PMID:39807213 SUPPORT Human Clinical
"We report 2 cases of adult-onset progressive weakness, ataxia, and neuropsychiatric symptoms in a 30-year-old man and 37-year-old woman."
Adult-onset cases directly document ataxia in late-onset Tay-Sachs disease.
Psychosis OCCASIONAL HP:0000709 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Psychosis (HP:0000709). HP:0000709 is a phenotype from the Human Phenotype Ontology.
Show evidence (3 references)
PMID:15714079 SUPPORT Human Clinical
"Affected individuals may also develop psychotic episodes."
Cohort conclusion explicitly reports psychotic episodes as part of late-onset Tay-Sachs disease.
PMID:39807213 SUPPORT Human Clinical
"We report 2 cases of adult-onset progressive weakness, ataxia, and neuropsychiatric symptoms in a 30-year-old man and 37-year-old woman."
Adult-onset cases support neuropsychiatric involvement in late-onset Tay-Sachs disease.
ORPHA:845 SUPPORT Other
"HP:0000709 | Psychosis | Occasional (29-5%)"
Orphanet lists psychosis as an occasional HPO phenotype for Tay-Sachs disease.
Dysarthria FREQUENT HP:0001260 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Dysarthria (HP:0001260). HP:0001260 is a phenotype from the Human Phenotype Ontology.
Show evidence (4 references)
PMID:17015493 SUPPORT Human Clinical
"Speech deterioration progressed more rapidly than gait abnormalities in both the Tay-Sachs variant and Sandhoff variant groups."
Juvenile GM2 gangliosidosis natural history documents progressive speech deterioration in the Tay-Sachs variant.
PMID:30524313 SUPPORT Other
"The juvenile form of the disease strikes in early childhood, usually at the age of 3–10 years. Common symptoms are ataxia, dysarthria, dysphagia development, hypotension, and spasm progression."
Review explicitly lists dysarthria among common juvenile Tay-Sachs symptoms.
ORPHA:845 SUPPORT Other
"HP:0001260 | Dysarthria | Frequent (79-30%)"
Orphanet lists dysarthria as a frequent HPO phenotype for Tay-Sachs disease.
+ 1 more reference
Hypomyelination Cerebral hypomyelination HP:0006808 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Cerebral hypomyelination (HP:0006808). HP:0006808 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:30524313 SUPPORT Other
"Common neurodegenerative symptoms in infants are hypotension, inability to sit or hold their head unsupported, eye movement abnormalities, dysphagia, spasms, and hypomyelination"
Review explicitly lists hypomyelination among common neurodegenerative findings in infantile Tay-Sachs disease.
PMID:34456134 SUPPORT Model Organism
"Myelination is reduced primarily in the forebrain illustrated by loss of white matter on MRI."
Sheep Tay-Sachs natural-history model recapitulates reduced forebrain myelination on MRI.
Cerebellar Atrophy HP:0001272 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Cerebellar Atrophy (HP:0001272). HP:0001272 is a phenotype from the Human Phenotype Ontology.
Show evidence (3 references)
PMID:17015493 SUPPORT Human Clinical
"Cerebellar atrophy was the most common finding on brain MRI (52.9%)."
Juvenile GM2 gangliosidosis natural history identifies cerebellar atrophy as the most common MRI finding.
PMID:15714079 SUPPORT Human Clinical
"Brain imaging studies revealed marked cerebellar atrophy in all patients (N = 18) tested, regardless of disease stage."
Late-onset cohort documents marked cerebellar atrophy in all imaged patients across disease stages.
PMID:28739864 SUPPORT Human Clinical
"MR scan of the brain showed isolated cerebellar atrophy"
Adult-onset Tay-Sachs case report documents isolated cerebellar atrophy on brain MRI.
Tremor HP:0001337 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Tremor (HP:0001337). HP:0001337 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:28739864 SUPPORT Human Clinical
"irregular action tremor and stimulus-sensitive myoclonus of the arms"
Adult-onset Tay-Sachs case report documents irregular action tremor and stimulus-sensitive myoclonus as motor features of late-onset disease.
Dystonia HP:0001332 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Dystonia (HP:0001332). HP:0001332 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301397 SUPPORT Other
"Late-onset TSD presents in older teens or young adults with a slowly progressive spectrum of neurologic symptoms including lower-extremity weakness with muscle atrophy, dysarthria, incoordination, tremor, mild spasticity and/or dystonia, and psychiatric manifestations including acute psychosis."
GeneReviews describes the late-onset motor and psychiatric spectrum.
Cognitive decline Mental deterioration HP:0001268 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Mental deterioration (HP:0001268). HP:0001268 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:20301397 SUPPORT Other
"the emergence of abnormal gait or dysarthria is noted followed by loss of previously acquired skills and cognitive decline."
Juvenile disease includes progressive cognitive loss.
PMID:31964693 SUPPORT Human Clinical
"Nine out of ten patients with LOGG had evidence of the CCAS (5/10 definite, 2/10 probable, 2/10 possible)."
Selected mixed late-onset GM2 cohort supports cognitive involvement without implying universal dementia.
Myoclonus HP:0001336 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Myoclonus (HP:0001336). HP:0001336 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:28739864 SUPPORT Human Clinical
"irregular action tremor and stimulus-sensitive myoclonus of the arms"
The clinical case separately documents action tremor and myoclonus.
Depression HP:0000716 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Depression (HP:0000716). HP:0000716 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:18642377 SUPPORT Human Clinical
"ataxia, weakness, spasticity, dysarthria, dysphagia, dystonia, seizures, psychosis, mania, depression, and cognitive decline."
The clinical cohort report recognizes a broad CNS symptom spectrum.
Sleep disturbance HP:0002360 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Sleep disturbance (HP:0002360). HP:0002360 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:17015493 SUPPORT Human Clinical
"However, dysphagia, sphincter incontinence, and sleep problems occurred earlier in those with the Tay-Sachs variant."
The juvenile cohort includes 15 Tay-Sachs and six Sandhoff patients; timing differs by subtype.
PMID:31964693 SUPPORT Human Clinical
"Excessive daytime sleepiness was present in 4/10 and 8/10 had poor subjective sleep quality."
Small mixed late-onset GM2 cohort; these are not Tay-Sachs-specific population prevalence estimates.
Other 2
Axonal polyneuropathy
Show evidence (1 reference)
PMID:18642377 SUPPORT Human Clinical
"found evidence of a predominantly axon loss polyneuropathy affecting distal nerve segments in the lower and upper extremities in eight patients (27%)."
Clinical and electrophysiologic examination of 30 LOTS patients supports peripheral involvement in a subset.
Sphincter incontinence
Free-text descriptor preserves the source’s combined sphincter finding without selecting an unsupported organ-specific HPO term.
Show evidence (1 reference)
PMID:17015493 SUPPORT Human Clinical
"Muscle wasting (10.6 +/- 7.4 years), proximal weakness (11.1 +/- 7.7 years), and incontinence of sphincters (14.6 +/- 9.7 years) appeared later in the course of the disease."
The prospective juvenile cohort included 15 Tay-Sachs and six Sandhoff patients; pooled ages are not Tay-Sachs-specific prevalence estimates.
🧬

Genetic Associations

1
HEXA (Causative)
Gene: HEXA hgnc:4878 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is HEXA (hgnc:4878). hgnc:4878 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE variant_origin: GERMLINE
Autosomal recessive
Show evidence (4 references)
PMID:40710901 SUPPORT Other
"Mechanistically, TSD is caused by mutations in the HEXA gene, which encodes the alpha subunit of hexosaminidase A."
Review supports HEXA as the causative gene for Tay-Sachs disease.
PMID:15714079 SUPPORT Human Clinical
"The patients' alpha-subunit mutations (beta-Hexosaminidase A genotype) were determined and correlated with their corresponding clinical findings and disease course."
Late-onset cohort links HEXA alpha-subunit genotypes to clinical disease course.
CGGV:assertion_1f7530b5-af31-40f9-ac18-a1b4d404285a-2020-05-27T160000.000Z SUPPORT Other
"HEXA | HGNC:4878 | Tay-Sachs disease | MONDO:0010100 | AR | Definitive"
ClinGen classifies the HEXA-Tay-Sachs disease gene-disease relationship as definitive with autosomal recessive inheritance.
+ 1 more reference
Variants (1)
HEXA p.Gly269Ser (G269S) Pathogenic
missense
Recurrent pathogenic residual-activity allele associated with late-onset disease. A single homozygous patient in the 21-person cohort had onset at 36 and relatively slow progression; this does not determine onset for every homozygote.
Show evidence (1 reference)
PMID:15714079 SUPPORT Human Clinical
"Disease onset (age 36 years) was delayed and progression relatively slower in the homozygous G269S patient."
Cohort data support G269S as a pathogenic residual-activity allele with a later and slower phenotype.
🗃️

External Assertions

1
Orphanet Tay-Sachs disease record
Orphanet structured disease record ORPHA:845
Orphanet curates ORPHA:845 as the Tay-Sachs disease disorder record and provides structured synonyms, definition, inheritance, natural history, epidemiology, HPO phenotype frequencies, and cross-references.
ORPHA:845 lists exact cross-references to MONDO:0010100, MeSH:D013661, MedDRA:10043147, OMIM:272800, and UMLS:C0039373, with narrower ICD-10:E75.0 and ICD-11:5C56.00 rows.
Show evidence (4 references)
ORPHA:845 SUPPORT Other
"ORPHA:845 Tay-Sachs disease"
The structured cache heading identifies ORPHA:845 as the Orphanet Tay-Sachs disease record.
ORPHA:845 SUPPORT Other
"MONDO:0010100 | Exact"
Orphanet maps ORPHA:845 exactly to the MONDO disease identifier used by this entry.
ORPHA:845 SUPPORT Other
"OMIM:272800 | Exact"
Orphanet lists OMIM:272800 as an exact cross-reference for Tay-Sachs disease.
+ 1 more reference
💊

Medical Actions

9
Hematopoietic stem cell transplantation (HSCT)
Action: hematopoietic stem cell transplantationNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is hematopoietic stem cell transplantation, annotated with Hematopoietic Cell Transplantation (NCIT:C15431). NCIT:C15431 is a clinical intervention from the NCI Thesaurus. Ontology label: Hematopoietic Cell Transplantation NCIT:C15431
Platform: Cell therapy
An uncontrolled late-onset case had normalized leukocyte HexA and nonprogressive tremor eight years after HSCT. Most features were already static before transplantation, so this does not establish that HSCT arrests neurodegeneration or normalizes CNS enzyme activity. Infantile natural-history data found no associated survival advantage; HSCT is not established standard care.
Show evidence (3 references)
PMID:29214523 SUPPORT Human Clinical
"HSCT is a potential treatment option which might arrest neurodegeneration in patients with LOTS."
One case provides a biochemical and longitudinal clinical signal; pretreatment stability and lack of controls limit causal efficacy inference.
PMID:29214523 SUPPORT Human Clinical
"His condition had had a static course apart from his tremor that had been gradually deteriorating."
The pretreatment course limits claims that transplantation halted otherwise progressive global disease.
PMID:22025593 SUPPORT Human Clinical
"Hematopoietic stem cell transplantation was not associated with prolonged survival."
Five transplant recipients were evaluated separately in this infantile GM2 natural-history study; this is observational evidence, not randomized efficacy testing.
Supportive Care
Action: Supportive CareNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Supportive Care (NCIT:C15747). NCIT:C15747 is a clinical intervention from the NCI Thesaurus. NCIT:C15747
Individualized seizure management, nutritional and swallowing assessment, airway clearance and aspiration prevention, and physical, occupational and speech therapy support function and comfort. Monitor constipation, mobility, skin/contracture risk, and psychiatric needs. Neurology follow-up is guided by clinical concerns; avoid excessive sedation, aspiration-promoting positioning and high fall risk.
Show evidence (3 references)
PMID:27491214 SUPPORT Other
"Both are devastating diseases without cure or specific treatment however, with the use of supportive aggressive medical management, the lifespan and quality of life has been extended for both diseases."
Review confirms supportive care extends lifespan and quality of life in GM2 gangliosidoses including Tay-Sachs disease.
PMID:20301397 SUPPORT Other
"Treatment is mostly supportive and directed to providing adequate nutrition and hydration, managing infectious disease, protecting the airway, and controlling seizures."
GeneReviews sets the clinical management priorities across systems.
PMID:20301397 SUPPORT Other
"psychiatric medications that have been associated with disease worsening, including haloperidol, risperidone, and chlorpromazine."
Psychiatric care requires disease-aware individualized drug selection.
Genetic Counseling
Action: Genetic CounselingNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Genetic Counseling (NCIT:C15240). NCIT:C15240 is a clinical intervention from the NCI Thesaurus. NCIT:C15240
Offer counseling, family/partner carrier testing and reproductive options across ancestries. Founder variants inform testing but do not exclude disease outside founder populations. Once familial variants are known, prenatal and preimplantation genetic testing are possible. Full-gene testing addresses limitations of founder-only panels.
Show evidence (2 references)
PMID:12108829 SUPPORT Other
"Carrier testing for Tay-Sachs disease should be offered to couples when at least one individual is of Ashkenazi Jewish (carrier frequency 1/30), Pennsylvania Dutch, Southern Louisiana Cajun, or Eastern Quebec French Canadian descent."
Review establishes carrier screening recommendations for high-risk populations including Ashkenazi Jews.
PMID:20301397 SUPPORT Other
"Once both HEXA pathogenic variants have been identified in an affected family member, targeted analysis for the specific familial variants can be used for carrier testing in at-risk relatives."
Family-specific molecular testing supports reproductive counseling.
Miglustat substrate reduction investigation
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: miglustat CHEBI:50381 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses miglustat (CHEBI:50381). CHEBI:50381 is a therapeutic agent from Chemical Entities of Biological Interest.
Platform: Small molecule
Miglustat reduces glycosphingolipid synthesis upstream of GM2. In a 30-patient late-onset Tay-Sachs randomized open-label study, no efficacy difference was observed; two infantile cases also continued neurologic deterioration despite CSF drug exposure. It is not an established disease-modifying treatment for Tay-Sachs.
Show evidence (2 references)
PMID:19346952 SUPPORT Human Clinical
"No differences were observed between the two groups in any efficacy measure, either during the 12-month randomized phase or the full 36 months."
Thirty LOTS patients were randomized 20:10 to miglustat versus no miglustat for 12 months, followed by an open extension; measurable benefit was not established.
PMID:16434676 SUPPORT Human Clinical
"SRT could not arrest the patients' neurologic deterioration."
Two infantile cases illustrate that CSF drug exposure is not sufficient evidence of clinical benefit.
Pharmacological Chaperone Therapy
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: pyrimethamine CHEBI:8673 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses pyrimethamine (CHEBI:8673). CHEBI:8673 is a therapeutic agent from Chemical Entities of Biological Interest.
Platform: Small molecule
Pyrimethamine can stabilize selected residual-activity HexA variants, but the response is allele- and dose-dependent. A four-patient extended pilot showed transient lymphocyte enzyme increases without discernible neurologic or psychiatric benefit. Peripheral enzyme activity does not establish CNS correction.
Show evidence (2 references)
PMID:35865957 SUPPORT Other
"This review summarizes multiple drug development strategies for TSD, including enzyme replacement therapy, pharmaceutical chaperone therapy, substrate reduction therapy, gene therapy, and hematopoietic stem cell replacement therapy."
Review of Tay-Sachs therapeutics establishes pharmaceutical chaperone therapy as one of the active drug-development strategies for the disease.
PMID:25896637 SUPPORT Human Clinical
"However, the observed increase is repeatedly transient and not associated with discernible beneficial neurological or psychiatric effects."
Four-patient extended pilot found transient lymphocyte HexA increases without discernible clinical benefit.
Gene Therapy
Action: Gene TherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Gene Therapy (NCIT:C15238). NCIT:C15238 is a clinical intervention from the NCI Thesaurus. NCIT:C15238
Platform: Gene therapy
Investigational CNS-directed AAV delivery of HEXA and HEXB aims to restore HexA. Expanded access treated two infants in 2022; a subsequent nonrandomized dose-escalation trial treated seven Tay-Sachs and two Sandhoff patients. CSF enzyme activity increased, peaking near 12 weeks before declining, with partial or temporary infantile clinical stabilization. Two of three juvenile participants developed new or worsening dystonia and juvenile enrollment stopped. Vector-associated immune/transaminase responses required corticosteroids. Clinical efficacy remains incomplete and uncontrolled; serum Hex activity is not a CNS surrogate. TSHA-101 uses a different bicistronic AAV9 product from the dual AAVrh8 vectors in these publications.
Mechanism Target:
RESTORES Hexosaminidase A deficiency — Gene delivery supplies HexA subunits and increases residual CNS enzyme activity; it does not correct the germline HEXA sequence.
Show evidence (1 reference)
PMID:40817303 SUPPORT Human Clinical
"Overall, HexA activity levels peaked in most participants at 12 weeks and declined somewhat thereafter, but remained above pretreatment levels throughout the duration of the study"
Nine-patient nonrandomized phase 1/2 trial (seven Tay-Sachs, two Sandhoff; six infantile, three juvenile) showed biochemical activity, with incomplete clinical efficacy.
Show evidence (4 references)
PMID:35145305 SUPPORT Human Clinical
"This study provides early safety and proof-of-concept data in humans for treatment of patients with TSD by AAV gene therapy."
Two-infant expanded-access study provides early feasibility information, not proof of long-term safety or efficacy.
PMID:40817303 SUPPORT Human Clinical
"Overall, HexA activity levels peaked in most participants at 12 weeks and declined somewhat thereafter, but remained above pretreatment levels throughout the duration of the study"
Nine-patient nonrandomized phase 1/2 trial (seven Tay-Sachs, two Sandhoff; six infantile, three juvenile) showed biochemical activity, with incomplete clinical efficacy.
PMID:40817303 SUPPORT Human Clinical
"Interestingly, two of three juvenile patients noted new or worsening dystonia, and the third experienced unexpected progression of the neurologic manifestations of their GM2 gangliosidosis."
Juvenile toxicity led to exclusion from further recruitment and outcome analysis; risk cannot be generalized across products or all delivery routes.
+ 1 more reference
Venglustat substrate reduction investigation
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: venglustat Relation: this treatment uses this therapeutic agent This treatment uses venglustat.
Platform: Small molecule
AMETHIST reduced CSF GM2 by 47.6% versus 11.3% with placebo over 104 weeks but did not improve the clinical endpoints assessed. The trial demonstrates biochemical target engagement without established clinical efficacy in late-onset GM2 gangliosidosis.
Show evidence (1 reference)
PMID:41108138 SUPPORT Human Clinical
"In adults with late-onset GM2 gangliosidoses, oral venglustat decreased CSF GM2 concentrations but without clinical improvement in the endpoints assessed."
AMETHIST randomized 40 to venglustat and 19 to placebo; 16 additional patients entered a separate open-label basket cohort.
N-acetyl-L-leucine investigation
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: N-acetyl-L-leucine CHEBI:17786 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses N-acetyl-L-leucine (CHEBI:17786). CHEBI:17786 is a therapeutic agent from Chemical Entities of Biological Interest.
Platform: Small molecule
A phase IIb open-label, rater-blinded treatment/washout study met its short-term functional endpoint in a mixed Tay-Sachs/Sandhoff cohort. The study provides Class IV evidence; long-term disease modification and the disease-specific mechanism remain unresolved.
Show evidence (1 reference)
PMID:36456200 SUPPORT Human Clinical
"This study provides Class IV evidence that NALL improves outcomes for patients with GM2 gangliosidoses."
Open-label, rater-blinded six-week treatment/washout study enrolled 30 mixed GM2 patients; short-term functional signals do not establish durable disease modification.
Nizubaglustat investigation
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Platform: Small molecule
Oral AZ-3102 is being studied in randomized and extension trials in GM2 gangliosidosis. Registry entries establish investigational status and study design; they do not establish a clinical benefit or a validated Tay-Sachs-specific mechanism.
Show evidence (1 reference)
clinicaltrials:NCT07082543 SUPPORT Other
"An 18-month double-blind, randomized, placebo-controlled, multicenter, Phase 3 study to evaluate the safety and efficacy of oral nizubaglustat (AZ-3102) in late-infantile and juvenile forms of GM1 gangliosidosis or GM2 gangliosidosis"
ClinicalTrials.gov study purpose; live status and enrollment were checked on 2026-09-04. Registration does not establish benefit.
🔬

Biochemical Markers

6
Hexosaminidase A Activity (Decreased)
Context: Absent or low activity in serum, leukocytes or fibroblasts, with HexB preserved; synthetic-substrate results depend on allele and assay. B1 alleles can cause false-negative results, whereas pseudodeficiency causes false-positive results.
Pathograph Readouts
Readout Of Hexosaminidase A deficiency Negative Diagnostic
The low enzyme activity state reports HexA deficiency; assay-specific residual activity is not a universal clinical severity threshold.
Show evidence (1 reference)
PMID:40710901 SUPPORT Other
"Diagnosis is based on enzymatic testing showing reduced or absent hexosaminidase A activity, confirmed by genetic testing."
Review states that reduced or absent Hexosaminidase A activity is the enzymatic diagnostic basis for Tay-Sachs disease.
Show evidence (1 reference)
PMID:40710901 SUPPORT Other
"Diagnosis is based on enzymatic testing showing reduced or absent hexosaminidase A activity, confirmed by genetic testing."
Supports reduced Hexosaminidase A activity as the diagnostic biochemical abnormality.
GM2 Ganglioside (Elevated)
Context: Accumulates in brain tissue
Pathograph Readouts
Readout Of GM2 ganglioside accumulation in neurons Positive
Tissue GM2 measures storage burden; this is not a routine standalone diagnostic test or validated clinical surrogate.
Show evidence (1 reference)
PMID:22025593 SUPPORT Human Clinical
"G(M2) gangliosidoses are caused by an inherited deficiency of lysosomal β-hexosaminidase and result in ganglioside accumulation in the brain."
Natural-history data link beta-hexosaminidase deficiency to ganglioside accumulation in the brain.
Show evidence (1 reference)
PMID:22025593 SUPPORT Human Clinical
"G(M2) gangliosidoses are caused by an inherited deficiency of lysosomal β-hexosaminidase and result in ganglioside accumulation in the brain."
Supports elevated GM2/ganglioside storage in affected brain tissue.
Plasma GM2 34:1 and GM2/GM3 ratio (INCREASED)
Context: Candidate plasma diagnostic and monitoring biomarkers in a small mixed GM2 cohort; 100% case-control discrimination must not be generalized to unselected clinical populations.
Pathograph Readouts
Correlates With GM2 ganglioside accumulation in neurons
Plasma lipid abundance is an indirect systemic marker, not a direct measurement of neuronal GM2 or a validated surrogate for neurologic benefit.
Show evidence (1 reference)
PMID:36709536 SUPPORT Human Clinical
"GM234:1 and GM234:1/GM334:1 ratio discriminated patients from controls with 100% sensitivity and specificity."
Perfect discrimination was in the study sample of 19 GM2 cases (nine Tay-Sachs) and 20 controls; independent diagnostic validation and therapeutic-surrogate validity are not established.
Show evidence (1 reference)
PMID:36709536 SUPPORT Human Clinical
"GM234:1 and GM234:1/GM334:1 ratio discriminated patients from controls with 100% sensitivity and specificity."
Perfect discrimination was in the study sample of 19 GM2 cases (nine Tay-Sachs) and 20 controls; independent diagnostic validation and therapeutic-surrogate validity are not established.
CSF GM2 concentration (INCREASED)
Context: Investigational pharmacodynamic marker; AMETHIST showed reduction without correlated clinical improvement.
Pathograph Readouts
Pharmacodynamic Marker Of GM2 ganglioside accumulation in neurons Pharmacodynamic
Reflects substrate-reduction target engagement; change is not established to predict clinical benefit.
Show evidence (1 reference)
PMID:41108138 SUPPORT Human Clinical
"Decreased CSF GM2 concentrations did not correlate with clinical endpoints."
The randomized trial directly limits use of CSF GM2 as a clinical efficacy surrogate.
Show evidence (1 reference)
PMID:41108138 SUPPORT Human Clinical
"In adults with late-onset GM2 gangliosidoses, oral venglustat decreased CSF GM2 concentrations but without clinical improvement in the endpoints assessed."
AMETHIST randomized 40 to venglustat and 19 to placebo; 16 additional patients entered a separate open-label basket cohort.
Cerebellar myo-inositol (INCREASED)
Context: Cross-sectional MRS finding in a small mixed late-onset GM2 cohort.
Pathograph Readouts
Correlates With Neuroinflammation and Astrogliosis
Nonspecific neurometabolic correlate; prospective outcome and treatment-response validity remain unresolved.
Show evidence (1 reference)
PMID:34226107 SUPPORT Human Clinical
"an increase in mI indicates possible neuroinflammation in LOGG (more so within the LOTS subvariant)."
MRI/MRS in seven LOTS and three late-onset Sandhoff patients plus seven controls provides a nonspecific cross-sectional proxy, not direct histology or causal confirmation.
Show evidence (1 reference)
PMID:34226107 SUPPORT Human Clinical
"an increase in mI indicates possible neuroinflammation in LOGG (more so within the LOTS subvariant)."
MRI/MRS in seven LOTS and three late-onset Sandhoff patients plus seven controls provides a nonspecific cross-sectional proxy, not direct histology or causal confirmation.
Cerebellar N-acetylaspartate (DECREASED)
Context: Cross-sectional MRS finding in a small mixed late-onset GM2 cohort.
Pathograph Readouts
Correlates With Neuronal injury
Nonspecific neurometabolic correlate; prospective outcome and treatment-response validity remain unresolved.
Show evidence (1 reference)
PMID:34226107 SUPPORT Human Clinical
"The decrease of NAA in the cerebellum suggests that, in addition to cerebellar atrophy, there is ongoing impaired neuronal function and/or loss"
MRI/MRS in seven LOTS and three late-onset Sandhoff patients plus seven controls provides a nonspecific cross-sectional proxy, not direct histology or causal confirmation.
Show evidence (1 reference)
PMID:34226107 SUPPORT Human Clinical
"The decrease of NAA in the cerebellum suggests that, in addition to cerebellar atrophy, there is ongoing impaired neuronal function and/or loss"
MRI/MRS in seven LOTS and three late-onset Sandhoff patients plus seven controls provides a nonspecific cross-sectional proxy, not direct histology or causal confirmation.
🔬

Diagnosis

2
Combined enzyme and molecular diagnosis
Confirm deficient HexA with preserved or elevated HexB and biallelic pathogenic or likely pathogenic HEXA variants. Sequence HEXA, then consider deletion/duplication testing if zero or one allele is identified; broader genomic testing can resolve atypical presentations. VUS findings alone do not establish diagnosis.
Show evidence (1 reference)
PMID:20301397 SUPPORT Other
"The diagnosis of a HEXA disorder is established in a proband with abnormally low HEX A activity on enzyme testing and biallelic pathogenic variants in HEXA identified by molecular genetic testing."
GeneReviews establishes combined biochemical and molecular diagnosis.
Distinguish pseudodeficiency and substrate-specific B1 alleles
Pseudodeficiency impairs hydrolysis of artificial substrates while preserving natural GM2 catabolism, producing false-positive biochemical results. B1 alleles can retain artificial-substrate activity but fail to hydrolyze natural GM2, producing false-negative results in some assays. Molecular testing resolves discordant biochemical and clinical findings.
Show evidence (2 references)
PMID:20301397 SUPPORT Other
"Pseudodeficiency refers to an in vitro phenomenon caused by specific HEXA variants that renders the enzyme unable to process the synthetic (but not the natural) GM2 substrates, and leads to false positive enzyme testing results."
Synthetic-substrate pseudodeficiency is not disease-causing GM2 storage.
PMID:10571007 SUPPORT Other
"The few exceptions to this generalization are missense mutations at two codons in HEXA, causing the unique biochemical phenotype known as the B1-variant, and one codon in both the HEXB and GM2A genes."
B1 alleles alter substrate-specific function; detailed assay interpretation was checked in GeneReviews.
📈

Progression

3
Age of onset
Age: All ages
Orphanet records onset across all ages, consistent with infantile, juvenile, and late-onset clinical subtypes.
Show evidence (1 reference)
ORPHA:845 SUPPORT Other
"Age of onset: All ages"
Orphanet's natural-history section records Tay-Sachs disease onset as occurring across all ages.
Infantile progression
Weakness and visual inattentiveness emerge at 3–6 months, followed by developmental plateau and regression. Seizures become common by 12 months; feeding and respiratory complications influence survival.
Show evidence (1 reference)
PMID:20301397 SUPPORT Other
"Seizures are common by 12 months with further deterioration in the second year of life and death occurring between ages two and three years with some survival to five to seven years."
Infantile progression and survival vary with stage and supportive care; a fixed death-by-four rule is inaccurate.
Juvenile and late-onset progression
Later-onset forms vary even within families. Juvenile disease includes cognitive decline, spasticity and bulbar dysfunction; late-onset disease can begin with weakness, cerebellar signs or psychiatric symptoms.
Show evidence (2 references)
PMID:20301397 SUPPORT Other
"Spasticity, dysphagia, and seizures are present by the end of the first decade of life, with death within the second decade of life, usually by aspiration."
GeneReviews supports juvenile motor/bulbar progression and aspiration complications.
PMID:20301397 SUPPORT Other
"Late-onset TSD presents in older teens or young adults with a slowly progressive spectrum of neurologic symptoms including lower-extremity weakness with muscle atrophy, dysarthria, incoordination, tremor, mild spasticity and/or dystonia, and psychiatric manifestations including acute psychosis."
The late-onset spectrum spans cerebellar, motor, and neuropsychiatric dysfunction.
📊

Prevalence

3
Ashkenazi Jewish population
Birth Prevalence 28.571429 per 100,000 1–9 per 10,000 (births)
Tay-Sachs disease has historically been far more common in Ashkenazi Jewish populations than in the general population. Community carrier screening and prenatal diagnosis programs reduced incidence in Jewish populations in the United States and Canada by more than 90%.
Show evidence (2 references)
PMID:11500789 SUPPORT Human Clinical
"In the Ashkenazi Jewish population the disease incidence is about 1 in every 3,500 newborns and the carrier frequency is 1 in every 29 individuals."
This study directly reports the historically high Tay-Sachs disease incidence in the Ashkenazi Jewish population.
PMID:11216898 SUPPORT Human Clinical
"In the United States and Canada, the incidence of TSD in the Jewish population has been reduced by more than 90%."
This review shows that the historically high disease burden in Jewish populations fell substantially after population carrier screening.
Worldwide live births
Birth Prevalence 0.1–0.9 per 100,000 1–9 per 1,000,000 (births)
Orphanet reports a worldwide prevalence-at-birth class of 1-9 per 1,000,000.
Show evidence (1 reference)
ORPHA:845 SUPPORT Other
"1-9 / 1 000 000 | Worldwide | Prevalence at birth | PMID:0870684507"
The Orphanet epidemiology table provides the worldwide prevalence-at-birth class for Tay-Sachs disease.
Specific population live births
Birth Prevalence 10.0–50.0 per 100,000 1–9 per 10,000 (births)
Orphanet records a higher prevalence-at-birth class in a specific population.
Show evidence (1 reference)
ORPHA:845 SUPPORT Other
"1-5 / 10 000 | Specific population | Prevalence at birth | PMID:20301397"
The Orphanet epidemiology table records a higher prevalence-at-birth class for a specific population.
🔀

Differential Diagnoses

4

Conditions with similar clinical presentations that must be differentiated from Tay-Sachs Disease:

Sandhoff disease
Overlapping Features Related GM2 storage disorder with overlapping infantile, juvenile and adult neurological phenotypes.
Distinguishing Features
  • Biallelic HEXB variants reduce both HexA and HexB; Tay-Sachs primarily reduces HexA with preserved or increased HexB.
  • Visceral involvement may be more prominent in Sandhoff disease, but enzyme and molecular testing determine the diagnosis.
Show evidence (1 reference)
PMID:10571007 SUPPORT Other
"A deficiency of any one of these proteins leads to storage of the ganglioside, primarily in the lysosomes of neuronal cells, and one of the three forms of GM2-gangliosidosis, Tay-Sachs disease, Sandhoff disease or the AB-variant form."
The review establishes three distinct genetic etiologies converging on GM2 storage.
GM2 activator deficiency
Overlapping Features The GM2A-related AB variant can resemble Tay-Sachs despite normal measured HexA and HexB activity.
Distinguishing Features
  • GM2 activator deficiency impairs presentation of membrane GM2 to HexA; biallelic GM2A variants establish the molecular cause.
Show evidence (1 reference)
PMID:8900233 SUPPORT Human Clinical
"Lysosomal degradation of ganglioside GM2 by beta-hexosaminidase A (hex A) requires the presence of the GM2 activator protein (GM2AP) as an essential cofactor."
Normal artificial-substrate enzyme measurements do not exclude GM2A-related disease.
Other disorders with a cherry-red macula
Overlapping Features GM1 gangliosidosis, other sphingolipidoses and central retinal artery occlusion can also produce a cherry-red appearance.
Distinguishing Features
  • A cherry-red spot is not diagnostic in isolation; clinical course, visceral findings, enzyme assays and molecular testing distinguish etiologies.
Show evidence (1 reference)
PMID:19820796 SUPPORT Human Clinical
"It is also seen in others neurometabolic diseases as well as in central retinal artery occlusion."
The Tay-Sachs case report explicitly states that the retinal finding is not specific.
Adult motor neuron and cerebellar disorders
Overlapping Features Late-onset Tay-Sachs can resemble spinal muscular atrophy, amyotrophic lateral sclerosis or inherited ataxia.
Distinguishing Features
  • A mixed pattern of proximal neurogenic weakness, cerebellar signs and psychiatric or cognitive features should prompt HexA and HEXA testing.
  • Marked cerebellar atrophy can occur even when the presenting complaint is weakness or psychiatric illness.
Show evidence (1 reference)
PMID:31995250 SUPPORT Human Clinical
"The main brain magnetic resonance imaging feature was cerebellar atrophy, even in patients without cerebellar symptoms."
Adult GM2 case series plus literature review supports the heterogeneous pattern; GeneReviews differential diagnosis was also checked.
📊

Related Datasets

3
Bulk RNA-seq of brain samples from fetuses with Tay-Sachs Disease geo:GSE224860
Bulk RNA-seq from regional fetal brain tissue with biallelic pathogenic HEXA variants and controls. The publication studied two affected sibling fetuses and two controls at 17 weeks; 19 samples are regional libraries, not 19 independent fetuses. GM2 storage and transcriptomic differences suggest developmental perturbation, with family, genotype and regional confounding.
human BULK RNA SEQ n=19
PMID:36700853
GEO metadata verified on 2026-09-04. Publication: PMID:36700853. No raw-data reanalysis was performed for this review; multiple tissue regions must not be treated as independent donors.
Modeling Tay-Sachs Disease in Astrocyte-Like Cells Reveals Significant Changes in the Transcriptomic Profile geo:GSE329156
RNA-seq study of a Tay-Sachs astrocyte-like cell model. Its six samples describe a cellular transcriptomic experiment; they do not establish human astrocyte state abundance, neuronal injury causality or population prevalence.
human BULK RNA SEQ n=6
GEO metadata verified on 2026-09-04. No associated peer-reviewed publication was identified in the checked record; no raw-data analysis was performed.
Autophagy and lysosomal dysfunction in Tay Sachs disease are restored by mTOR modulation geo:GSE184906
Expression profiling associated with studies of autophagy, mTOR signaling and lysosomal integrity in Tay-Sachs/GM2 patient fibroblasts. Cellular findings and partial L-arginine rescue do not establish a neuronal or clinical therapeutic effect.
human MICROARRAY n=12
PMID:34831346
GEO metadata verified on 2026-09-04; the 12 expression samples are not a clinical trial or a 12-patient efficacy cohort.
🔬

Clinical Trials

9
NCT04798235 PHASE_I ACTIVE_NOT_RECRUITING
Phase 1/2 open-label study evaluating intrathecal TSHA-101 AAV9 gene therapy carrying HEXA and HEXB for infantile-onset GM2 gangliosidosis; ClinicalTrials.gov currently lists the study as active, not recruiting.
Target Phenotypes: Developmental Regression HP:0002376 Human Phenotype Ontology (HP) Relation: this clinical trial targets this phenotype This clinical trial targets Developmental Regression (HP:0002376). HP:0002376 is a phenotype from the Human Phenotype Ontology. Seizures HP:0001250 Human Phenotype Ontology (HP) Relation: this clinical trial targets this phenotype This clinical trial targets Seizures, annotated with Seizure (HP:0001250). HP:0001250 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
clinicaltrials:NCT04798235 SUPPORT Other
"The primary purpose of the current study is to assess the safety and tolerability of TSHA101 administered via IT injection."
ClinicalTrials.gov record supports TSHA-101 as an intrathecal gene-therapy trial for infantile-onset GM2 gangliosidosis.
NCT04669535 PHASE_I TERMINATED
Terminated open-label AXO-AAV-GM2 dose-escalation study, with nine treated participants and published results (PMID:40817303). Stage 2 did not proceed after sponsor withdrawal/funding loss. New or worsening dystonia in juvenile patients led to exclusion of further juvenile enrollment during stage 1; infantile biochemical and partial clinical responses remain uncontrolled.
Target Phenotypes: Developmental Regression HP:0002376 Human Phenotype Ontology (HP) Relation: this clinical trial targets this phenotype This clinical trial targets Developmental Regression (HP:0002376). HP:0002376 is a phenotype from the Human Phenotype Ontology. Seizures HP:0001250 Human Phenotype Ontology (HP) Relation: this clinical trial targets this phenotype This clinical trial targets Seizures, annotated with Seizure (HP:0001250). HP:0001250 is a phenotype from the Human Phenotype Ontology.
Show evidence (3 references)
clinicaltrials:NCT04669535 SUPPORT Other
"AXO-AAV-GM2 is an investigational gene therapy that aims to restore HexA function by introducing a functional copy of the HEXA and HEXB genes via co-administration of two vectors utilizing the neurotropic adeno-associated virus recombinant human 8 serotype (AAVrh.8) capsid carrying the human..."
ClinicalTrials.gov record supports AXO-AAV-GM2 as a dual-vector HEXA/HEXB gene-therapy trial relevant to Tay-Sachs disease.
PMID:40817303 SUPPORT Human Clinical
"Overall, HexA activity levels peaked in most participants at 12 weeks and declined somewhat thereafter, but remained above pretreatment levels throughout the duration of the study"
Nine-patient nonrandomized phase 1/2 trial (seven Tay-Sachs, two Sandhoff; six infantile, three juvenile) showed biochemical activity, with incomplete clinical efficacy.
PMID:40817303 SUPPORT Human Clinical
"Interestingly, two of three juvenile patients noted new or worsening dystonia, and the third experienced unexpected progression of the neurologic manifestations of their GM2 gangliosidosis."
Juvenile toxicity led to exclusion from further recruitment and outcome analysis; risk cannot be generalized across products or all delivery routes.
NCT06614569 NOT_APPLICABLE ACTIVE_NOT_RECRUITING
Observational five-year follow-up of participants previously dosed with AXO-AAV-GM2; estimated enrollment seven. This follows the original treatment cohort and is not a second independent efficacy trial.
Show evidence (1 reference)
clinicaltrials:NCT06614569 SUPPORT Other
"This study is to continue Long-Term Follow-Up of Patients who were previously treated with AXO-AAV-GM2 Gene Therapy as treatment for Tay-Sachs or Sandhoff Disease to follow the subjects through 5 years after their initial gene therapy treatment."
ClinicalTrials.gov study purpose; live status and enrollment were checked on 2026-09-04. Registration does not establish benefit.
NCT04221451 PHASE_III TERMINATED
AMETHIST enrolled 75 across a randomized adult late-onset GM2 cohort (40 venglustat, 19 placebo) and a separate 16-participant open-label basket. Published 104-week findings show CSF GM2 reduction without improvement on the measured clinical endpoints.
Show evidence (2 references)
clinicaltrials:NCT04221451 SUPPORT Other
"Primary population (adult participants with late-onset GM2 gangliosidosis): To assess the efficacy and pharmacodynamics (PD) of daily oral dosing of venglustat when administered over a 104-week period"
ClinicalTrials.gov study purpose; live status and enrollment were checked on 2026-09-04. Registration does not establish benefit.
PMID:41108138 SUPPORT Human Clinical
"In adults with late-onset GM2 gangliosidoses, oral venglustat decreased CSF GM2 concentrations but without clinical improvement in the endpoints assessed."
AMETHIST randomized 40 to venglustat and 19 to placebo; 16 additional patients entered a separate open-label basket cohort.
NCT03759665 PHASE_II COMPLETED
N-acetyl-L-leucine open-label, rater-blinded study enrolled 30 patients with Tay-Sachs or Sandhoff disease. The parent study and exploratory extension assess different time horizons; the short-term Class IV functional signal does not establish long-term disease modification.
Show evidence (2 references)
clinicaltrials:NCT03759665 SUPPORT Other
"The Extension Phase evaluates the long-term safety and efficacy of IB1001 for the neuroprotective, disease-modifying treatment of GM2 Gangliosidosis. The Extension Phase was considered exploratory."
ClinicalTrials.gov study purpose; live status and enrollment were checked on 2026-09-04. Registration does not establish benefit.
PMID:36456200 SUPPORT Human Clinical
"This study provides Class IV evidence that NALL improves outcomes for patients with GM2 gangliosidoses."
Open-label, rater-blinded six-week treatment/washout study enrolled 30 mixed GM2 patients; short-term functional signals do not establish durable disease modification.
NCT01102686 PHASE_I COMPLETED
Combined phase 1/2 pyrimethamine safety/biochemical investigation in late-onset GM2 disease. The registry estimated 20 participants; the published initial study enrolled nine, with six eligible for the main analysis. Enzyme increases have not established neurological efficacy.
Show evidence (1 reference)
clinicaltrials:NCT01102686 SUPPORT Other
"The objectives of this clinical trial are to assess the safety and tolerability, as well as efficacy, of a stepwise dosing regimen of pyrimethamine, starting at 25 mg/day, given as a single dose daily for 4 weeks in patients affected with chronic Tay-Sachs or Sandhoff variants."
ClinicalTrials.gov study purpose; live status and enrollment were checked on 2026-09-04. Registration does not establish benefit.
NCT05758922 PHASE_II COMPLETED
RAINBOW randomized, double-blind, 12-week nizubaglustat (AZ-3102) study in GM2 gangliosidosis and Niemann-Pick C. The registered safety/pharmacokinetic objectives should not be mistaken for demonstrated neurological efficacy.
Show evidence (1 reference)
clinicaltrials:NCT05758922 SUPPORT Other
"This phase 2 is a randomized, double-blind, placebo controlled, 12 weeks study with daily oral administration of AZ-3102 aiming to evaluate the safety and pharmacokinetic (PK) profile in GM2 Gangliosidosis and Niemann-Pick type C disease (NP-C) patients."
ClinicalTrials.gov study purpose; live status and enrollment were checked on 2026-09-04. Registration does not establish benefit.
NCT07399704 PHASE_II RECRUITING
Open-label long-term nizubaglustat follow-up. GM2 participants enter as prior RAINBOW participants (cohort 1); the separate cohort transitioning from miglustat is for Niemann-Pick C, not treatment-naive GM2 disease. Estimated total enrollment 21.
Show evidence (1 reference)
clinicaltrials:NCT07399704 SUPPORT Other
"This open-label study aims to gather long-term safety, tolerability, PK, biomarker, and clinical efficacy data relating to daily administration of Nizubaglustat in participants previously enrolled in the Phase 2 RAINBOW study (Cohort 1)."
ClinicalTrials.gov study purpose; live status and enrollment were checked on 2026-09-04. Registration does not establish benefit.
NCT07082543 PHASE_III ACTIVE_NOT_RECRUITING
Eighteen-month randomized, placebo-controlled nizubaglustat study in late-infantile and juvenile GM1/GM2 gangliosidosis; estimated enrollment 75. This GMx subprotocol belongs to master protocol NCT07054515. The master record remains recruiting for its broader disease program; that does not imply this GM1/GM2 subprotocol is recruiting.
Show evidence (1 reference)
clinicaltrials:NCT07082543 SUPPORT Other
"An 18-month double-blind, randomized, placebo-controlled, multicenter, Phase 3 study to evaluate the safety and efficacy of oral nizubaglustat (AZ-3102) in late-infantile and juvenile forms of GM1 gangliosidosis or GM2 gangliosidosis"
ClinicalTrials.gov study purpose; live status and enrollment were checked on 2026-09-04. Registration does not establish benefit.
🧫

Experimental Models

3
GM2-loaded neuronal cultures PRIMARY_CELL_CULTURE
GM2 loading with PERK inhibition and calcineurin/CHOP knockdown.
Pathograph links
GM2-associated PERK activation partially recapitulates fidelity: moderate observes: cellular
Limitations: Experimental GM2 delivery does not reproduce the complete HEXA-genotype-to-ER trafficking route.
Show evidence (2 references)
PMID:30389374 SUPPORT In Vitro
"We found that ER GM2 accumulation in cultured neurons induces luminal Ca2+ depletion, which in turn activates PERK (protein kinase RNA [PKR]-like ER kinase), one of three UPR sensors."
Cultured-neuron GM2 loading supports an ER calcium/PERK mechanism; lysosomal-to-ER trafficking and necessity in human Tay-Sachs are unresolved.
+ 1 more reference
Patient-derived GM2 skin fibroblasts PRIMARY_CELL_CULTURE
Tay-Sachs and Sandhoff fibroblast lysosomal, mTOR and autophagic-flux assays.
Pathograph links
Impaired autophagic flux and lysosomal integrity partially recapitulates fidelity: moderate observes: cellular
Limitations: Mixed genetic diagnoses and non-neuronal cells; no demonstrated clinical benefit of L-arginine.
Show evidence (2 references)
PMID:34831346 SUPPORT In Vitro
"GM2 fibroblasts showed diminished mTOR signalling with reduced basal mTOR activity."
Patient-derived Tay-Sachs and Sandhoff fibroblasts reveal an autophagy/lysosomal phenotype; neuronal in vivo generalization is unproven.
+ 1 more reference
Sandhoff cerebral organoids with isogenic correction ORGANOID
HEXB-corrected isogenic organoids compared with patient-derived Sandhoff organoids.
Pathograph links
Prenatal neurodevelopmental perturbation partially recapitulates fidelity: low observes: tissue
Limitations: Sandhoff genotype, not a Tay-Sachs organoid model; developmental effects do not prove irreversible prenatal damage in all patients.
Show evidence (1 reference)
PMID:29358305 SUPPORT In Vitro
"The Sandhoff disease organoids, but not the HEXB-corrected organoids, accumulated GM2 ganglioside and exhibited increased size and cellular proliferation compared with the HEXB-corrected organoids."
Isogenic rescue supports a developmental effect in a related GM2 disorder.
🐁

Animal Models

4
Hexa knockout mouse
Models biochemical storage with limited clinical fidelity.
Species
Mouse
Genotype
Hexa-null
Publication
PMID:7610760
Pathograph links
GM2 ganglioside accumulation in neurons partially recapitulates fidelity: moderate observes: organism
Limitations: Murine sialidase bypass restricts storage and disease severity.
Show evidence (1 reference)
PMID:7610760 SUPPORT Model Organism
"Storage neurons were absent in the olfactory bulb, cerebellar cortex and spinal anterior horns."
Hexa-null mice reproduce substrate storage but have markedly different regional vulnerability from severe human disease.
Hexa/Neu3 double-knockout mouse
Severe storage, Purkinje loss and inflammatory mouse model. A separate study documented reduced trabecular bone measures; this does not establish human osteoporosis penetrance.
Species
Mouse
Genotype
Hexa-null; Neu3-null
Publication
PMID:32951593
Pathograph links
Neuroinflammation and Astrogliosis partially recapitulates fidelity: moderate observes: organism
Limitations: Additional Neu3 loss alters physiology; it does not fully reproduce every human phenotype.
Show evidence (2 references)
PMID:32951593 SUPPORT Model Organism
"We found elevated levels of pro-inflammatory cytokine and chemokine transcripts, such as Ccl2, Ccl3, Ccl4, and Cxcl10 and also extensive microglial and astrocyte activation and proliferation, accompanied by peripheral blood mononuclear cell infiltration in the vicinity of neurons and oligodendrocytes."
Hexa/Neu3 double-knockout mice demonstrate the inflammatory branch; this is not direct human causal evidence.
+ 1 more reference
GM2 ganglioside accumulation in neurons partially recapitulates fidelity: moderate observes: organism
Limitations: Brain-wide storage is only obtained by also deleting Neu3, a sialidase not mutated in human Tay-Sachs disease, so the genotype is a compensating construct rather than a genocopy; results obtained by manipulating Neu3 in this background test a pathway human patients do not depend on in the same way.
Readouts
Brain GM2 ganglioside content
Direction: INCREASED
Interpretation: Biochemical measurement of the stored substrate in double-knockout brain tissue.
Show evidence (1 reference)
PMID:41819452 SUPPORT Model Organism
"Abnormal GM2 accumulation was revealed in the brains of Hexa-/-Neu3-/- mice using thin-layer chromatography and mass spectrometric analyses."
Thin-layer chromatography and mass spectrometry quantify the accumulated substrate directly, rather than inferring storage from histology.
Show evidence (1 reference)
PMID:41819452 SUPPORT Model Organism
"Hence, Hexa-/-Neu3-/- mice, which mimic the neuropathological and clinical abnormalities observed in patients, were considered the early-onset TSD model."
The authors treat this genotype as their early-onset Tay-Sachs storage model on the strength of brain-wide GM2, astrogliosis, Purkinje cell loss and a motor phenotype. This is a model-level claim about fidelity, not human causal evidence.
Show evidence (1 reference)
PMID:39514043 SUPPORT Model Organism
"Micro-computed tomography and analysis show reduced trabecular bone volume, mineral density, number, and thickness in Hexa-/-Neu3-/- mice."
Five-month double-knockout mouse bone phenotype; direct GM2 effects are not separated from genotype, mobility, growth or systemic factors.
Gly269Ser knock-in/Neu3-null mouse
Allele-specific model with GM2 turnover but unexpectedly severe survival phenotype.
Species
Mouse
Genotype
Hexa Gly269Ser knock-in; Neu3-null
Publication
PMID:40916664
Pathograph links
Residual but insufficient HexA activity in late-onset disease partially recapitulates fidelity: low observes: organism
Limitations: Both knock-in and knockout combinations died by 24 weeks; not a faithful chronic LOTS clinical model.
Show evidence (1 reference)
PMID:40916664 SUPPORT Model Organism
"Although survival and behavioural phenotypes did not differ between KO and KI models, the KI model had substantial Hexa mRNA and evidence of GM2 turnover."
G269S/Neu3-null mice retain a biochemical partial-deficiency feature but do not reproduce a chronic human late-onset survival course.
Naturally occurring Jacob sheep Tay-Sachs disease
Large-brain storage model with glial/myelin pathology and gene-delivery studies.
Species
Sheep
Genotype
HEXA exon-11 splice-disrupting variant
Publication
PMID:20817517
Pathograph links
GM2 ganglioside accumulation in neurons partially recapitulates fidelity: moderate observes: organism
Limitations: Species and route/dose differences constrain human translation; up to five years is the maximum reported follow-up.
Show evidence (2 references)
PMID:20817517 SUPPORT Model Organism
"A missense mutation was found in the hexa cDNA of the affected sheep caused by a single nucleotide change at the end of exon 11 resulting in skipping of exon 11."
Naturally occurring Jacob sheep disease has a splice-disrupting HEXA variant and deficient HexA.
+ 1 more reference
{ }

Source YAML

click to show 
name: Tay-Sachs Disease
creation_date: '2026-01-06T04:44:07Z'
description: >-
  Tay-Sachs disease is an autosomal recessive GM2 gangliosidosis caused by
  biallelic pathogenic variants in HEXA, which encodes the alpha subunit of the
  lysosomal enzyme beta-hexosaminidase A. Deficient hexosaminidase A activity
  blocks degradation of GM2 ganglioside, which accumulates progressively within
  neurons and triggers neuroinflammation and neuronal death. The classic
  infantile form presents with developmental regression, hypotonia, an exaggerated
  startle response, a macular cherry-red spot, seizures, and blindness, while
  juvenile and late-onset forms with residual enzyme activity follow a more
  protracted course dominated by ataxia and motor neuron involvement.
category: Genetic
parents:
- Lysosomal Storage Disorder
- Neurodegenerative Disease
disease_term:
  preferred_term: Tay-Sachs disease
  term:
    id: MONDO:0010100
    label: Tay-Sachs disease
mappings:
  mondo_mappings:
  - term:
      id: MONDO:0010100
      label: Tay-Sachs disease
    mapping_predicate: skos:exactMatch
    mapping_source: ORPHA:845
    mapping_justification: Orphanet lists MONDO:0010100 as an exact cross-reference for Tay-Sachs disease.
    consistency:
    - reference: ORPHA:845
      consistent: CONSISTENT
      notes: "MONDO:0010100 | Exact"
external_assertions:
- name: Orphanet Tay-Sachs disease record
  source: Orphanet
  assertion_type: structured_disease_record
  external_id: ORPHA:845
  url: http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=845
  description: >-
    Orphanet curates ORPHA:845 as the Tay-Sachs disease disorder record and
    provides structured synonyms, definition, inheritance, natural history,
    epidemiology, HPO phenotype frequencies, and cross-references.
  notes: >-
    ORPHA:845 lists exact cross-references to MONDO:0010100, MeSH:D013661,
    MedDRA:10043147, OMIM:272800, and UMLS:C0039373, with
    narrower ICD-10:E75.0 and ICD-11:5C56.00 rows.
  evidence:
  - reference: ORPHA:845
    reference_title: "Tay-Sachs disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "ORPHA:845  Tay-Sachs disease"
    explanation: The structured cache heading identifies ORPHA:845 as the Orphanet Tay-Sachs disease record.
  - reference: ORPHA:845
    reference_title: "Tay-Sachs disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "MONDO:0010100 | Exact"
    explanation: Orphanet maps ORPHA:845 exactly to the MONDO disease identifier used by this entry.
  - reference: ORPHA:845
    reference_title: "Tay-Sachs disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "OMIM:272800 | Exact"
    explanation: Orphanet lists OMIM:272800 as an exact cross-reference for Tay-Sachs disease.
  - reference: ORPHA:845
    reference_title: "Tay-Sachs disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "MeSH:D013661 | Exact"
    explanation: Orphanet lists MeSH:D013661 as an exact cross-reference for Tay-Sachs disease.
inheritance:
- name: Autosomal recessive inheritance
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  description: >-
    When both parents carry a pathogenic HEXA variant, each conception has a 25% affected, 50% carrier and 25% unaffected noncarrier probability. Heterozygous carriers are asymptomatic.
  evidence:
  - reference: ORPHA:845
    reference_title: "Tay-Sachs disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Autosomal recessive"
    explanation: Orphanet directly lists autosomal recessive inheritance for ORPHA:845.
  - reference: PMID:20301397
    reference_title: HEXA Disorders.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier.
    explanation: >-
      Mendelian recurrence applies when both parents are confirmed carriers.
progression:
- phase: Age of onset
  age_range: All ages
  notes: Orphanet records onset across all ages, consistent with infantile, juvenile, and late-onset clinical subtypes.
  evidence:
  - reference: ORPHA:845
    reference_title: "Tay-Sachs disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Age of onset: All ages"
    explanation: Orphanet's natural-history section records Tay-Sachs disease onset as occurring across all ages.
- phase: Infantile progression
  notes: >-
    Weakness and visual inattentiveness emerge at 3–6 months, followed by developmental plateau and regression. Seizures become common by 12 months; feeding and respiratory complications influence survival.
  evidence:
  - reference: PMID:20301397
    reference_title: HEXA Disorders.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Seizures are common by 12 months with further deterioration in the second year of life and death occurring between ages two and three years with some survival to five to seven years.
    explanation: >-
      Infantile progression and survival vary with stage and supportive care; a fixed death-by-four rule is inaccurate.
- phase: Juvenile and late-onset progression
  notes: >-
    Later-onset forms vary even within families. Juvenile disease includes cognitive decline, spasticity and bulbar dysfunction; late-onset disease can begin with weakness, cerebellar signs or psychiatric symptoms.
  evidence:
  - reference: PMID:20301397
    reference_title: HEXA Disorders.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Spasticity, dysphagia, and seizures are present by the end of the first decade of life, with death within the second decade of life, usually by aspiration.
    explanation: >-
      GeneReviews supports juvenile motor/bulbar progression and aspiration complications.
  - reference: PMID:20301397
    reference_title: HEXA Disorders.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Late-onset TSD presents in older teens or young adults with a slowly progressive spectrum of neurologic symptoms including lower-extremity weakness with muscle atrophy, dysarthria, incoordination, tremor, mild spasticity and/or dystonia, and psychiatric manifestations including acute psychosis.
    explanation: >-
      The late-onset spectrum spans cerebellar, motor, and neuropsychiatric dysfunction.
has_subtypes:
- name: Infantile Tay-Sachs
  description: >-
    Onset usually at 3–6 months; rapid progression with survival influenced by airway and nutritional support, sometimes to 5–7 years.
  evidence:
  - reference: PMID:20301397
    reference_title: HEXA Disorders.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Seizures are common by 12 months with further deterioration in the second year of life and death occurring between ages two and three years with some survival to five to seven years.
    explanation: >-
      Infantile progression and survival vary with stage and supportive care; a fixed death-by-four rule is inaccurate.
- name: Juvenile Tay-Sachs
  description: >-
    Childhood onset with variable progression, often fatal in the second decade; subtype boundaries are approximate.
  evidence:
  - reference: PMID:20301397
    reference_title: HEXA Disorders.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Spasticity, dysphagia, and seizures are present by the end of the first decade of life, with death within the second decade of life, usually by aspiration.
    explanation: >-
      GeneReviews supports juvenile motor/bulbar progression and aspiration complications.
- name: Late-Onset Tay-Sachs
  description: >-
    Onset in older teens or adulthood with variable neurologic and psychiatric progression over decades.
  evidence:
  - reference: PMID:20301397
    reference_title: HEXA Disorders.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Late-onset TSD presents in older teens or young adults with a slowly progressive spectrum of neurologic symptoms including lower-extremity weakness with muscle atrophy, dysarthria, incoordination, tremor, mild spasticity and/or dystonia, and psychiatric manifestations including acute psychosis.
    explanation: >-
      The late-onset spectrum spans cerebellar, motor, and neuropsychiatric dysfunction.
prevalence:
- population: Ashkenazi Jewish population
  measure_type: BIRTH_PREVALENCE
  prevalence_class: BAND_1_5_PER_10000
  rate_per_100000: 28.571429
  percentage: 1 in 3,500 newborns
  notes: >-
    Tay-Sachs disease has historically been far more common in Ashkenazi Jewish
    populations than in the general population. Community carrier screening and
    prenatal diagnosis programs reduced incidence in Jewish populations in the
    United States and Canada by more than 90%.
  evidence:
  - reference: PMID:11500789
    reference_title: "The frequency of Tay-Sachs disease causing mutations in the Brazilian Jewish population justifies a carrier screening program"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In the Ashkenazi Jewish population the disease incidence is about 1 in every 3,500 newborns and the carrier frequency is 1 in every 29 individuals."
    explanation: This study directly reports the historically high Tay-Sachs disease incidence in the Ashkenazi Jewish population.
  - reference: PMID:11216898
    reference_title: "Population-based genetic screening for reproductive counseling: the Tay-Sachs disease model"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In the United States and Canada, the incidence of TSD in the Jewish population has been reduced by more than 90%."
    explanation: This review shows that the historically high disease burden in Jewish populations fell substantially after population carrier screening.
- population: Worldwide live births
  measure_type: BIRTH_PREVALENCE
  prevalence_class: BAND_1_9_PER_1000000
  rate_low: 0.1
  rate_high: 0.9
  percentage: "1-9 / 1 000 000 prevalence at birth"
  notes: Orphanet reports a worldwide prevalence-at-birth class of 1-9 per 1,000,000.
  evidence:
  - reference: ORPHA:845
    reference_title: "Tay-Sachs disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "1-9 / 1 000 000 | Worldwide | Prevalence at birth | PMID:0870684507"
    explanation: The Orphanet epidemiology table provides the worldwide prevalence-at-birth class for Tay-Sachs disease.
- population: Specific population live births
  measure_type: BIRTH_PREVALENCE
  prevalence_class: BAND_1_5_PER_10000
  rate_low: 10.0
  rate_high: 50.0
  percentage: "1-5 / 10 000 prevalence at birth"
  notes: Orphanet records a higher prevalence-at-birth class in a specific population.
  evidence:
  - reference: ORPHA:845
    reference_title: "Tay-Sachs disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "1-5 / 10 000 | Specific population | Prevalence at birth | PMID:20301397"
    explanation: The Orphanet epidemiology table records a higher prevalence-at-birth class for a specific population.
mechanistic_hypotheses:
- hypothesis_group_id: canonical_hexa_gm2_ganglioside_neuronal_storage_model
  hypothesis_label: Canonical HEXA Deficiency / GM2 Ganglioside Neuronal Storage Model
  status: CANONICAL
  description: >-
    Biallelic pathogenic HEXA variants impair the alpha subunit of lysosomal HexA, an alpha/beta heterodimer requiring the GM2 activator protein for membrane GM2 hydrolysis. Deficient catabolism causes neuronal GM2 storage, followed by neuronal dysfunction and loss, glial inflammation and variable myelin abnormalities. Residual activity shapes a continuum from infantile to juvenile and late-onset disease. The downstream contributions of ER stress, autophagy and neurodevelopmental perturbation require context-specific interpretation. Mouse neuraminidase bypass metabolism limits translation from Hexa-null animals.
  notes: >-
    The core mechanism remains canonical. OpenScientist correctly identified the Hexa/Neu3 mouse-model correction and several experimental downstream mechanisms, but overstated HSCT causal inference and missed published human AAV results and fetal-brain transcriptomics. Human biochemical target engagement does not ensure clinical benefit; the report is assessed separately against primary studies.
  evidence:
  - reference: PMID:20301397
    reference_title: HEXA Disorders.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: HEXA disorders are best considered as a disease continuum based on the amount of residual beta-hexosaminidase A (HEX A) enzyme activity.
    explanation: >-
      GeneReviews supports a residual-activity continuum rather than fixed activity thresholds or survival cutoffs.
  - reference: PMID:16698036
    reference_title: 'Crystallographic structure of human beta-hexosaminidase A: interpretation of Tay-Sachs mutations and loss of GM2 ganglioside hydrolysis.'
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Only the alpha-subunit active site can hydrolyze GM2 gangliosides due to a flexible loop structure that is removed post-translationally from beta, and to the presence of alphaAsn423 and alphaArg424.
    explanation: >-
      Crystallography identifies alpha-subunit-specific substrate and activator interactions.
- hypothesis_group_id: gm2_er_stress
  hypothesis_label: GM2-associated ER stress and neuronal injury
  status: EMERGING
  description: >-
    GM2 loading in neuronal cultures activates a biphasic PERK response, progressing from adaptation to CHOP-associated injury. Trafficking from lysosomal storage to ER membranes and the contribution in human disease remain unresolved.
  evidence:
  - reference: PMID:30389374
    reference_title: Neurite atrophy and apoptosis mediated by PERK signaling after accumulation of GM2-ganglioside.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: We found that ER GM2 accumulation in cultured neurons induces luminal Ca2+ depletion, which in turn activates PERK (protein kinase RNA [PKR]-like ER kinase), one of three UPR sensors.
    explanation: >-
      Cultured-neuron GM2 loading supports an ER calcium/PERK mechanism; lysosomal-to-ER trafficking and necessity in human Tay-Sachs are unresolved.
  - reference: PMID:30389374
    reference_title: Neurite atrophy and apoptosis mediated by PERK signaling after accumulation of GM2-ganglioside.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Both processes were effectively modulated by treatment with the selective PERK inhibitor GSK2606414, by CN knockdown, and by CHOP knockdown.
    explanation: >-
      PERK inhibition and calcineurin/CHOP knockdown provide direct cellular perturbation evidence for neurite atrophy/apoptosis.
- hypothesis_group_id: autophagy_lysosomal_integrity
  hypothesis_label: Autophagic flux and lysosomal integrity impairment
  status: EMERGING
  description: >-
    GM2 patient fibroblasts show reduced basal mTOR signaling, impaired flux and lysosomal permeability; L-arginine partly rescues these cellular abnormalities. This is not a demonstrated neuronal or clinical treatment mechanism.
  evidence:
  - reference: PMID:34831346
    reference_title: L-Arginine Ameliorates Defective Autophagy in GM2 Gangliosidoses by mTOR Modulation.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: GM2 fibroblasts showed diminished mTOR signalling with reduced basal mTOR activity.
    explanation: >-
      Patient-derived Tay-Sachs and Sandhoff fibroblasts reveal an autophagy/lysosomal phenotype; neuronal in vivo generalization is unproven.
  - reference: PMID:34831346
    reference_title: L-Arginine Ameliorates Defective Autophagy in GM2 Gangliosidoses by mTOR Modulation.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Pathological autophagosomes with impaired autophagic flux, an abnormality confirmed by electron microscopy and biochemical studies revealing the accelerated release of mature cathepsins and HexA into the cytosol, indicating increased lysosomal permeability.
    explanation: >-
      Patient fibroblast assays document impaired flux and lysosomal leakage, not the full human neurodegenerative sequence.
- hypothesis_group_id: prenatal_developmental_perturbation
  hypothesis_label: Prenatal developmental perturbation
  status: EMERGING
  description: >-
    Fetal Tay-Sachs brain RNA-seq and Sandhoff organoids suggest a developmental component preceding end-stage neurodegeneration. Genotype, family, brain region and model differences limit generalization.
  evidence:
  - reference: PMID:36700853
    reference_title: Gene expression changes in Tay-Sachs disease begin early in fetal brain development.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: We find that the transcriptomes are perturbed by 17 week’s gestation, suggesting abnormal neurodevelopment, which has implications for therapeutic intervention for TSD.
    explanation: >-
      Two affected sibling fetuses with a juvenile-associated genotype and two controls were sampled across brain regions; 19 GEO libraries are not 19 independent fetuses.
pathophysiology:
- name: HEXA mutations
  description: >
    Biallelic pathogenic variants in HEXA disrupt the alpha subunit of
    hexosaminidase A. Severe alleles cause the classic infantile enzyme
    deficiency, while residual-activity alleles can produce later-onset disease.
  genes:
  - preferred_term: HEXA
    term:
      id: hgnc:4878
      label: HEXA
  molecular_functions:
  - preferred_term: beta-N-acetylhexosaminidase activity
    term:
      id: GO:0004563
      label: beta-N-acetylhexosaminidase activity
    modifier: DECREASED
  downstream:
  - target: Hexosaminidase A deficiency
    description: Loss of functional alpha subunit reduces enzyme activity.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:20301397
      reference_title: HEXA Disorders.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: HEXA disorders are best considered as a disease continuum based on the amount of residual beta-hexosaminidase A (HEX A) enzyme activity.
      explanation: >-
        GeneReviews supports a residual-activity continuum rather than fixed activity thresholds or survival cutoffs.
    - reference: PMID:16698036
      reference_title: 'Crystallographic structure of human beta-hexosaminidase A: interpretation of Tay-Sachs mutations and loss of GM2 ganglioside hydrolysis.'
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: Only the alpha-subunit active site can hydrolyze GM2 gangliosides due to a flexible loop structure that is removed post-translationally from beta, and to the presence of alphaAsn423 and alphaArg424.
      explanation: >-
        Crystallography identifies alpha-subunit-specific substrate and activator interactions.
  - target: Residual but insufficient HexA activity in late-onset disease
    description: Some pathogenic HEXA alleles, especially G269S, retain residual enzyme activity and shift expression toward late-onset disease.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:15714079
      reference_title: "Late-onset Tay-Sachs disease: phenotypic characterization and genotypic correlations in 21 affected patients."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "In most cases, the later-onset of expression results from the presence of at least one allele (usually the G269S mutation), associated with residual enzyme (beta-hexosaminidase A) activity."
      explanation: Directly links late-onset disease expression to residual beta-hexosaminidase A activity from alleles such as G269S.
  - target: Prenatal neurodevelopmental perturbation
    description: >-
      A juvenile-associated biallelic HEXA genotype was associated with early fetal storage and developmental transcriptomic changes; causal intermediates and clinical consequences remain unresolved.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:36700853
      reference_title: Gene expression changes in Tay-Sachs disease begin early in fetal brain development.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: We find that the transcriptomes are perturbed by 17 week’s gestation, suggesting abnormal neurodevelopment, which has implications for therapeutic intervention for TSD.
      explanation: >-
        Two affected sibling fetuses with a juvenile-associated genotype and two controls were sampled across brain regions; 19 GEO libraries are not 19 independent fetuses.
    hypothesis_groups:
    - prenatal_developmental_perturbation
  evidence:
  - reference: PMID:40710901
    reference_title: "Advances in Diagnosis, Pathological Mechanisms, Clinical Impact, and Future Therapeutic Perspectives in Tay-Sachs Disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Mechanistically, TSD is caused by mutations in the HEXA gene, which encodes the alpha subunit of hexosaminidase A."
    explanation: Review states Tay-Sachs disease is caused by HEXA mutations affecting hexosaminidase A.
  - reference: PMID:15714079
    reference_title: "Late-onset Tay-Sachs disease: phenotypic characterization and genotypic correlations in 21 affected patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Analysis of the beta-hex A gene revealed the G269S mutation as the most common disease allele; found in homozygosity (N = 1) or heterozygosity (N = 18; including 2 sib pairs)."
    explanation: Late-onset cohort identifies G269S as the major HEXA allele associated with residual-activity late-onset Tay-Sachs disease.
- name: Hexosaminidase A deficiency
  conforms_to: "lysosomal_substrate_accumulation#Lysosomal Hydrolase or Cofactor Deficiency"
  description: >-
    Loss or reduction of the alpha subunit impairs the HexA heterodimer and GM2 hydrolysis; HexB activity is normally preserved or elevated. Synthetic-substrate assays require distinction from pseudodeficiency and B1 alleles.
  biological_processes:
  - preferred_term: ganglioside catabolic process
    modifier: DECREASED
    term:
      id: GO:0006689
      label: ganglioside catabolic process
  downstream:
  - target: Failure of lysosomal GM2 hydrolysis
    description: >-
      HexA deficiency prevents alpha-subunit-specific cleavage of membrane GM2 presented by GM2 activator protein.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:16698036
      reference_title: 'Crystallographic structure of human beta-hexosaminidase A: interpretation of Tay-Sachs mutations and loss of GM2 ganglioside hydrolysis.'
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: Only the alpha-subunit active site can hydrolyze GM2 gangliosides due to a flexible loop structure that is removed post-translationally from beta, and to the presence of alphaAsn423 and alphaArg424.
      explanation: >-
        Crystallography identifies alpha-subunit-specific substrate and activator interactions.
  evidence:
  - reference: PMID:19820796
    reference_title: "'Cherry red spot' in a patient with Tay-Sachs disease: case report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Tay-Sachs disease is an autosomal recessive disorder of sphingolipid metabolism, caused by enzyme hexosaminidase A deficiency that leads to an accumulation of GM2 in neurocytes which results in progressive loss of neurological function."
    explanation: Supports hexosaminidase A deficiency as a core defect in Tay-Sachs disease.
  - reference: PMID:36700853
    reference_title: "Gene expression changes in Tay-Sachs disease begin early in fetal brain development."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We also observed a shift in the expression of the sphingolipid metabolic pathway away from production of the HEXA substrate, GM2 ganglioside, presumptively to compensate for dysfunction of the enzyme."
    explanation: Fetal-brain transcriptomics shows compensatory remodeling of the sphingolipid metabolic pathway in HEXA-deficient brain, indicating that enzyme dysfunction perturbs sphingolipid metabolism prenatally.
  - reference: PMID:36700853
    reference_title: "Gene expression changes in Tay-Sachs disease begin early in fetal brain development."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We identified dramatic changes in the transcriptome, suggesting a perturbation of normal development."
    explanation: Fetal-brain transcriptomics in HEXA-mutant samples documents dramatic transcriptomic changes consistent with perturbed neurodevelopment preceding overt neurodegeneration.
  - reference: PMID:16698036
    reference_title: 'Crystallographic structure of human beta-hexosaminidase A: interpretation of Tay-Sachs mutations and loss of GM2 ganglioside hydrolysis.'
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Only the alpha-subunit active site can hydrolyze GM2 gangliosides due to a flexible loop structure that is removed post-translationally from beta, and to the presence of alphaAsn423 and alphaArg424.
    explanation: >-
      Crystallography identifies alpha-subunit-specific substrate and activator interactions.
- name: Failure of lysosomal GM2 hydrolysis
  description: >-
    Deficient HexA cannot remove terminal N-acetylgalactosamine from GM2 presented by GM2 activator protein, interrupting GM2-to-GM3 catabolism.
  evidence:
  - reference: PMID:12662933
    reference_title: 'Crystal structure of human beta-hexosaminidase B: understanding the molecular basis of Sandhoff and Tay-Sachs disease.'
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Hex A degrades G(M2) by removing a terminal N-acetyl-D-galactosamine (beta-GalNAc) residue, and this activity requires the G(M2)-activator, a protein which solubilizes the ganglioside for presentation to Hex A.
    explanation: >-
      Structural and biochemical analysis specifies the hydrolytic step.
  downstream:
  - target: GM2 ganglioside accumulation in neurons
    description: >-
      Failure of lysosomal GM2 degradation permits progressive substrate accumulation.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:20301397
      reference_title: HEXA Disorders.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: HEX A is necessary for degradation of GM2 ganglioside; without well-functioning enzymes, GM2 ganglioside builds up in the lysosomes of brain and nerve cells.
      explanation: >-
        GeneReviews directly links failure of HexA-mediated GM2 degradation to lysosomal substrate accumulation in neural cells.
- name: Residual but insufficient HexA activity in late-onset disease
  description: >
    Late-onset Tay-Sachs disease is usually associated with at least one HEXA
    allele that preserves residual beta-hexosaminidase A activity. Partial
    enzyme activity delays onset but does not prevent progressive neurologic and
    neuropsychiatric disease.
  subtypes:
  - Late-Onset Tay-Sachs
  genes:
  - preferred_term: HEXA
    term:
      id: hgnc:4878
      label: HEXA
  molecular_functions:
  - preferred_term: beta-N-acetylhexosaminidase activity
    term:
      id: GO:0004563
      label: beta-N-acetylhexosaminidase activity
    modifier: DECREASED
  biological_processes:
  - preferred_term: ganglioside catabolic process
    modifier: DECREASED
    term:
      id: GO:0006689
      label: ganglioside catabolic process
  downstream:
  - target: GM2 ganglioside accumulation in neurons
    description: >-
      Residual enzyme activity delays substrate accumulation and onset but remains insufficient for normal neuronal GM2 turnover.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:15714079
      reference_title: "Late-onset Tay-Sachs disease: phenotypic characterization and genotypic correlations in 21 affected patients."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "In most cases, the later-onset of expression results from the presence of at least one allele (usually the G269S mutation), associated with residual enzyme (beta-hexosaminidase A) activity."
      explanation: Directly links late-onset disease expression to residual beta-hexosaminidase A activity from alleles such as G269S.
  evidence:
  - reference: PMID:15714079
    reference_title: "Late-onset Tay-Sachs disease: phenotypic characterization and genotypic correlations in 21 affected patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In most cases, the later-onset of expression results from the presence of at least one allele (usually the G269S mutation), associated with residual enzyme (beta-hexosaminidase A) activity."
    explanation: Directly links late-onset disease expression to residual beta-hexosaminidase A activity from alleles such as G269S.
- name: GM2 ganglioside accumulation in neurons
  conforms_to: "lysosomal_substrate_accumulation#Lysosomal Substrate Accumulation"
  description: >
    GM2 ganglioside accumulates in neuronal lysosomes, particularly in the brain.
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  downstream:
  - target: GM2 Ganglioside Accumulation
    description: Neuronal lysosomal storage manifests clinically as GM2-ganglioside accumulation.
    causal_link_type: DIRECT
    evidence:
    - reference: ORPHA:845
      reference_title: "Tay-Sachs disease"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "HP:0003495 | GM2-ganglioside accumulation | Very frequent (99-80%)"
      explanation: Orphanet lists GM2-ganglioside accumulation as a very frequent Tay-Sachs phenotype, matching the neuronal storage mechanism.
  - target: Neuroinflammation and Astrogliosis
    description: GM2 storage activates microglia and astrocytes, amplifying inflammatory neuronal injury.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - lysosomal storage stress
    - activated microglia expansion
    - astrocyte activation
    evidence:
    - reference: PMID:32951593
      reference_title: GM2 ganglioside accumulation causes neuroinflammation and behavioral alterations in a mouse model of early onset Tay-Sachs disease.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: We found elevated levels of pro-inflammatory cytokine and chemokine transcripts, such as Ccl2, Ccl3, Ccl4, and Cxcl10 and also extensive microglial and astrocyte activation and proliferation, accompanied by peripheral blood mononuclear cell infiltration in the vicinity of neurons and oligodendrocytes.
      explanation: >-
        Hexa/Neu3 double-knockout mice demonstrate the inflammatory branch; this is not direct human causal evidence.
  - target: Oligodendrocyte and myelin abnormalities
    description: >-
      Storage and glial inflammation accompany oligodendrocyte and myelin abnormalities in Tay-Sachs sheep; the complete causal sequence has not been isolated.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:34456134
      reference_title: "Natural history of Tay-Sachs disease in sheep."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Microglial activation and reactive astrocytes were observed globally on histopathology in TSD sheep with a widespread reduction in oligodendrocyte density."
      explanation: Sheep Tay-Sachs natural-history study directly documents widespread reduction in oligodendrocyte density alongside microglial and astrocyte activation.
    - reference: PMID:34456134
      reference_title: "Natural history of Tay-Sachs disease in sheep."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Myelination is reduced primarily in the forebrain illustrated by loss of white matter on MRI."
      explanation: Sheep data document reduced forebrain myelination without resolving impaired formation versus later myelin loss.
  - target: Neuronal injury
    description: Storage-related toxicity contributes to neuronal loss.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - lysosomal storage stress
    - neuronal dysfunction
    evidence:
    - reference: PMID:41026525
      reference_title: Five-year analysis of efficacy and safety of a bidirectional AAV gene therapy in Tay-Sachs sheep.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: Extension in survival was accompanied by lasting improvement in neurological examination and maze testing.
      explanation: >-
        HexA/HexB gene delivery rescues storage-associated disease in sheep; it does not isolate each downstream toxic pathway.
  - target: Retinal ganglion cell lipid storage
    description: GM2/lipid storage also occurs in retinal ganglion cells, producing the characteristic fundus change.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - lysosomal lipid accumulation
    evidence:
    - reference: PMID:19820796
      reference_title: "'Cherry red spot' in a patient with Tay-Sachs disease: case report."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The accumulation of lipid in retinal ganglion cells that leads to a chalk-white appearance of the fundus called 'cherry red spot' is the hallmark of Tay-Sachs disease."
      explanation: Directly supports the retinal-ganglion-cell storage mechanism leading to cherry-red spot.
  - target: Late-onset multifocal neuronal dysfunction
    description: >-
      Slow storage-associated neuronal dysfunction in residual-activity disease produces a variable late-onset syndrome.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:20301397
      reference_title: HEXA Disorders.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Late-onset TSD presents in older teens or young adults with a slowly progressive spectrum of neurologic symptoms including lower-extremity weakness with muscle atrophy, dysarthria, incoordination, tremor, mild spasticity and/or dystonia, and psychiatric manifestations including acute psychosis.
      explanation: >-
        The late-onset spectrum spans cerebellar, motor, and neuropsychiatric dysfunction.
  evidence:
  - reference: PMID:22025593
    reference_title: "Natural history of infantile G(M2) gangliosidosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "G(M2) gangliosidoses are caused by an inherited deficiency of lysosomal β-hexosaminidase and result in ganglioside accumulation in the brain."
    explanation: GM2 gangliosidosis (includes Tay-Sachs) shows ganglioside accumulation in brain.
- name: Neuroinflammation and Astrogliosis
  description: >
    GM2 ganglioside storage is accompanied by activated microglia, astrocyte
    activation, and inflammatory mediator production that can worsen neuronal
    injury.
  cell_types:
  - preferred_term: Microglia
    term:
      id: CL:0000129
      label: microglial cell
  - preferred_term: Astrocyte
    term:
      id: CL:0000127
      label: astrocyte
  biological_processes:
  - preferred_term: microglial cell activation
    term:
      id: GO:0001774
      label: microglial cell activation
  - preferred_term: astrocyte activation
    term:
      id: GO:0048143
      label: astrocyte activation
  - preferred_term: neuroinflammatory response
    term:
      id: GO:0150076
      label: neuroinflammatory response
  downstream:
  - target: Neuronal injury
    description: >-
      Inflammatory glial responses may amplify neuronal injury; timing and marker-reduction studies do not prove a dominant mechanism in human disease.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - inflammatory mediator production
    - chemokine induction
    - activated glial crosstalk
    evidence:
    - reference: PMID:32951593
      reference_title: GM2 ganglioside accumulation causes neuroinflammation and behavioral alterations in a mouse model of early onset Tay-Sachs disease.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: We found elevated levels of pro-inflammatory cytokine and chemokine transcripts, such as Ccl2, Ccl3, Ccl4, and Cxcl10 and also extensive microglial and astrocyte activation and proliferation, accompanied by peripheral blood mononuclear cell infiltration in the vicinity of neurons and oligodendrocytes.
      explanation: >-
        Hexa/Neu3 double-knockout mice demonstrate the inflammatory branch; this is not direct human causal evidence.
    - reference: PMID:40019557
      reference_title: Combined treatment of Ketogenic diet and propagermanium reduces neuroinflammation in Tay-Sachs disease mouse model.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: This study aimed to display the effect of combining the ketogenic diet and propagermanium treatment on chronic neuroinflammation in the Tay-Sachs disease mouse model.
      explanation: >-
        Mouse combination treatment tests inflammatory modulation; it does not establish a human treatment effect or that inflammation is the sole driver.
  evidence:
  - reference: PMID:32951593
    reference_title: GM2 ganglioside accumulation causes neuroinflammation and behavioral alterations in a mouse model of early onset Tay-Sachs disease.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: We found elevated levels of pro-inflammatory cytokine and chemokine transcripts, such as Ccl2, Ccl3, Ccl4, and Cxcl10 and also extensive microglial and astrocyte activation and proliferation, accompanied by peripheral blood mononuclear cell infiltration in the vicinity of neurons and oligodendrocytes.
    explanation: >-
      Hexa/Neu3 double-knockout mice demonstrate the inflammatory branch; this is not direct human causal evidence.
  - reference: PMID:12615653
    reference_title: Central nervous system inflammation is a hallmark of pathogenesis in mouse models of GM1 and GM2 gangliosidosis.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Substrate reduction therapy in the Sandhoff mouse model slowed the rate of accumulation of glycosphingolipids in the CNS, thus delaying the onset of the inflammatory process and disease pathogenesis.
    explanation: >-
      Substrate intervention supports storage-dependent inflammation in Sandhoff mice, providing indirect support for Tay-Sachs.
- name: Oligodendrocyte and myelin abnormalities
  description: >-
    Tay-Sachs sheep have reduced oligodendrocyte density and forebrain myelination alongside glial activation. Cross-sectional observations do not fully separate failure of myelin formation from later myelin loss, and species-specific results require qualified human interpretation.
  cell_types:
  - preferred_term: Oligodendrocyte
    term:
      id: CL:0000128
      label: oligodendrocyte
  biological_processes:
  - preferred_term: myelination
    modifier: DECREASED
    term:
      id: GO:0042552
      label: myelination
  downstream:
  - target: Hypomyelination
    description: >-
      Reduced myelination is observed in the sheep model; human pediatric GM2 imaging also documents hypomyelination, but does not isolate oligodendrocyte loss as its sole cause.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:34456134
      reference_title: "Natural history of Tay-Sachs disease in sheep."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Microglial activation and reactive astrocytes were observed globally on histopathology in TSD sheep with a widespread reduction in oligodendrocyte density."
      explanation: Sheep Tay-Sachs natural-history study directly documents widespread reduction in oligodendrocyte density alongside microglial and astrocyte activation.
    - reference: PMID:34456134
      reference_title: "Natural history of Tay-Sachs disease in sheep."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Myelination is reduced primarily in the forebrain illustrated by loss of white matter on MRI."
      explanation: Sheep data document reduced forebrain myelination without resolving impaired formation versus later myelin loss.
  evidence:
  - reference: PMID:34456134
    reference_title: "Natural history of Tay-Sachs disease in sheep."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Microglial activation and reactive astrocytes were observed globally on histopathology in TSD sheep with a widespread reduction in oligodendrocyte density."
    explanation: Sheep Tay-Sachs natural-history study directly documents widespread reduction in oligodendrocyte density alongside microglial and astrocyte activation.
  - reference: PMID:34456134
    reference_title: "Natural history of Tay-Sachs disease in sheep."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Myelination is reduced primarily in the forebrain illustrated by loss of white matter on MRI."
    explanation: Sheep data document reduced forebrain myelination without resolving impaired formation versus later myelin loss.
- name: Retinal ganglion cell lipid storage
  description: >-
    Lipid-filled retinal ganglion cells make the surrounding fundus appear pale, leaving the fovea as a cherry-red macular spot. This finding does not by itself establish the mechanism or severity of visual loss.
  cell_types:
  - preferred_term: Retinal ganglion cell
    term:
      id: CL:0000740
      label: retinal ganglion cell
  cellular_components:
  - preferred_term: lysosome
    term:
      id: GO:0005764
      label: lysosome
  downstream:
  - target: Cherry-Red Spot
    description: Retinal ganglion cell lipid storage creates the chalk-white fundus around the fovea.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:19820796
      reference_title: "'Cherry red spot' in a patient with Tay-Sachs disease: case report."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The accumulation of lipid in retinal ganglion cells that leads to a chalk-white appearance of the fundus called 'cherry red spot' is the hallmark of Tay-Sachs disease."
      explanation: Directly supports the retinal-ganglion-cell storage mechanism leading to cherry-red spot.
  evidence:
  - reference: PMID:19820796
    reference_title: "'Cherry red spot' in a patient with Tay-Sachs disease: case report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The accumulation of lipid in retinal ganglion cells that leads to a chalk-white appearance of the fundus called 'cherry red spot' is the hallmark of Tay-Sachs disease."
    explanation: Directly supports the retinal-ganglion-cell storage mechanism leading to cherry-red spot.
- name: Neuronal injury
  description: >-
    Storage-associated neuronal dysfunction can precede progressive loss. Diverse affected circuits account for developmental, motor, sensory and epileptic manifestations; apoptosis is one experimentally studied route, not the definition of all injury.
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  downstream:
  - target: Developmental Regression
    description: Rapid infantile neurodegeneration causes developmental arrest and loss of attained milestones.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - developmental arrest
    - loss of attained milestones
    evidence:
    - reference: PMID:25143775
      reference_title: "GM2-Gangliosidosis (Sandhoff and Tay Sachs disease): Diagnosis and Neuroimaging Findings (An Iranian Pediatric Case Series)."
      supports: SUPPORT
      snippet: "All of them had a developmental disorder as a chief complaint. 38%of patients had a history of developmental delay or regression"
      explanation: Case series confirms developmental regression as a key presenting feature in GM2 gangliosidosis patients.
      evidence_source: HUMAN_CLINICAL
    - reference: PMID:22025593
      reference_title: "Natural history of infantile G(M2) gangliosidosis."
      supports: SUPPORT
      snippet: "Common symptoms at onset were developmental arrest (83%), startling (65%), and hypotonia (60%)."
      explanation: Natural history study of 97 patients confirms developmental arrest in 83% of infantile GM2 gangliosidosis cases.
      evidence_source: HUMAN_CLINICAL
    - reference: PMID:29618308
      reference_title: "Genetics and Therapies for GM2 Gangliosidosis."
      supports: SUPPORT
      snippet: "Inherited as a classical autosomal recessive disorder, this global disease of the nervous system induces developmental arrest with regression of attained milestones; neurodegeneration progresses rapidly to cause premature death in young children."
      explanation: Review describes developmental arrest with regression of milestones as a core feature of Tay-Sachs disease.
      evidence_source: OTHER
  - target: Hypotonia
    description: Early neuronal dysfunction presents with hypotonia in infantile GM2 gangliosidosis.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - motor pathway dysfunction
    evidence:
    - reference: PMID:22025593
      reference_title: "Natural history of infantile G(M2) gangliosidosis."
      supports: SUPPORT
      snippet: "Common symptoms at onset were developmental arrest (83%), startling (65%), and hypotonia (60%)."
      explanation: Natural history study confirms hypotonia in 60% of infantile GM2 gangliosidosis patients at disease onset.
      evidence_source: HUMAN_CLINICAL
  - target: Exaggerated Startle Response
    description: >-
      Altered pontine reticular reflex excitability may mediate exaggerated startle; precise cell loss is not established.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - altered pontine reflex excitability
    evidence:
    - reference: PMID:24534057
      reference_title: Correlation of augmented startle reflex with brainstem electrophysiological responses in Tay-Sachs disease.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: The blink reflex with high amplitudes may represent augmented excitability of reticular formation at the pontine tegmentum in Tay-Sachs disease, where the pattern generators for the augmented startle and blink reflexes may functionally overlap.
      explanation: >-
        Three-patient electrophysiology supports altered pontine reflex excitability as a candidate intermediate, not an established consequence of completed neuronal death.
  - target: Seizures
    description: Progressive cortical neurodegeneration contributes to epileptic seizures.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - cortical neuronal dysfunction
    evidence:
    - reference: PMID:20301397
      reference_title: HEXA Disorders.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Seizures are common by 12 months with further deterioration in the second year of life and death occurring between ages two and three years with some survival to five to seven years.
      explanation: >-
        Infantile progression and survival vary with stage and supportive care; a fixed death-by-four rule is inaccurate.
  - target: Spasticity
    description: Progressive upper motor neuron and corticospinal dysfunction contributes to late-stage spasticity.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - corticospinal tract dysfunction
    - upper motor neuron involvement
    evidence:
    - reference: PMID:20301397
      reference_title: HEXA Disorders.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Spasticity, dysphagia, and seizures are present by the end of the first decade of life, with death within the second decade of life, usually by aspiration.
      explanation: >-
        GeneReviews supports juvenile motor/bulbar progression and aspiration complications.
  - target: Dysphagia
    description: Progressive bulbar and brainstem dysfunction contributes to swallowing impairment.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - bulbar motor dysfunction
    - brainstem involvement
    evidence:
    - reference: PMID:20301397
      reference_title: HEXA Disorders.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Spasticity, dysphagia, and seizures are present by the end of the first decade of life, with death within the second decade of life, usually by aspiration.
      explanation: >-
        GeneReviews supports juvenile motor/bulbar progression and aspiration complications.
  - target: Juvenile cerebellar and bulbar involvement
    description: Slower childhood-onset neurodegeneration produces cerebellar, bulbar, and motor pathway manifestations.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - chronic neuronal GM2 storage
    - progressive cerebellar involvement
    - bulbar motor dysfunction
    evidence:
    - reference: PMID:20301397
      reference_title: HEXA Disorders.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Spasticity, dysphagia, and seizures are present by the end of the first decade of life, with death within the second decade of life, usually by aspiration.
      explanation: >-
        GeneReviews supports juvenile motor/bulbar progression and aspiration complications.
  evidence:
  - reference: PMID:29618308
    reference_title: "Genetics and Therapies for GM2 Gangliosidosis."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Inherited as a classical autosomal recessive disorder, this global disease of the nervous system induces developmental arrest with regression of attained milestones; neurodegeneration progresses rapidly to cause premature death in young children."
    explanation: Review describes rapid neurodegeneration in infantile GM2 gangliosidosis, consistent with neuronal loss.
  - reference: PMID:20301397
    reference_title: HEXA Disorders.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: HEXA disorders are best considered as a disease continuum based on the amount of residual beta-hexosaminidase A (HEX A) enzyme activity.
    explanation: >-
      GeneReviews supports a residual-activity continuum rather than fixed activity thresholds or survival cutoffs.
- name: Juvenile cerebellar and bulbar involvement
  description: >
    Juvenile Tay-Sachs disease progresses through cerebellar, bulbar, and motor
    pathway involvement, producing gait, speech, swallowing, tone, and weakness
    manifestations over childhood.
  subtypes:
  - Juvenile Tay-Sachs
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  downstream:
  - target: Ataxia
    description: Cerebellar involvement produces incoordination and gait disturbance.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:17015493
      reference_title: "The natural history of juvenile or subacute GM2 gangliosidosis: 21 new cases and literature review of 134 previously reported."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The most common symptoms at onset were gait disturbances (66.7%), incoordination (52.4%), speech problems (28.6%), and developmental delay (28.6%)."
      explanation: Prospective juvenile GM2 gangliosidosis cohort supports gait, coordination, and speech involvement in juvenile Tay-Sachs disease.
  - target: Proximal Muscle Weakness
    description: Progressive motor involvement contributes to limb weakness and muscle wasting.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - motor pathway dysfunction
    - muscle wasting
    evidence:
    - reference: PMID:17015493
      reference_title: 'The natural history of juvenile or subacute GM2 gangliosidosis: 21 new cases and literature review of 134 previously reported.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Muscle wasting (10.6 +/- 7.4 years), proximal weakness (11.1 +/- 7.7 years), and incontinence of sphincters (14.6 +/- 9.7 years) appeared later in the course of the disease.
      explanation: >-
        The prospective juvenile cohort included 15 Tay-Sachs and six Sandhoff patients; pooled ages are not Tay-Sachs-specific prevalence estimates.
  - target: Muscle Weakness
    description: Progressive motor pathway and anterior motor neuron involvement produce generalized muscle weakness across Tay-Sachs subtypes.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - motor pathway dysfunction
    - anterior motor neuron involvement
    evidence:
    - reference: PMID:17015493
      reference_title: "The natural history of juvenile or subacute GM2 gangliosidosis: 21 new cases and literature review of 134 previously reported."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Muscle wasting (10.6 +/- 7.4 years), proximal weakness (11.1 +/- 7.7 years), and incontinence of sphincters (14.6 +/- 9.7 years) appeared later in the course of the disease."
      explanation: Juvenile GM2 gangliosidosis natural history documents proximal weakness during disease progression.
  - target: Skeletal Muscle Atrophy
    description: Progressive motor involvement produces muscle wasting that corresponds to skeletal muscle atrophy.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - motor pathway dysfunction
    - anterior motor neuron involvement
    evidence:
    - reference: PMID:17015493
      reference_title: "The natural history of juvenile or subacute GM2 gangliosidosis: 21 new cases and literature review of 134 previously reported."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Muscle wasting (10.6 +/- 7.4 years), proximal weakness (11.1 +/- 7.7 years), and incontinence of sphincters (14.6 +/- 9.7 years) appeared later in the course of the disease."
      explanation: The juvenile GM2 gangliosidosis natural-history cohort directly reports muscle wasting during disease progression.
  - target: Dysarthria
    description: Bulbar and motor speech pathway involvement produces dysarthria and speech deterioration.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - bulbar motor dysfunction
    - motor speech impairment
    evidence:
    - reference: PMID:17015493
      reference_title: "The natural history of juvenile or subacute GM2 gangliosidosis: 21 new cases and literature review of 134 previously reported."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The most common symptoms at onset were gait disturbances (66.7%), incoordination (52.4%), speech problems (28.6%), and developmental delay (28.6%)."
      explanation: Prospective juvenile GM2 gangliosidosis cohort supports gait, coordination, and speech involvement in juvenile Tay-Sachs disease.
  - target: Dysphagia
    description: Bulbar involvement contributes to swallowing impairment in juvenile disease.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - bulbar motor dysfunction
    evidence:
    - reference: PMID:20301397
      reference_title: HEXA Disorders.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Spasticity, dysphagia, and seizures are present by the end of the first decade of life, with death within the second decade of life, usually by aspiration.
      explanation: >-
        GeneReviews supports juvenile motor/bulbar progression and aspiration complications.
  - target: Spasticity
    description: Progressive motor pathway involvement contributes to increasing tone and spasm progression.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - corticospinal tract dysfunction
    - upper motor neuron involvement
    evidence:
    - reference: PMID:20301397
      reference_title: HEXA Disorders.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Spasticity, dysphagia, and seizures are present by the end of the first decade of life, with death within the second decade of life, usually by aspiration.
      explanation: >-
        GeneReviews supports juvenile motor/bulbar progression and aspiration complications.
  - target: Progressive Spasticity
    description: Progressive motor pathway involvement manifests as increasing spasm progression and progressive spasticity.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - corticospinal tract dysfunction
    - upper motor neuron involvement
    evidence:
    - reference: PMID:20301397
      reference_title: HEXA Disorders.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Spasticity, dysphagia, and seizures are present by the end of the first decade of life, with death within the second decade of life, usually by aspiration.
      explanation: >-
        GeneReviews supports juvenile motor/bulbar progression and aspiration complications.
  - target: Cerebellar Atrophy
    description: Chronic cerebellar involvement produces cerebellar atrophy on brain MRI in juvenile disease.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:17015493
      reference_title: 'The natural history of juvenile or subacute GM2 gangliosidosis: 21 new cases and literature review of 134 previously reported.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Cerebellar atrophy was the most common finding on brain MRI (52.9%).
      explanation: >-
        MRI finding in the mixed juvenile GM2 cohort; the denominator is the imaged subgroup.
  evidence:
  - reference: PMID:17015493
    reference_title: "The natural history of juvenile or subacute GM2 gangliosidosis: 21 new cases and literature review of 134 previously reported."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The most common symptoms at onset were gait disturbances (66.7%), incoordination (52.4%), speech problems (28.6%), and developmental delay (28.6%)."
    explanation: Prospective juvenile GM2 gangliosidosis cohort supports gait, coordination, and speech involvement in juvenile Tay-Sachs disease.
  - reference: PMID:20301397
    reference_title: HEXA Disorders.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Spasticity, dysphagia, and seizures are present by the end of the first decade of life, with death within the second decade of life, usually by aspiration.
    explanation: >-
      GeneReviews supports juvenile motor/bulbar progression and aspiration complications.
- name: Late-onset multifocal neuronal dysfunction
  description: >-
    Late-onset disease affects cerebellar and motor systems and can involve distributed neuropsychiatric networks. Regional vulnerability and the mechanism of psychiatric symptoms remain incompletely resolved.
  subtypes:
  - Late-Onset Tay-Sachs
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  downstream:
  - target: Ataxia
    description: Cerebellar involvement causes gait and balance impairment.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:15714079
      reference_title: "Late-onset Tay-Sachs disease: phenotypic characterization and genotypic correlations in 21 affected patients."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Early on, the majority of patients develop signs of either cerebellar or anterior motor neuron involvement."
      explanation: Cohort conclusion supports cerebellar and anterior motor neuron involvement as the early late-onset phenotype mechanism.
  - target: Proximal Muscle Weakness
    description: Anterior motor neuron involvement contributes to progressive proximal weakness.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:15714079
      reference_title: "Late-onset Tay-Sachs disease: phenotypic characterization and genotypic correlations in 21 affected patients."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Early on, the majority of patients develop signs of either cerebellar or anterior motor neuron involvement."
      explanation: Cohort conclusion supports cerebellar and anterior motor neuron involvement as the early late-onset phenotype mechanism.
  - target: Cerebellar Atrophy
    description: Chronic cerebellar involvement produces marked cerebellar atrophy on neuroimaging in late-onset disease.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:17015493
      reference_title: "The natural history of juvenile or subacute GM2 gangliosidosis: 21 new cases and literature review of 134 previously reported."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Cerebellar atrophy was the most common finding on brain MRI (52.9%)."
      explanation: Juvenile GM2 gangliosidosis natural history identifies cerebellar atrophy as the most common MRI finding.
    - reference: PMID:15714079
      reference_title: "Late-onset Tay-Sachs disease: phenotypic characterization and genotypic correlations in 21 affected patients."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Brain imaging studies revealed marked cerebellar atrophy in all patients (N = 18) tested, regardless of disease stage."
      explanation: Late-onset cohort documents marked cerebellar atrophy in all imaged patients across disease stages.
    - reference: PMID:28739864
      reference_title: "Late-onset Tay-Sachs disease."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "MR scan of the brain showed isolated cerebellar atrophy"
      explanation: Adult-onset Tay-Sachs case report documents isolated cerebellar atrophy on brain MRI.
  - target: Tremor
    description: Cerebellar and motor pathway involvement contributes to action tremor and stimulus-sensitive myoclonus in late-onset disease.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - cerebellar dysfunction
    - motor pathway involvement
    evidence:
    - reference: PMID:15714079
      reference_title: "Late-onset Tay-Sachs disease: phenotypic characterization and genotypic correlations in 21 affected patients."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Early on, the majority of patients develop signs of either cerebellar or anterior motor neuron involvement."
      explanation: Cohort conclusion supports cerebellar and anterior motor neuron involvement as the early late-onset phenotype mechanism.
  - target: Psychosis
    description: >-
      Psychosis occurs in late-onset disease, but the specific affected circuits and causal intermediates are unresolved.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:20301397
      reference_title: HEXA Disorders.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Late-onset TSD presents in older teens or young adults with a slowly progressive spectrum of neurologic symptoms including lower-extremity weakness with muscle atrophy, dysarthria, incoordination, tremor, mild spasticity and/or dystonia, and psychiatric manifestations including acute psychosis.
      explanation: >-
        The late-onset spectrum spans cerebellar, motor, and neuropsychiatric dysfunction.
  - target: Dystonia
    description: >-
      Multifocal neuronal dysfunction can contribute to this late-onset manifestation; the detailed circuit-specific sequence is unresolved.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:20301397
      reference_title: HEXA Disorders.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Late-onset TSD presents in older teens or young adults with a slowly progressive spectrum of neurologic symptoms including lower-extremity weakness with muscle atrophy, dysarthria, incoordination, tremor, mild spasticity and/or dystonia, and psychiatric manifestations including acute psychosis.
      explanation: >-
        GeneReviews describes the late-onset motor and psychiatric spectrum.
  - target: Cognitive decline
    description: >-
      Multifocal neuronal dysfunction can contribute to this late-onset manifestation; the detailed circuit-specific sequence is unresolved.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:31964693
      reference_title: Quantitative oculomotor and nonmotor assessments in late-onset GM2 gangliosidosis.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Nine out of ten patients with LOGG had evidence of the CCAS (5/10 definite, 2/10 probable, 2/10 possible).
      explanation: >-
        Cognitive-affective deficits were found in a small mixed late-onset GM2 cohort.
  - target: Frequent falls
    description: >-
      Multifocal neuronal dysfunction can contribute to this late-onset manifestation; the detailed circuit-specific sequence is unresolved.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:20301397
      reference_title: HEXA Disorders.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: circumstances that exacerbate the risk of falls (i.e., walking on uneven or unstable surfaces)
      explanation: >-
        GeneReviews identifies fall risk requiring preventive care.
  - target: Myoclonus
    description: >-
      Multifocal neuronal dysfunction can contribute to this late-onset manifestation; the detailed circuit-specific sequence is unresolved.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:28739864
      reference_title: Late-onset Tay-Sachs disease.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: irregular action tremor and stimulus-sensitive myoclonus of the arms
      explanation: >-
        The clinical case separately documents action tremor and myoclonus.
  evidence:
  - reference: PMID:15714079
    reference_title: "Late-onset Tay-Sachs disease: phenotypic characterization and genotypic correlations in 21 affected patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Early on, the majority of patients develop signs of either cerebellar or anterior motor neuron involvement."
    explanation: Cohort conclusion supports cerebellar and anterior motor neuron involvement as the early late-onset phenotype mechanism.
  - reference: PMID:39807213
    reference_title: "Diagnosing Late-Onset Tay-Sachs Through Next Generation Sequencing and Functional Enzyme Testing: From Genes to Enzymes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We report 2 cases of adult-onset progressive weakness, ataxia, and neuropsychiatric symptoms in a 30-year-old man and 37-year-old woman."
    explanation: Recent adult-onset cases confirm the weakness, ataxia, and neuropsychiatric manifestation cluster.
- name: GM2-associated PERK activation
  mechanism_confidence: PROVISIONAL
  description: >-
    In GM2-loaded neuronal cultures, ER calcium depletion activates PERK, with early adaptive calcineurin and later CHOP-associated responses. This node represents experimental signaling; the upstream lysosomal-to-ER route in patients remains unresolved.
  evidence:
  - reference: PMID:30389374
    reference_title: Neurite atrophy and apoptosis mediated by PERK signaling after accumulation of GM2-ganglioside.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: We found that ER GM2 accumulation in cultured neurons induces luminal Ca2+ depletion, which in turn activates PERK (protein kinase RNA [PKR]-like ER kinase), one of three UPR sensors.
    explanation: >-
      Cultured-neuron GM2 loading supports an ER calcium/PERK mechanism; lysosomal-to-ER trafficking and necessity in human Tay-Sachs are unresolved.
  biological_processes:
  - preferred_term: endoplasmic reticulum unfolded protein response
    term:
      id: GO:0030968
      label: endoplasmic reticulum unfolded protein response
  downstream:
  - target: CHOP-associated neuronal injury
    description: >-
      Prolonged experimental ER stress engages CHOP-associated neurite atrophy and apoptosis.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:30389374
      reference_title: Neurite atrophy and apoptosis mediated by PERK signaling after accumulation of GM2-ganglioside.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: Both processes were effectively modulated by treatment with the selective PERK inhibitor GSK2606414, by CN knockdown, and by CHOP knockdown.
      explanation: >-
        PERK inhibition and calcineurin/CHOP knockdown provide direct cellular perturbation evidence for neurite atrophy/apoptosis.
    intermediate_mechanisms:
    - prolonged PERK signaling and CHOP induction
    hypothesis_groups:
    - gm2_er_stress
- name: CHOP-associated neuronal injury
  mechanism_confidence: PROVISIONAL
  description: >-
    Cultured-neuron neurite atrophy and apoptosis respond to PERK inhibition and CHOP/calcineurin knockdown. A chemical chaperone acting on PERK reduces the same two readouts together in primary neuron cultures.
  evidence:
  - reference: PMID:30389374
    reference_title: Neurite atrophy and apoptosis mediated by PERK signaling after accumulation of GM2-ganglioside.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Both processes were effectively modulated by treatment with the selective PERK inhibitor GSK2606414, by CN knockdown, and by CHOP knockdown.
    explanation: >-
      PERK inhibition and calcineurin/CHOP knockdown provide direct cellular perturbation evidence for neurite atrophy/apoptosis.
  - reference: PMID:37108372
    reference_title: Ursodeoxycholic Acid Binds PERK and Ameliorates Neurite Atrophy in a Cellular Model of GM2 Gangliosidosis.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Here, we found that UDCA significantly diminished the neurite atrophy induced by GM2 accumulation in primary neuron cultures. It also decreased the up-regulation of pro-apoptotic CHOP, a downstream PERK-signaling component.
    explanation: >-
      A second, pharmacological perturbation from an independent study moves neurite atrophy and CHOP induction together, which is the coupling this node asserts. It remains primary-culture evidence; ursodeoxycholic acid has not been tested clinically in Tay-Sachs disease.
  downstream:
  - target: Neuronal injury
    description: >-
      This experimentally supported injury pathway may contribute to GM2-associated neurodegeneration; its in vivo importance in Tay-Sachs remains unquantified.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:30389374
      reference_title: Neurite atrophy and apoptosis mediated by PERK signaling after accumulation of GM2-ganglioside.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: Both processes were effectively modulated by treatment with the selective PERK inhibitor GSK2606414, by CN knockdown, and by CHOP knockdown.
      explanation: >-
        PERK inhibition and calcineurin/CHOP knockdown provide direct cellular perturbation evidence for neurite atrophy/apoptosis.
    hypothesis_groups:
    - gm2_er_stress
- name: Impaired autophagic flux and lysosomal integrity
  mechanism_confidence: PROVISIONAL
  description: >-
    Tay-Sachs/Sandhoff skin fibroblasts show abnormal autophagosomes, reduced basal mTOR signaling and lysosomal leakage. This is an experimental cellular branch; a direct arrow to neuronal death is not established.
  evidence:
  - reference: PMID:34831346
    reference_title: L-Arginine Ameliorates Defective Autophagy in GM2 Gangliosidoses by mTOR Modulation.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: GM2 fibroblasts showed diminished mTOR signalling with reduced basal mTOR activity.
    explanation: >-
      Patient-derived Tay-Sachs and Sandhoff fibroblasts reveal an autophagy/lysosomal phenotype; neuronal in vivo generalization is unproven.
  - reference: PMID:34831346
    reference_title: L-Arginine Ameliorates Defective Autophagy in GM2 Gangliosidoses by mTOR Modulation.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Pathological autophagosomes with impaired autophagic flux, an abnormality confirmed by electron microscopy and biochemical studies revealing the accelerated release of mature cathepsins and HexA into the cytosol, indicating increased lysosomal permeability.
    explanation: >-
      Patient fibroblast assays document impaired flux and lysosomal leakage, not the full human neurodegenerative sequence.
  biological_processes:
  - preferred_term: autophagy
    term:
      id: GO:0006914
      label: autophagy
    modifier: DYSREGULATED
- name: Prenatal neurodevelopmental perturbation
  mechanism_confidence: PROVISIONAL
  description: >-
    In two affected sibling fetuses at 17 weeks, GM2 storage and bulk transcriptomic changes suggest altered differentiation/proliferation before end-stage neuroinflammatory signatures. The findings are hypothesis-generating across a small number of biological donors.
  evidence:
  - reference: PMID:36700853
    reference_title: Gene expression changes in Tay-Sachs disease begin early in fetal brain development.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: We find that the transcriptomes are perturbed by 17 week’s gestation, suggesting abnormal neurodevelopment, which has implications for therapeutic intervention for TSD.
    explanation: >-
      Two affected sibling fetuses with a juvenile-associated genotype and two controls were sampled across brain regions; 19 GEO libraries are not 19 independent fetuses.
phenotypes:
- name: Developmental Regression
  category: Neurological
  diagnostic: true
  notes: >-
    Infantile weakness may begin at 3–6 months, followed by developmental plateau and loss of skills, often after 8–10 months. Developmental arrest percentages are not equivalent to regression prevalence.
  phenotype_term:
    preferred_term: Developmental Regression
    term:
      id: HP:0002376
      label: Developmental regression
  evidence:
  - reference: PMID:25143775
    reference_title: "GM2-Gangliosidosis (Sandhoff and Tay Sachs disease): Diagnosis and Neuroimaging Findings (An Iranian Pediatric Case Series)."
    supports: SUPPORT
    snippet: "All of them had a developmental disorder as a chief complaint. 38%of patients had a history of developmental delay or regression"
    explanation: Case series confirms developmental regression as a key presenting feature in GM2 gangliosidosis patients.
    evidence_source: HUMAN_CLINICAL
  - reference: PMID:22025593
    reference_title: "Natural history of infantile G(M2) gangliosidosis."
    supports: SUPPORT
    snippet: "Common symptoms at onset were developmental arrest (83%), startling (65%), and hypotonia (60%)."
    explanation: Natural history study of 97 patients confirms developmental arrest in 83% of infantile GM2 gangliosidosis cases.
    evidence_source: HUMAN_CLINICAL
  - reference: PMID:29618308
    reference_title: "Genetics and Therapies for GM2 Gangliosidosis."
    supports: SUPPORT
    snippet: "Inherited as a classical autosomal recessive disorder, this global disease of the nervous system induces developmental arrest with regression of attained milestones; neurodegeneration progresses rapidly to cause premature death in young children."
    explanation: Review describes developmental arrest with regression of milestones as a core feature of Tay-Sachs disease.
    evidence_source: OTHER
  subtypes:
  - Infantile Tay-Sachs
  - Juvenile Tay-Sachs
- name: Cherry-Red Spot
  category: Ophthalmologic
  frequency: VERY_FREQUENT
  diagnostic: true
  notes: >-
    Characteristic of infantile disease but not pathognomonic; also occurs in other storage diseases and central retinal artery occlusion. Rare in juvenile disease.
  phenotype_term:
    preferred_term: Cherry-Red Spot
    term:
      id: HP:0010729
      label: Cherry red spot of the macula
  evidence:
  - reference: PMID:19820796
    reference_title: "'Cherry red spot' in a patient with Tay-Sachs disease: case report."
    supports: SUPPORT
    snippet: "The accumulation of lipid in retinal ganglion cells that leads to a chalk-white appearance of the fundus called 'cherry red spot' is the hallmark of Tay-Sachs disease."
    explanation: Case report describes cherry-red spot as the hallmark ophthalmologic finding in Tay-Sachs disease.
    evidence_source: HUMAN_CLINICAL
  - reference: PMID:19820796
    reference_title: "'Cherry red spot' in a patient with Tay-Sachs disease: case report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: It is also seen in others neurometabolic diseases as well as in central retinal artery occlusion.
    explanation: >-
      The source explicitly rules out disease specificity of a cherry-red spot.
  subtypes:
  - Infantile Tay-Sachs
- name: Exaggerated Startle Response
  category: Neurological
  frequency: FREQUENT
  notes: 65% at presentation in a mixed infantile GM2 cohort; this is not a prevalence estimate across all Tay-Sachs subtypes.
  phenotype_term:
    preferred_term: Exaggerated Startle Response
    term:
      id: HP:0002267
      label: Exaggerated startle response
  evidence:
  - reference: PMID:22025593
    reference_title: "Natural history of infantile G(M2) gangliosidosis."
    supports: SUPPORT
    snippet: "Common symptoms at onset were developmental arrest (83%), startling (65%), and hypotonia (60%)."
    explanation: Natural history study of 97 infantile GM2 gangliosidosis patients confirms exaggerated startle response in 65%, consistent with FREQUENT frequency in the infantile subtype.
    evidence_source: HUMAN_CLINICAL
  - reference: PMID:24534057
    reference_title: "Correlation of augmented startle reflex with brainstem electrophysiological responses in Tay-Sachs disease."
    supports: SUPPORT
    snippet: "The augmented startle reflex appeared between the age of 3 and 17 months and disappeared between the age of 4 and 6 years."
    explanation: Electrophysiological study documents the temporal evolution of the augmented startle reflex in Tay-Sachs disease.
    evidence_source: HUMAN_CLINICAL
  - reference: ORPHA:845
    reference_title: "Tay-Sachs disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002267 | Exaggerated startle response | Occasional (29-5%)"
    explanation: Orphanet reports occasional frequency across all subtypes in aggregate; the infantile-specific cohort literature (65%) supports FREQUENT as the appropriate designation for infantile-onset disease.
  subtypes:
  - Infantile Tay-Sachs
- name: Hypotonia
  category: Neurological
  frequency: FREQUENT
  notes: Reported at onset in 60% of the mixed infantile GM2 natural-history cohort; later tone may become spastic.
  phenotype_term:
    preferred_term: Hypotonia
    term:
      id: HP:0001252
      label: Hypotonia
  evidence:
  - reference: PMID:22025593
    reference_title: "Natural history of infantile G(M2) gangliosidosis."
    supports: SUPPORT
    snippet: "Common symptoms at onset were developmental arrest (83%), startling (65%), and hypotonia (60%)."
    explanation: Natural history study confirms hypotonia in 60% of infantile GM2 gangliosidosis patients at disease onset.
    evidence_source: HUMAN_CLINICAL
  subtypes:
  - Infantile Tay-Sachs
- name: Seizures
  category: Neurological
  phenotype_term:
    preferred_term: Seizures
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:25143775
    reference_title: "GM2-Gangliosidosis (Sandhoff and Tay Sachs disease): Diagnosis and Neuroimaging Findings (An Iranian Pediatric Case Series)."
    supports: SUPPORT
    snippet: "38%of patients had a history of developmental delay or regression and 22% had seizures."
    explanation: Case series documents seizures in 22% of GM2 gangliosidosis patients, consistent with the OCCASIONAL frequency band.
    evidence_source: HUMAN_CLINICAL
  - reference: ORPHA:845
    reference_title: "Tay-Sachs disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001250 | Seizure | Occasional (29-5%)"
    explanation: Orphanet lists seizure as an occasional HPO phenotype for Tay-Sachs disease, consistent with the 22% frequency reported in cohort studies.
  - reference: PMID:20301397
    reference_title: HEXA Disorders.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Seizures are common by 12 months with further deterioration in the second year of life and death occurring between ages two and three years with some survival to five to seven years.
    explanation: >-
      Infantile progression and survival vary with stage and supportive care; a fixed death-by-four rule is inaccurate.
  notes: >-
    Seizures become common during infantile progression and occur in juvenile disease. The 22% mixed-series presentation figure and aggregate Orphanet band do not describe lifetime infantile frequency.
- name: Macrocephaly
  category: Neurological
  notes: >-
    Macrocephaly can occur in infantile disease; a single case does not establish frequency or distinguish the contributions of storage, gliosis and ventricular enlargement.
  phenotype_term:
    preferred_term: Macrocephaly
    term:
      id: HP:0000256
      label: Macrocephaly
  evidence:
  - reference: PMID:7732608
    reference_title: "Tay-Sachs disease: a case report."
    supports: SUPPORT
    snippet: "Generalized hypotonia, macrocephaly, hyperacusis and a retinal cherry red spot appearance were present."
    explanation: Case report documents macrocephaly in Tay-Sachs disease.
    evidence_source: HUMAN_CLINICAL
  subtypes:
  - Infantile Tay-Sachs
- name: Blindness
  category: Ophthalmologic
  frequency: OCCASIONAL
  notes: >-
    Visual loss can progress to blindness in infantile disease. Aggregate Orphanet frequencies combine subtypes and stages.
  phenotype_term:
    preferred_term: Blindness
    term:
      id: HP:0000618
      label: Blindness
  evidence:
  - reference: PMID:24011710
    reference_title: "Beyond the cherry-red spot: Ocular manifestations of sphingolipid-mediated neurodegenerative and inflammatory disorders."
    supports: SUPPORT
    snippet: "Disorders such as Tay-Sachs or Niemann-Pick disease are the most familiar examples of dysfunction in sphingolipid metabolism and are typically associated with neurodegeneration and ocular findings such as blindness."
    explanation: Review establishes blindness as a characteristic ocular finding in sphingolipidoses including Tay-Sachs disease, though without quantitative frequency data.
    evidence_source: OTHER
  - reference: ORPHA:845
    reference_title: "Tay-Sachs disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000618 | Blindness | Occasional (29-5%)"
    explanation: Orphanet lists blindness as occasional for Tay-Sachs disease; visual impairment (HP:0000505) is more common at FREQUENT frequency.
- name: Visual Impairment
  category: Ophthalmologic
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Visual Impairment
    term:
      id: HP:0000505
      label: Visual impairment
  evidence:
  - reference: ORPHA:845
    reference_title: "Tay-Sachs disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000505 | Visual impairment | Frequent (79-30%)"
    explanation: Orphanet lists visual impairment as a frequent HPO phenotype for Tay-Sachs disease.
- name: Ataxia
  category: Neurological
  subtypes:
  - Juvenile Tay-Sachs
  - Late-Onset Tay-Sachs
  description: Gait and balance impairment are common presenting features of juvenile and late-onset Tay-Sachs disease.
  phenotype_term:
    preferred_term: Ataxia
    term:
      id: HP:0001251
      label: Ataxia
  evidence:
  - reference: PMID:17015493
    reference_title: "The natural history of juvenile or subacute GM2 gangliosidosis: 21 new cases and literature review of 134 previously reported."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The most common symptoms at onset were gait disturbances (66.7%), incoordination (52.4%), speech problems (28.6%), and developmental delay (28.6%)."
    explanation: Juvenile GM2 gangliosidosis cohort documents gait disturbance and incoordination at onset, supporting juvenile Tay-Sachs ataxia.
  - reference: PMID:15714079
    reference_title: "Late-onset Tay-Sachs disease: phenotypic characterization and genotypic correlations in 21 affected patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Mean age at onset was 18.1 years; balance problems and difficulty climbing stairs were the most frequent presenting complaints."
    explanation: Late-onset cohort identifies balance problems as a leading presenting complaint, supporting ataxia as a subtype-specific phenotype.
  - reference: PMID:39807213
    reference_title: "Diagnosing Late-Onset Tay-Sachs Through Next Generation Sequencing and Functional Enzyme Testing: From Genes to Enzymes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We report 2 cases of adult-onset progressive weakness, ataxia, and neuropsychiatric symptoms in a 30-year-old man and 37-year-old woman."
    explanation: Adult-onset cases directly document ataxia in late-onset Tay-Sachs disease.
- name: Muscle Weakness
  category: Neurological
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Muscle Weakness
    term:
      id: HP:0001324
      label: Muscle weakness
  evidence:
  - reference: ORPHA:845
    reference_title: "Tay-Sachs disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001324 | Muscle weakness | Very frequent (99-80%)"
    explanation: Orphanet lists muscle weakness as a very frequent HPO phenotype for Tay-Sachs disease.
- name: Skeletal Muscle Atrophy
  category: Neurological
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Skeletal Muscle Atrophy
    term:
      id: HP:0003202
      label: Skeletal muscle atrophy
  evidence:
  - reference: ORPHA:845
    reference_title: "Tay-Sachs disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0003202 | Skeletal muscle atrophy | Very frequent (99-80%)"
    explanation: Orphanet lists skeletal muscle atrophy as a very frequent HPO phenotype for Tay-Sachs disease.
- name: Proximal Muscle Weakness
  category: Neurological
  subtypes:
  - Juvenile Tay-Sachs
  - Late-Onset Tay-Sachs
  description: Progressive proximal weakness reflects motor neuron and motor pathway involvement in juvenile and late-onset disease.
  phenotype_term:
    preferred_term: Proximal muscle weakness
    term:
      id: HP:0003701
      label: Proximal muscle weakness
  evidence:
  - reference: PMID:17015493
    reference_title: "The natural history of juvenile or subacute GM2 gangliosidosis: 21 new cases and literature review of 134 previously reported."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Muscle wasting (10.6 +/- 7.4 years), proximal weakness (11.1 +/- 7.7 years), and incontinence of sphincters (14.6 +/- 9.7 years) appeared later in the course of the disease."
    explanation: Juvenile GM2 gangliosidosis natural-history cohort documents later proximal weakness, supporting juvenile Tay-Sachs motor weakness.
  - reference: PMID:39807213
    reference_title: "Diagnosing Late-Onset Tay-Sachs Through Next Generation Sequencing and Functional Enzyme Testing: From Genes to Enzymes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We report 2 cases of adult-onset progressive weakness, ataxia, and neuropsychiatric symptoms in a 30-year-old man and 37-year-old woman."
    explanation: Recent adult-onset cases directly document progressive weakness.
  - reference: PMID:15714079
    reference_title: "Late-onset Tay-Sachs disease: phenotypic characterization and genotypic correlations in 21 affected patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Early on, the majority of patients develop signs of either cerebellar or anterior motor neuron involvement."
    explanation: Anterior motor neuron involvement mechanistically supports progressive proximal weakness in late-onset disease.
- name: Psychosis
  category: Neuropsychiatric
  frequency: OCCASIONAL
  subtypes:
  - Late-Onset Tay-Sachs
  description: Psychotic episodes and other neuropsychiatric symptoms can dominate late-onset Tay-Sachs disease in some patients.
  phenotype_term:
    preferred_term: Psychosis
    term:
      id: HP:0000709
      label: Psychosis
  evidence:
  - reference: PMID:15714079
    reference_title: "Late-onset Tay-Sachs disease: phenotypic characterization and genotypic correlations in 21 affected patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Affected individuals may also develop psychotic episodes."
    explanation: Cohort conclusion explicitly reports psychotic episodes as part of late-onset Tay-Sachs disease.
  - reference: PMID:39807213
    reference_title: "Diagnosing Late-Onset Tay-Sachs Through Next Generation Sequencing and Functional Enzyme Testing: From Genes to Enzymes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We report 2 cases of adult-onset progressive weakness, ataxia, and neuropsychiatric symptoms in a 30-year-old man and 37-year-old woman."
    explanation: Adult-onset cases support neuropsychiatric involvement in late-onset Tay-Sachs disease.
  - reference: ORPHA:845
    reference_title: "Tay-Sachs disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000709 | Psychosis | Occasional (29-5%)"
    explanation: Orphanet lists psychosis as an occasional HPO phenotype for Tay-Sachs disease.
- name: Progressive Spasticity
  category: Neurological
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Progressive Spasticity
    term:
      id: HP:0002191
      label: Progressive spasticity
  evidence:
  - reference: ORPHA:845
    reference_title: "Tay-Sachs disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002191 | Progressive spasticity | Very frequent (99-80%)"
    explanation: Orphanet lists progressive spasticity as a very frequent HPO phenotype for Tay-Sachs disease.
- name: Spasticity
  category: Neurological
  subtypes:
  - Infantile Tay-Sachs
  - Juvenile Tay-Sachs
  - Late-Onset Tay-Sachs
  description: >-
    Progressive motor pathway dysfunction produces spasticity, particularly in juvenile disease; this is distinct from an unspecified spasm.
  phenotype_term:
    preferred_term: Spasticity
    term:
      id: HP:0001257
      label: Spasticity
  evidence:
  - reference: PMID:20301397
    reference_title: HEXA Disorders.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Spasticity, dysphagia, and seizures are present by the end of the first decade of life, with death within the second decade of life, usually by aspiration.
    explanation: >-
      GeneReviews supports juvenile motor/bulbar progression and aspiration complications.
  - reference: PMID:20301397
    reference_title: HEXA Disorders.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Late-onset TSD presents in older teens or young adults with a slowly progressive spectrum of neurologic symptoms including lower-extremity weakness with muscle atrophy, dysarthria, incoordination, tremor, mild spasticity and/or dystonia, and psychiatric manifestations including acute psychosis.
    explanation: >-
      The late-onset spectrum spans cerebellar, motor, and neuropsychiatric dysfunction.
- name: Dysarthria
  category: Neurological
  frequency: FREQUENT
  subtypes:
  - Juvenile Tay-Sachs
  - Late-Onset Tay-Sachs
  description: >-
    Motor speech impairment occurs in juvenile and late-onset disease.
  phenotype_term:
    preferred_term: Dysarthria
    term:
      id: HP:0001260
      label: Dysarthria
  evidence:
  - reference: PMID:17015493
    reference_title: "The natural history of juvenile or subacute GM2 gangliosidosis: 21 new cases and literature review of 134 previously reported."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Speech deterioration progressed more rapidly than gait abnormalities in both the Tay-Sachs variant and Sandhoff variant groups."
    explanation: Juvenile GM2 gangliosidosis natural history documents progressive speech deterioration in the Tay-Sachs variant.
  - reference: PMID:30524313
    reference_title: "New Approaches to Tay-Sachs Disease Therapy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The juvenile form of the disease strikes in early childhood, usually at the age of 3–10 years. Common symptoms are ataxia, dysarthria, dysphagia development, hypotension, and spasm progression."
    explanation: Review explicitly lists dysarthria among common juvenile Tay-Sachs symptoms.
  - reference: ORPHA:845
    reference_title: "Tay-Sachs disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001260 | Dysarthria | Frequent (79-30%)"
    explanation: Orphanet lists dysarthria as a frequent HPO phenotype for Tay-Sachs disease.
  - reference: PMID:20301397
    reference_title: HEXA Disorders.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Late-onset TSD presents in older teens or young adults with a slowly progressive spectrum of neurologic symptoms including lower-extremity weakness with muscle atrophy, dysarthria, incoordination, tremor, mild spasticity and/or dystonia, and psychiatric manifestations including acute psychosis.
    explanation: >-
      The late-onset spectrum spans cerebellar, motor, and neuropsychiatric dysfunction.
- name: Dysphagia
  category: Neurological
  frequency: FREQUENT
  subtypes:
  - Infantile Tay-Sachs
  - Juvenile Tay-Sachs
  description: Swallowing dysfunction occurs in infantile and juvenile Tay-Sachs disease as neurodegeneration progresses.
  phenotype_term:
    preferred_term: Dysphagia
    term:
      id: HP:0002015
      label: Dysphagia
  evidence:
  - reference: PMID:30524313
    reference_title: "New Approaches to Tay-Sachs Disease Therapy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Common neurodegenerative symptoms in infants are hypotension, inability to sit or hold their head unsupported, eye movement abnormalities, dysphagia, spasms, and hypomyelination"
    explanation: Review lists dysphagia among common infantile Tay-Sachs neurodegenerative symptoms.
  - reference: PMID:17015493
    reference_title: "The natural history of juvenile or subacute GM2 gangliosidosis: 21 new cases and literature review of 134 previously reported."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "However, dysphagia, sphincter incontinence, and sleep problems occurred earlier in those with the Tay-Sachs variant."
    explanation: Juvenile GM2 gangliosidosis natural history documents earlier dysphagia in the Tay-Sachs variant.
  - reference: ORPHA:845
    reference_title: "Tay-Sachs disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002015 | Dysphagia | Frequent (79-30%)"
    explanation: Orphanet lists dysphagia as a frequent HPO phenotype for Tay-Sachs disease.
- name: GM2 Ganglioside Accumulation
  category: Biochemical
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: GM2 Ganglioside Accumulation
    term:
      id: HP:0003495
      label: GM2-ganglioside accumulation
  evidence:
  - reference: ORPHA:845
    reference_title: "Tay-Sachs disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0003495 | GM2-ganglioside accumulation | Very frequent (99-80%)"
    explanation: Orphanet lists GM2-ganglioside accumulation as a very frequent HPO phenotype for Tay-Sachs disease.
- name: Hypomyelination
  category: Neurological
  subtypes:
  - Infantile Tay-Sachs
  description: >-
    Reduced cerebral myelination is observed in infantile disease; oligodendrocyte density loss is directly documented in sheep and should not be assumed to explain all human white-matter abnormalities.
  phenotype_term:
    preferred_term: Cerebral hypomyelination
    term:
      id: HP:0006808
      label: Cerebral hypomyelination
  evidence:
  - reference: PMID:30524313
    reference_title: "New Approaches to Tay-Sachs Disease Therapy."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Common neurodegenerative symptoms in infants are hypotension, inability to sit or hold their head unsupported, eye movement abnormalities, dysphagia, spasms, and hypomyelination"
    explanation: Review explicitly lists hypomyelination among common neurodegenerative findings in infantile Tay-Sachs disease.
  - reference: PMID:34456134
    reference_title: "Natural history of Tay-Sachs disease in sheep."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Myelination is reduced primarily in the forebrain illustrated by loss of white matter on MRI."
    explanation: Sheep Tay-Sachs natural-history model recapitulates reduced forebrain myelination on MRI.
- name: Cerebellar Atrophy
  category: Neurological
  subtypes:
  - Juvenile Tay-Sachs
  - Late-Onset Tay-Sachs
  description: Cerebellar atrophy is the most common neuroimaging finding in juvenile and late-onset Tay-Sachs disease and may be present even when focal neurologic deficits are subtle.
  phenotype_term:
    preferred_term: Cerebellar Atrophy
    term:
      id: HP:0001272
      label: Cerebellar atrophy
  evidence:
  - reference: PMID:17015493
    reference_title: "The natural history of juvenile or subacute GM2 gangliosidosis: 21 new cases and literature review of 134 previously reported."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Cerebellar atrophy was the most common finding on brain MRI (52.9%)."
    explanation: Juvenile GM2 gangliosidosis natural history identifies cerebellar atrophy as the most common MRI finding.
  - reference: PMID:15714079
    reference_title: "Late-onset Tay-Sachs disease: phenotypic characterization and genotypic correlations in 21 affected patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Brain imaging studies revealed marked cerebellar atrophy in all patients (N = 18) tested, regardless of disease stage."
    explanation: Late-onset cohort documents marked cerebellar atrophy in all imaged patients across disease stages.
  - reference: PMID:28739864
    reference_title: "Late-onset Tay-Sachs disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "MR scan of the brain showed isolated cerebellar atrophy"
    explanation: Adult-onset Tay-Sachs case report documents isolated cerebellar atrophy on brain MRI.
- name: Tremor
  category: Neurological
  subtypes:
  - Late-Onset Tay-Sachs
  description: Action tremor may occur in late-onset disease; co-occurring myoclonus is represented separately.
  phenotype_term:
    preferred_term: Tremor
    term:
      id: HP:0001337
      label: Tremor
  evidence:
  - reference: PMID:28739864
    reference_title: "Late-onset Tay-Sachs disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "irregular action tremor and stimulus-sensitive myoclonus of the arms"
    explanation: Adult-onset Tay-Sachs case report documents irregular action tremor and stimulus-sensitive myoclonus as motor features of late-onset disease.
- name: Dystonia
  description: >-
    May accompany late-onset motor disease.
  phenotype_term:
    preferred_term: Dystonia
    term:
      id: HP:0001332
      label: Dystonia
  evidence:
  - reference: PMID:20301397
    reference_title: HEXA Disorders.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Late-onset TSD presents in older teens or young adults with a slowly progressive spectrum of neurologic symptoms including lower-extremity weakness with muscle atrophy, dysarthria, incoordination, tremor, mild spasticity and/or dystonia, and psychiatric manifestations including acute psychosis.
    explanation: >-
      GeneReviews describes the late-onset motor and psychiatric spectrum.
  subtypes:
  - Late-Onset Tay-Sachs
- name: Cognitive decline
  description: >-
    Progressive cognitive loss occurs in juvenile disease; later-onset patients may show subtler executive and affective dysfunction.
  phenotype_term:
    preferred_term: Mental deterioration
    term:
      id: HP:0001268
      label: Mental deterioration
  evidence:
  - reference: PMID:20301397
    reference_title: HEXA Disorders.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: the emergence of abnormal gait or dysarthria is noted followed by loss of previously acquired skills and cognitive decline.
    explanation: >-
      Juvenile disease includes progressive cognitive loss.
  - reference: PMID:31964693
    reference_title: Quantitative oculomotor and nonmotor assessments in late-onset GM2 gangliosidosis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Nine out of ten patients with LOGG had evidence of the CCAS (5/10 definite, 2/10 probable, 2/10 possible).
    explanation: >-
      Selected mixed late-onset GM2 cohort supports cognitive involvement without implying universal dementia.
  subtypes:
  - Juvenile Tay-Sachs
  - Late-Onset Tay-Sachs
- name: Frequent falls
  description: >-
    Lower-extremity weakness and impaired balance increase fall risk in later-onset disease.
  phenotype_term:
    preferred_term: Frequent falls
    term:
      id: HP:0002359
      label: Frequent falls
  evidence:
  - reference: PMID:20301397
    reference_title: HEXA Disorders.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: circumstances that exacerbate the risk of falls (i.e., walking on uneven or unstable surfaces)
    explanation: >-
      GeneReviews identifies fall risk requiring preventive care.
  subtypes:
  - Late-Onset Tay-Sachs
- name: Myoclonus
  description: >-
    Myoclonic movements can occur; this is distinct from tremor and does not imply that every jerk is epileptic.
  phenotype_term:
    preferred_term: Myoclonus
    term:
      id: HP:0001336
      label: Myoclonus
  evidence:
  - reference: PMID:28739864
    reference_title: Late-onset Tay-Sachs disease.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: irregular action tremor and stimulus-sensitive myoclonus of the arms
    explanation: >-
      The clinical case separately documents action tremor and myoclonus.
  subtypes:
  - Late-Onset Tay-Sachs
- name: Depression
  description: >-
    Mood symptoms are part of the late-onset neuropsychiatric spectrum.
  phenotype_term:
    preferred_term: Depression
    term:
      id: HP:0000716
      label: Depression
  evidence:
  - reference: PMID:18642377
    reference_title: 'Late-onset Tay-Sachs disease: the spectrum of peripheral neuropathy in 30 affected patients.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: ataxia, weakness, spasticity, dysarthria, dysphagia, dystonia, seizures, psychosis, mania, depression, and cognitive decline.
    explanation: >-
      The clinical cohort report recognizes a broad CNS symptom spectrum.
  subtypes:
  - Late-Onset Tay-Sachs
- name: Sleep disturbance
  description: >-
    Reported in juvenile disease and late-onset cohorts, with subtype and stage-dependent expression.
  phenotype_term:
    preferred_term: Sleep disturbance
    term:
      id: HP:0002360
      label: Sleep disturbance
  evidence:
  - reference: PMID:17015493
    reference_title: 'The natural history of juvenile or subacute GM2 gangliosidosis: 21 new cases and literature review of 134 previously reported.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: However, dysphagia, sphincter incontinence, and sleep problems occurred earlier in those with the Tay-Sachs variant.
    explanation: >-
      The juvenile cohort includes 15 Tay-Sachs and six Sandhoff patients; timing differs by subtype.
  - reference: PMID:31964693
    reference_title: Quantitative oculomotor and nonmotor assessments in late-onset GM2 gangliosidosis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Excessive daytime sleepiness was present in 4/10 and 8/10 had poor subjective sleep quality.
    explanation: >-
      Small mixed late-onset GM2 cohort; these are not Tay-Sachs-specific population prevalence estimates.
- name: Abnormal saccadic eye movements
  description: >-
    Quantitative testing can detect cerebellar eye-movement abnormalities despite an apparently normal bedside examination.
  phenotype_term:
    preferred_term: Abnormal saccadic eye movements
    term:
      id: HP:0000570
      label: Abnormal saccadic eye movements
  evidence:
  - reference: PMID:31964693
    reference_title: Quantitative oculomotor and nonmotor assessments in late-onset GM2 gangliosidosis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Oculomotor abnormalities were found in all participants, including 3/10 with clinically normal eye movements.
    explanation: >-
      Cross-sectional mixed late-onset GM2 study supports sensitive oculomotor findings, not universal Tay-Sachs penetrance.
  subtypes:
  - Late-Onset Tay-Sachs
- name: Axonal polyneuropathy
  description: >-
    Predominantly distal axon-loss polyneuropathy was found in 8/30 late-onset Tay-Sachs patients. This is distinct from the lower motor neuron syndrome; a broader mixed demyelinating/axonal ontology term would be inaccurate.
  phenotype_term:
    preferred_term: Axonal polyneuropathy
  evidence:
  - reference: PMID:18642377
    reference_title: 'Late-onset Tay-Sachs disease: the spectrum of peripheral neuropathy in 30 affected patients.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: found evidence of a predominantly axon loss polyneuropathy affecting distal nerve segments in the lower and upper extremities in eight patients (27%).
    explanation: >-
      Clinical and electrophysiologic examination of 30 LOTS patients supports peripheral involvement in a subset.
  subtypes:
  - Late-Onset Tay-Sachs
- name: Sphincter incontinence
  description: >-
    Sphincter incontinence is a later feature of juvenile GM2 disease. The mixed natural-history cohort found earlier onset in the Tay-Sachs subgroup; no bowel-versus-bladder frequency is inferred.
  phenotype_term:
    preferred_term: Sphincter incontinence
  evidence:
  - reference: PMID:17015493
    reference_title: 'The natural history of juvenile or subacute GM2 gangliosidosis: 21 new cases and literature review of 134 previously reported.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Muscle wasting (10.6 +/- 7.4 years), proximal weakness (11.1 +/- 7.7 years), and incontinence of sphincters (14.6 +/- 9.7 years) appeared later in the course of the disease.
    explanation: >-
      The prospective juvenile cohort included 15 Tay-Sachs and six Sandhoff patients; pooled ages are not Tay-Sachs-specific prevalence estimates.
  subtypes:
  - Juvenile Tay-Sachs
  notes: Free-text descriptor preserves the source’s combined sphincter finding without selecting an unsupported organ-specific HPO term.
biochemical:
- name: Hexosaminidase A Activity
  presence: Decreased
  context: >-
    Absent or low activity in serum, leukocytes or fibroblasts, with HexB preserved; synthetic-substrate results depend on allele and assay. B1 alleles can cause false-negative results, whereas pseudodeficiency causes false-positive results.
  readouts:
  - target: Hexosaminidase A deficiency
    relationship: READOUT_OF
    direction: NEGATIVE
    endpoint_context: DIAGNOSTIC
    interpretation: The low enzyme activity state reports HexA deficiency; assay-specific residual activity is not a universal clinical severity threshold.
    evidence:
    - reference: PMID:40710901
      reference_title: "Advances in Diagnosis, Pathological Mechanisms, Clinical Impact, and Future Therapeutic Perspectives in Tay-Sachs Disease."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Diagnosis is based on enzymatic testing showing reduced or absent hexosaminidase A activity, confirmed by genetic testing."
      explanation: Review states that reduced or absent Hexosaminidase A activity is the enzymatic diagnostic basis for Tay-Sachs disease.
  evidence:
  - reference: PMID:40710901
    reference_title: "Advances in Diagnosis, Pathological Mechanisms, Clinical Impact, and Future Therapeutic Perspectives in Tay-Sachs Disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Diagnosis is based on enzymatic testing showing reduced or absent hexosaminidase A activity, confirmed by genetic testing."
    explanation: Supports reduced Hexosaminidase A activity as the diagnostic biochemical abnormality.
- name: GM2 Ganglioside
  presence: Elevated
  context: Accumulates in brain tissue
  readouts:
  - target: GM2 ganglioside accumulation in neurons
    relationship: READOUT_OF
    direction: POSITIVE
    interpretation: Tissue GM2 measures storage burden; this is not a routine standalone diagnostic test or validated clinical surrogate.
    evidence:
    - reference: PMID:22025593
      reference_title: "Natural history of infantile G(M2) gangliosidosis."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "G(M2) gangliosidoses are caused by an inherited deficiency of lysosomal β-hexosaminidase and result in ganglioside accumulation in the brain."
      explanation: Natural-history data link beta-hexosaminidase deficiency to ganglioside accumulation in the brain.
  evidence:
  - reference: PMID:22025593
    reference_title: "Natural history of infantile G(M2) gangliosidosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "G(M2) gangliosidoses are caused by an inherited deficiency of lysosomal β-hexosaminidase and result in ganglioside accumulation in the brain."
    explanation: Supports elevated GM2/ganglioside storage in affected brain tissue.
- name: Plasma GM2 34:1 and GM2/GM3 ratio
  presence: INCREASED
  context: >-
    Candidate plasma diagnostic and monitoring biomarkers in a small mixed GM2 cohort; 100% case-control discrimination must not be generalized to unselected clinical populations.
  evidence:
  - reference: PMID:36709536
    reference_title: Plasma G(M2) ganglioside potential biomarker for diagnosis, prognosis and disease monitoring of GM2-Gangliosidosis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: GM234:1 and GM234:1/GM334:1 ratio discriminated patients from controls with 100% sensitivity and specificity.
    explanation: >-
      Perfect discrimination was in the study sample of 19 GM2 cases (nine Tay-Sachs) and 20 controls; independent diagnostic validation and therapeutic-surrogate validity are not established.
  readouts:
  - target: GM2 ganglioside accumulation in neurons
    relationship: CORRELATES_WITH
    interpretation: Plasma lipid abundance is an indirect systemic marker, not a direct measurement of neuronal GM2 or a validated surrogate for neurologic benefit.
    evidence:
    - reference: PMID:36709536
      reference_title: Plasma G(M2) ganglioside potential biomarker for diagnosis, prognosis and disease monitoring of GM2-Gangliosidosis.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: GM234:1 and GM234:1/GM334:1 ratio discriminated patients from controls with 100% sensitivity and specificity.
      explanation: >-
        Perfect discrimination was in the study sample of 19 GM2 cases (nine Tay-Sachs) and 20 controls; independent diagnostic validation and therapeutic-surrogate validity are not established.
- name: CSF GM2 concentration
  presence: INCREASED
  context: >-
    Investigational pharmacodynamic marker; AMETHIST showed reduction without correlated clinical improvement.
  evidence:
  - reference: PMID:41108138
    reference_title: 'Venglustat in GM2 gangliosidoses and related disorders: Results of the AMETHIST randomized controlled and basket trials.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: In adults with late-onset GM2 gangliosidoses, oral venglustat decreased CSF GM2 concentrations but without clinical improvement in the endpoints assessed.
    explanation: >-
      AMETHIST randomized 40 to venglustat and 19 to placebo; 16 additional patients entered a separate open-label basket cohort.
  readouts:
  - target: GM2 ganglioside accumulation in neurons
    relationship: PHARMACODYNAMIC_MARKER_OF
    endpoint_context: PHARMACODYNAMIC
    interpretation: Reflects substrate-reduction target engagement; change is not established to predict clinical benefit.
    evidence:
    - reference: PMID:41108138
      reference_title: 'Venglustat in GM2 gangliosidoses and related disorders: Results of the AMETHIST randomized controlled and basket trials.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Decreased CSF GM2 concentrations did not correlate with clinical endpoints.
      explanation: >-
        The randomized trial directly limits use of CSF GM2 as a clinical efficacy surrogate.
- name: Cerebellar myo-inositol
  presence: INCREASED
  context: Cross-sectional MRS finding in a small mixed late-onset GM2 cohort.
  evidence:
  - reference: PMID:34226107
    reference_title: Magnetic resonance imaging and spectroscopy in late-onset GM2-gangliosidosis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: an increase in mI indicates possible neuroinflammation in LOGG (more so within the LOTS subvariant).
    explanation: >-
      MRI/MRS in seven LOTS and three late-onset Sandhoff patients plus seven controls provides a nonspecific cross-sectional proxy, not direct histology or causal confirmation.
  readouts:
  - target: Neuroinflammation and Astrogliosis
    relationship: CORRELATES_WITH
    interpretation: Nonspecific neurometabolic correlate; prospective outcome and treatment-response validity remain unresolved.
    evidence:
    - reference: PMID:34226107
      reference_title: Magnetic resonance imaging and spectroscopy in late-onset GM2-gangliosidosis.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: an increase in mI indicates possible neuroinflammation in LOGG (more so within the LOTS subvariant).
      explanation: >-
        MRI/MRS in seven LOTS and three late-onset Sandhoff patients plus seven controls provides a nonspecific cross-sectional proxy, not direct histology or causal confirmation.
- name: Cerebellar N-acetylaspartate
  presence: DECREASED
  context: Cross-sectional MRS finding in a small mixed late-onset GM2 cohort.
  evidence:
  - reference: PMID:34226107
    reference_title: Magnetic resonance imaging and spectroscopy in late-onset GM2-gangliosidosis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The decrease of NAA in the cerebellum suggests that, in addition to cerebellar atrophy, there is ongoing impaired neuronal function and/or loss
    explanation: >-
      MRI/MRS in seven LOTS and three late-onset Sandhoff patients plus seven controls provides a nonspecific cross-sectional proxy, not direct histology or causal confirmation.
  readouts:
  - target: Neuronal injury
    relationship: CORRELATES_WITH
    interpretation: Nonspecific neurometabolic correlate; prospective outcome and treatment-response validity remain unresolved.
    evidence:
    - reference: PMID:34226107
      reference_title: Magnetic resonance imaging and spectroscopy in late-onset GM2-gangliosidosis.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: The decrease of NAA in the cerebellum suggests that, in addition to cerebellar atrophy, there is ongoing impaired neuronal function and/or loss
      explanation: >-
        MRI/MRS in seven LOTS and three late-onset Sandhoff patients plus seven controls provides a nonspecific cross-sectional proxy, not direct histology or causal confirmation.
genetic:
- name: HEXA
  gene_term:
    preferred_term: HEXA
    term:
      id: hgnc:4878
      label: HEXA
  association: Causative
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  inheritance:
  - name: Autosomal recessive
    inheritance_term:
      preferred_term: Autosomal recessive inheritance
      term:
        id: HP:0000007
        label: Autosomal recessive inheritance
  variants:
  - name: HEXA p.Gly269Ser (G269S)
    description: >-
      Recurrent pathogenic residual-activity allele associated with late-onset disease. A single homozygous patient in the 21-person cohort had onset at 36 and relatively slow progression; this does not determine onset for every homozygote.
    clinical_significance: PATHOGENIC
    type: missense
    evidence:
    - reference: PMID:15714079
      reference_title: "Late-onset Tay-Sachs disease: phenotypic characterization and genotypic correlations in 21 affected patients."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Disease onset (age 36 years) was delayed and progression relatively slower in the homozygous G269S patient."
      explanation: Cohort data support G269S as a pathogenic residual-activity allele with a later and slower phenotype.
  evidence:
  - reference: PMID:40710901
    reference_title: "Advances in Diagnosis, Pathological Mechanisms, Clinical Impact, and Future Therapeutic Perspectives in Tay-Sachs Disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Mechanistically, TSD is caused by mutations in the HEXA gene, which encodes the alpha subunit of hexosaminidase A."
    explanation: Review supports HEXA as the causative gene for Tay-Sachs disease.
  - reference: PMID:15714079
    reference_title: "Late-onset Tay-Sachs disease: phenotypic characterization and genotypic correlations in 21 affected patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The patients' alpha-subunit mutations (beta-Hexosaminidase A genotype) were determined and correlated with their corresponding clinical findings and disease course."
    explanation: Late-onset cohort links HEXA alpha-subunit genotypes to clinical disease course.
  - reference: CGGV:assertion_1f7530b5-af31-40f9-ac18-a1b4d404285a-2020-05-27T160000.000Z
    reference_title: "HEXA / Tay-Sachs disease (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HEXA | HGNC:4878 | Tay-Sachs disease | MONDO:0010100 | AR | Definitive"
    explanation: ClinGen classifies the HEXA-Tay-Sachs disease gene-disease relationship as definitive with autosomal recessive inheritance.
  - reference: PMID:10571007
    reference_title: Biochemical consequences of mutations causing the GM2 gangliosidoses.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: It appears that the detrimental effect of most mutations is not specifically on functional elements of the protein, but rather on the proteins' overall folding and/or intracellular transport.
    explanation: >-
      Biochemical review distinguishes variant effects on folding/transport from the rarer substrate-specific functional changes.
  notes: >-
    Biallelic loss-of-function HEXA alleles impair synthesis, splicing, folding, transport, stability or catalytic function of the HexA alpha subunit. Variant severity and residual activity contribute to the clinical continuum, with incomplete individual genotype-phenotype prediction. Founder alleles enrich some populations, but disease occurs across ancestries.
treatments:
- name: Hematopoietic stem cell transplantation (HSCT)
  description: >-
    An uncontrolled late-onset case had normalized leukocyte HexA and nonprogressive tremor eight years after HSCT. Most features were already static before transplantation, so this does not establish that HSCT arrests neurodegeneration or normalizes CNS enzyme activity. Infantile natural-history data found no associated survival advantage; HSCT is not established standard care.
  therapeutic_modality: CELL_THERAPY
  treatment_term:
    preferred_term: hematopoietic stem cell transplantation
    term:
      id: NCIT:C15431
      label: Hematopoietic Cell Transplantation
  evidence:
  - reference: PMID:29214523
    reference_title: "Haematopoietic Stem Cell Transplantation Arrests the Progression of Neurodegenerative Disease in Late-Onset Tay-Sachs Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "HSCT is a potential treatment option which might arrest neurodegeneration in patients with LOTS."
    explanation: >-
      One case provides a biochemical and longitudinal clinical signal; pretreatment stability and lack of controls limit causal efficacy inference.
  - reference: PMID:29214523
    reference_title: Haematopoietic Stem Cell Transplantation Arrests the Progression of Neurodegenerative Disease in Late-Onset Tay-Sachs Disease.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: His condition had had a static course apart from his tremor that had been gradually deteriorating.
    explanation: >-
      The pretreatment course limits claims that transplantation halted otherwise progressive global disease.
  - reference: PMID:22025593
    reference_title: Natural history of infantile G(M2) gangliosidosis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Hematopoietic stem cell transplantation was not associated with prolonged survival.
    explanation: >-
      Five transplant recipients were evaluated separately in this infantile GM2 natural-history study; this is observational evidence, not randomized efficacy testing.
- name: Supportive Care
  description: >-
    Individualized seizure management, nutritional and swallowing assessment, airway clearance and aspiration prevention, and physical, occupational and speech therapy support function and comfort. Monitor constipation, mobility, skin/contracture risk, and psychiatric needs. Neurology follow-up is guided by clinical concerns; avoid excessive sedation, aspiration-promoting positioning and high fall risk.
  treatment_term:
    preferred_term: Supportive Care
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - reference: PMID:27491214
    reference_title: "The GM1 and GM2 Gangliosidoses: Natural History and Progress toward Therapy."
    supports: SUPPORT
    snippet: "Both are devastating diseases without cure or specific treatment however, with the use of supportive aggressive medical management, the lifespan and quality of life has been extended for both diseases."
    explanation: Review confirms supportive care extends lifespan and quality of life in GM2 gangliosidoses including Tay-Sachs disease.
    evidence_source: OTHER
  - reference: PMID:20301397
    reference_title: HEXA Disorders.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Treatment is mostly supportive and directed to providing adequate nutrition and hydration, managing infectious disease, protecting the airway, and controlling seizures.
    explanation: >-
      GeneReviews sets the clinical management priorities across systems.
  - reference: PMID:20301397
    reference_title: HEXA Disorders.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: psychiatric medications that have been associated with disease worsening, including haloperidol, risperidone, and chlorpromazine.
    explanation: >-
      Psychiatric care requires disease-aware individualized drug selection.
- name: Genetic Counseling
  description: >-
    Offer counseling, family/partner carrier testing and reproductive options across ancestries. Founder variants inform testing but do not exclude disease outside founder populations. Once familial variants are known, prenatal and preimplantation genetic testing are possible. Full-gene testing addresses limitations of founder-only panels.
  treatment_term:
    preferred_term: Genetic Counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
  evidence:
  - reference: PMID:12108829
    reference_title: "Tay-Sachs disease screening and counseling families at risk for metabolic disease."
    supports: SUPPORT
    snippet: "Carrier testing for Tay-Sachs disease should be offered to couples when at least one individual is of Ashkenazi Jewish (carrier frequency 1/30), Pennsylvania Dutch, Southern Louisiana Cajun, or Eastern Quebec French Canadian descent."
    explanation: Review establishes carrier screening recommendations for high-risk populations including Ashkenazi Jews.
    evidence_source: OTHER
  - reference: PMID:20301397
    reference_title: HEXA Disorders.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Once both HEXA pathogenic variants have been identified in an affected family member, targeted analysis for the specific familial variants can be used for carrier testing in at-risk relatives.
    explanation: >-
      Family-specific molecular testing supports reproductive counseling.
- name: Miglustat substrate reduction investigation
  description: >-
    Miglustat reduces glycosphingolipid synthesis upstream of GM2. In a 30-patient late-onset Tay-Sachs randomized open-label study, no efficacy difference was observed; two infantile cases also continued neurologic deterioration despite CSF drug exposure. It is not an established disease-modifying treatment for Tay-Sachs.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: miglustat
      term:
        id: CHEBI:50381
        label: miglustat
  evidence:
  - reference: PMID:19346952
    reference_title: 'Miglustat in late-onset Tay-Sachs disease: a 12-month, randomized, controlled clinical study with 24 months of extended treatment.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: No differences were observed between the two groups in any efficacy measure, either during the 12-month randomized phase or the full 36 months.
    explanation: >-
      Thirty LOTS patients were randomized 20:10 to miglustat versus no miglustat for 12 months, followed by an open extension; measurable benefit was not established.
  - reference: PMID:16434676
    reference_title: Substrate reduction therapy in the infantile form of Tay-Sachs disease.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: SRT could not arrest the patients' neurologic deterioration.
    explanation: >-
      Two infantile cases illustrate that CSF drug exposure is not sufficient evidence of clinical benefit.
  therapeutic_modality: SMALL_MOLECULE
- name: Pharmacological Chaperone Therapy
  description: >-
    Pyrimethamine can stabilize selected residual-activity HexA variants, but the response is allele- and dose-dependent. A four-patient extended pilot showed transient lymphocyte enzyme increases without discernible neurologic or psychiatric benefit. Peripheral enzyme activity does not establish CNS correction.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: pyrimethamine
      term:
        id: CHEBI:8673
        label: pyrimethamine
  evidence:
  - reference: PMID:35865957
    reference_title: "Therapeutic Strategies For Tay-Sachs Disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "This review summarizes multiple drug development strategies for TSD, including enzyme replacement therapy, pharmaceutical chaperone therapy, substrate reduction therapy, gene therapy, and hematopoietic stem cell replacement therapy."
    explanation: Review of Tay-Sachs therapeutics establishes pharmaceutical chaperone therapy as one of the active drug-development strategies for the disease.
  - reference: PMID:25896637
    reference_title: 'Effect of cyclic, low dose pyrimethamine treatment in patients with Late Onset Tay Sachs: an open label, extended pilot study.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: However, the observed increase is repeatedly transient and not associated with discernible beneficial neurological or psychiatric effects.
    explanation: >-
      Four-patient extended pilot found transient lymphocyte HexA increases without discernible clinical benefit.
  therapeutic_modality: SMALL_MOLECULE
- name: Gene Therapy
  description: >-
    Investigational CNS-directed AAV delivery of HEXA and HEXB aims to restore HexA. Expanded access treated two infants in 2022; a subsequent nonrandomized dose-escalation trial treated seven Tay-Sachs and two Sandhoff patients. CSF enzyme activity increased, peaking near 12 weeks before declining, with partial or temporary infantile clinical stabilization. Two of three juvenile participants developed new or worsening dystonia and juvenile enrollment stopped. Vector-associated immune/transaminase responses required corticosteroids. Clinical efficacy remains incomplete and uncontrolled; serum Hex activity is not a CNS surrogate. TSHA-101 uses a different bicistronic AAV9 product from the dual AAVrh8 vectors in these publications.
  treatment_term:
    preferred_term: Gene Therapy
    term:
      id: NCIT:C15238
      label: Gene Therapy
  evidence:
  - reference: PMID:35145305
    reference_title: AAV gene therapy for Tay-Sachs disease.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: This study provides early safety and proof-of-concept data in humans for treatment of patients with TSD by AAV gene therapy.
    explanation: >-
      Two-infant expanded-access study provides early feasibility information, not proof of long-term safety or efficacy.
  - reference: PMID:40817303
    reference_title: 'Dual-vector rAAVrh8 gene therapy for GM2 gangliosidosis: a phase 1/2 trial.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Overall, HexA activity levels peaked in most participants at 12 weeks and declined somewhat thereafter, but remained above pretreatment levels throughout the duration of the study
    explanation: >-
      Nine-patient nonrandomized phase 1/2 trial (seven Tay-Sachs, two Sandhoff; six infantile, three juvenile) showed biochemical activity, with incomplete clinical efficacy.
  - reference: PMID:40817303
    reference_title: 'Dual-vector rAAVrh8 gene therapy for GM2 gangliosidosis: a phase 1/2 trial.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Interestingly, two of three juvenile patients noted new or worsening dystonia, and the third experienced unexpected progression of the neurologic manifestations of their GM2 gangliosidosis.
    explanation: >-
      Juvenile toxicity led to exclusion from further recruitment and outcome analysis; risk cannot be generalized across products or all delivery routes.
  - reference: PMID:40817303
    reference_title: 'Dual-vector rAAVrh8 gene therapy for GM2 gangliosidosis: a phase 1/2 trial.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Despite partial or temporary stabilization in disease course, there was no clear effect on the development of seizures.
    explanation: >-
      The discussion tempers the abstract’s seizure-benefit wording; historical comparisons and nine patients do not establish controlled efficacy.
  therapeutic_modality: GENE_THERAPY
  target_mechanisms:
  - target: Hexosaminidase A deficiency
    treatment_effect: RESTORES
    description: Gene delivery supplies HexA subunits and increases residual CNS enzyme activity; it does not correct the germline HEXA sequence.
    evidence:
    - reference: PMID:40817303
      reference_title: 'Dual-vector rAAVrh8 gene therapy for GM2 gangliosidosis: a phase 1/2 trial.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Overall, HexA activity levels peaked in most participants at 12 weeks and declined somewhat thereafter, but remained above pretreatment levels throughout the duration of the study
      explanation: >-
        Nine-patient nonrandomized phase 1/2 trial (seven Tay-Sachs, two Sandhoff; six infantile, three juvenile) showed biochemical activity, with incomplete clinical efficacy.
- name: Venglustat substrate reduction investigation
  description: >-
    AMETHIST reduced CSF GM2 by 47.6% versus 11.3% with placebo over 104 weeks but did not improve the clinical endpoints assessed. The trial demonstrates biochemical target engagement without established clinical efficacy in late-onset GM2 gangliosidosis.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: venglustat
  evidence:
  - reference: PMID:41108138
    reference_title: 'Venglustat in GM2 gangliosidoses and related disorders: Results of the AMETHIST randomized controlled and basket trials.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: In adults with late-onset GM2 gangliosidoses, oral venglustat decreased CSF GM2 concentrations but without clinical improvement in the endpoints assessed.
    explanation: >-
      AMETHIST randomized 40 to venglustat and 19 to placebo; 16 additional patients entered a separate open-label basket cohort.
  therapeutic_modality: SMALL_MOLECULE
- name: N-acetyl-L-leucine investigation
  description: >-
    A phase IIb open-label, rater-blinded treatment/washout study met its short-term functional endpoint in a mixed Tay-Sachs/Sandhoff cohort. The study provides Class IV evidence; long-term disease modification and the disease-specific mechanism remain unresolved.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: N-acetyl-L-leucine
      term:
        id: CHEBI:17786
        label: N-acetyl-L-leucine
  evidence:
  - reference: PMID:36456200
    reference_title: Efficacy and Safety of N-Acetyl-l-Leucine in Children and Adults With GM2 Gangliosidoses.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: This study provides Class IV evidence that NALL improves outcomes for patients with GM2 gangliosidoses.
    explanation: >-
      Open-label, rater-blinded six-week treatment/washout study enrolled 30 mixed GM2 patients; short-term functional signals do not establish durable disease modification.
  therapeutic_modality: SMALL_MOLECULE
- name: Nizubaglustat investigation
  description: >-
    Oral AZ-3102 is being studied in randomized and extension trials in GM2 gangliosidosis. Registry entries establish investigational status and study design; they do not establish a clinical benefit or a validated Tay-Sachs-specific mechanism.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  evidence:
  - reference: clinicaltrials:NCT07082543
    reference_title: 18-month Double-blind, Randomized, Placebo-controlled, Multicenter, Phase 3 Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease and in Late-infantile and Juvenile-onset Forms of GM1 Gangliosidosis or GM2 Gangliosidosis
    supports: SUPPORT
    evidence_source: OTHER
    snippet: An 18-month double-blind, randomized, placebo-controlled, multicenter, Phase 3 study to evaluate the safety and efficacy of oral nizubaglustat (AZ-3102) in late-infantile and juvenile forms of GM1 gangliosidosis or GM2 gangliosidosis
    explanation: >-
      ClinicalTrials.gov study purpose; live status and enrollment were checked on 2026-09-04. Registration does not establish benefit.
  therapeutic_modality: SMALL_MOLECULE
clinical_trials:
- name: NCT04798235
  phase: PHASE_I
  status: ACTIVE_NOT_RECRUITING
  description: >-
    Phase 1/2 open-label study evaluating intrathecal TSHA-101 AAV9 gene
    therapy carrying HEXA and HEXB for infantile-onset GM2 gangliosidosis;
    ClinicalTrials.gov currently lists the study as active, not recruiting.
  target_phenotypes:
  - preferred_term: Developmental Regression
    term:
      id: HP:0002376
      label: Developmental regression
  - preferred_term: Seizures
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: clinicaltrials:NCT04798235
    reference_title: "Phase 1/2, Open-Label Clinical Study to Evaluate the Safety and Efficacy of Intrathecal TSHA-101 Gene Therapy for Treatment of Infantile Onset GM2 Gangliosidosis"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The primary purpose of the current study is to assess the safety and tolerability of TSHA101 administered via IT injection."
    explanation: ClinicalTrials.gov record supports TSHA-101 as an intrathecal gene-therapy trial for infantile-onset GM2 gangliosidosis.
  notes: >-
    ClinicalTrials.gov lists this as a combined phase 1 and phase 2 study; the schema entry uses PHASE_I because the study begins with safety and tolerability assessment. Registry status checked 2026-09-04; registration is not evidence of efficacy.
- name: NCT04669535
  phase: PHASE_I
  status: TERMINATED
  description: >-
    Terminated open-label AXO-AAV-GM2 dose-escalation study, with nine treated participants and published results (PMID:40817303). Stage 2 did not proceed after sponsor withdrawal/funding loss. New or worsening dystonia in juvenile patients led to exclusion of further juvenile enrollment during stage 1; infantile biochemical and partial clinical responses remain uncontrolled.
  target_phenotypes:
  - preferred_term: Developmental Regression
    term:
      id: HP:0002376
      label: Developmental regression
  - preferred_term: Seizures
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: clinicaltrials:NCT04669535
    reference_title: "A Two-Stage, Dose-Escalation and Safety & Efficacy Study of Bilateral Intraparenchymal Thalamic and Intracisternal/Intrathecal Administration of AXO-AAV-GM2 in Tay-Sachs or Sandhoff Disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "AXO-AAV-GM2 is an investigational gene therapy that aims to restore HexA function by introducing a functional copy of the HEXA and HEXB genes via co-administration of two vectors utilizing the neurotropic adeno-associated virus recombinant human 8 serotype (AAVrh.8) capsid carrying the human HEXA or HEXB cDNA."
    explanation: ClinicalTrials.gov record supports AXO-AAV-GM2 as a dual-vector HEXA/HEXB gene-therapy trial relevant to Tay-Sachs disease.
  - reference: PMID:40817303
    reference_title: 'Dual-vector rAAVrh8 gene therapy for GM2 gangliosidosis: a phase 1/2 trial.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Overall, HexA activity levels peaked in most participants at 12 weeks and declined somewhat thereafter, but remained above pretreatment levels throughout the duration of the study
    explanation: >-
      Nine-patient nonrandomized phase 1/2 trial (seven Tay-Sachs, two Sandhoff; six infantile, three juvenile) showed biochemical activity, with incomplete clinical efficacy.
  - reference: PMID:40817303
    reference_title: 'Dual-vector rAAVrh8 gene therapy for GM2 gangliosidosis: a phase 1/2 trial.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Interestingly, two of three juvenile patients noted new or worsening dystonia, and the third experienced unexpected progression of the neurologic manifestations of their GM2 gangliosidosis.
    explanation: >-
      Juvenile toxicity led to exclusion from further recruitment and outcome analysis; risk cannot be generalized across products or all delivery routes.
  notes: >2-
     Registry status checked 2026-09-04; registration is not evidence of efficacy.
- name: NCT06614569
  phase: NOT_APPLICABLE
  status: ACTIVE_NOT_RECRUITING
  description: >-
    Observational five-year follow-up of participants previously dosed with AXO-AAV-GM2; estimated enrollment seven. This follows the original treatment cohort and is not a second independent efficacy trial.
  evidence:
  - reference: clinicaltrials:NCT06614569
    reference_title: Long-Term Follow-Up of A Two-Stage Dose-Escalation Study to Evaluate the Safety and Efficacy of Bilateral Intraparenchymal Thalamic and Intracisternal/Intrathecal Admin of AXO-AAV-GM2 in Tay-Sachs or Sandhoff Disease
    supports: SUPPORT
    evidence_source: OTHER
    snippet: This study is to continue Long-Term Follow-Up of Patients who were previously treated with AXO-AAV-GM2 Gene Therapy as treatment for Tay-Sachs or Sandhoff Disease to follow the subjects through 5 years after their initial gene therapy treatment.
    explanation: >-
      ClinicalTrials.gov study purpose; live status and enrollment were checked on 2026-09-04. Registration does not establish benefit.
  notes: Registry status checked 2026-09-04.
- name: NCT04221451
  phase: PHASE_III
  status: TERMINATED
  description: >-
    AMETHIST enrolled 75 across a randomized adult late-onset GM2 cohort (40 venglustat, 19 placebo) and a separate 16-participant open-label basket. Published 104-week findings show CSF GM2 reduction without improvement on the measured clinical endpoints.
  evidence:
  - reference: clinicaltrials:NCT04221451
    reference_title: A Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Venglustat in Late-onset GM2 Gangliosidosis (Tay-Sachs Disease and Sandhoff Disease) Together With a Separate Basket for Juvenile/Adolescent Late-onset GM2 Gangliosidosis and Ultra-rare Diseases Within the Same and Similar Glucosylceramide-based Sphingolipid Pathway
    supports: SUPPORT
    evidence_source: OTHER
    snippet: 'Primary population (adult participants with late-onset GM2 gangliosidosis): To assess the efficacy and pharmacodynamics (PD) of daily oral dosing of venglustat when administered over a 104-week period'
    explanation: >-
      ClinicalTrials.gov study purpose; live status and enrollment were checked on 2026-09-04. Registration does not establish benefit.
  - reference: PMID:41108138
    reference_title: 'Venglustat in GM2 gangliosidoses and related disorders: Results of the AMETHIST randomized controlled and basket trials.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: In adults with late-onset GM2 gangliosidoses, oral venglustat decreased CSF GM2 concentrations but without clinical improvement in the endpoints assessed.
    explanation: >-
      AMETHIST randomized 40 to venglustat and 19 to placebo; 16 additional patients entered a separate open-label basket cohort.
  notes: Registry status checked 2026-09-04.
- name: NCT03759665
  phase: PHASE_II
  status: COMPLETED
  description: >-
    N-acetyl-L-leucine open-label, rater-blinded study enrolled 30 patients with Tay-Sachs or Sandhoff disease. The parent study and exploratory extension assess different time horizons; the short-term Class IV functional signal does not establish long-term disease modification.
  evidence:
  - reference: clinicaltrials:NCT03759665
    reference_title: 'Effects of N-Acetyl-L-Leucine on GM2 Gangliosidosis (Tay-Sachs and Sandhoff Disease): A Multinational, Multicenter, Open-label, Rater-blinded Phase II Study'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: The Extension Phase evaluates the long-term safety and efficacy of IB1001 for the neuroprotective, disease-modifying treatment of GM2 Gangliosidosis. The Extension Phase was considered exploratory.
    explanation: >-
      ClinicalTrials.gov study purpose; live status and enrollment were checked on 2026-09-04. Registration does not establish benefit.
  - reference: PMID:36456200
    reference_title: Efficacy and Safety of N-Acetyl-l-Leucine in Children and Adults With GM2 Gangliosidoses.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: This study provides Class IV evidence that NALL improves outcomes for patients with GM2 gangliosidoses.
    explanation: >-
      Open-label, rater-blinded six-week treatment/washout study enrolled 30 mixed GM2 patients; short-term functional signals do not establish durable disease modification.
  notes: Registry status checked 2026-09-04.
- name: NCT01102686
  phase: PHASE_I
  status: COMPLETED
  description: >-
    Combined phase 1/2 pyrimethamine safety/biochemical investigation in late-onset GM2 disease. The registry estimated 20 participants; the published initial study enrolled nine, with six eligible for the main analysis. Enzyme increases have not established neurological efficacy.
  evidence:
  - reference: clinicaltrials:NCT01102686
    reference_title: Proposed Investigator-Initiated Clinical Trial of Pyrimethamine as a Treatment for Late-Onset GM2-gangliosidosis (Tay-Sachs and Sandhoff Disease)
    supports: SUPPORT
    evidence_source: OTHER
    snippet: The objectives of this clinical trial are to assess the safety and tolerability, as well as efficacy, of a stepwise dosing regimen of pyrimethamine, starting at 25 mg/day, given as a single dose daily for 4 weeks in patients affected with chronic Tay-Sachs or Sandhoff variants.
    explanation: >-
      ClinicalTrials.gov study purpose; live status and enrollment were checked on 2026-09-04. Registration does not establish benefit.
  notes: Registry status checked 2026-09-04.
- name: NCT05758922
  phase: PHASE_II
  status: COMPLETED
  description: >-
    RAINBOW randomized, double-blind, 12-week nizubaglustat (AZ-3102) study in GM2 gangliosidosis and Niemann-Pick C. The registered safety/pharmacokinetic objectives should not be mistaken for demonstrated neurological efficacy.
  evidence:
  - reference: clinicaltrials:NCT05758922
    reference_title: Randomized, Double Blind, Placebo Controlled, Multicenter, 12 Weeks Phase 2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AZ-3102 in Patients With GM2 Gangliosidosis or Niemann-Pick Type C Disease
    supports: SUPPORT
    evidence_source: OTHER
    snippet: This phase 2 is a randomized, double-blind, placebo controlled, 12 weeks study with daily oral administration of AZ-3102 aiming to evaluate the safety and pharmacokinetic (PK) profile in GM2 Gangliosidosis and Niemann-Pick type C disease (NP-C) patients.
    explanation: >-
      ClinicalTrials.gov study purpose; live status and enrollment were checked on 2026-09-04. Registration does not establish benefit.
  notes: Registry status checked 2026-09-04.
- name: NCT07399704
  phase: PHASE_II
  status: RECRUITING
  description: >-
    Open-label long-term nizubaglustat follow-up. GM2 participants enter as prior RAINBOW participants (cohort 1); the separate cohort transitioning from miglustat is for Niemann-Pick C, not treatment-naive GM2 disease. Estimated total enrollment 21.
  evidence:
  - reference: clinicaltrials:NCT07399704
    reference_title: Open-label Study to Evaluate the Long-term Safety, Tolerability, Pharmacokinetics and Efficacy of Nizubaglustat (AZ-3102) in Patients With GM2 Gangliosidosis or Niemann-Pick Type C Disease, With or Without Previous Administration of Miglustat
    supports: SUPPORT
    evidence_source: OTHER
    snippet: This open-label study aims to gather long-term safety, tolerability, PK, biomarker, and clinical efficacy data relating to daily administration of Nizubaglustat in participants previously enrolled in the Phase 2 RAINBOW study (Cohort 1).
    explanation: >-
      ClinicalTrials.gov study purpose; live status and enrollment were checked on 2026-09-04. Registration does not establish benefit.
  notes: Registry status checked 2026-09-04.
- name: NCT07082543
  phase: PHASE_III
  status: ACTIVE_NOT_RECRUITING
  description: >-
    Eighteen-month randomized, placebo-controlled nizubaglustat study in late-infantile and juvenile GM1/GM2 gangliosidosis; estimated enrollment 75. This GMx subprotocol belongs to master protocol NCT07054515. The master record remains recruiting for its broader disease program; that does not imply this GM1/GM2 subprotocol is recruiting.
  evidence:
  - reference: clinicaltrials:NCT07082543
    reference_title: 18-month Double-blind, Randomized, Placebo-controlled, Multicenter, Phase 3 Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease and in Late-infantile and Juvenile-onset Forms of GM1 Gangliosidosis or GM2 Gangliosidosis
    supports: SUPPORT
    evidence_source: OTHER
    snippet: An 18-month double-blind, randomized, placebo-controlled, multicenter, Phase 3 study to evaluate the safety and efficacy of oral nizubaglustat (AZ-3102) in late-infantile and juvenile forms of GM1 gangliosidosis or GM2 gangliosidosis
    explanation: >-
      ClinicalTrials.gov study purpose; live status and enrollment were checked on 2026-09-04. Registration does not establish benefit.
  notes: Registry status checked 2026-09-04.
datasets:
- accession: geo:GSE224860
  title: Bulk RNA-seq of brain samples from fetuses with Tay-Sachs Disease
  description: >-
    Bulk RNA-seq from regional fetal brain tissue with biallelic pathogenic HEXA variants and controls. The publication studied two affected sibling fetuses and two controls at 17 weeks; 19 samples are regional libraries, not 19 independent fetuses. GM2 storage and transcriptomic differences suggest developmental perturbation, with family, genotype and regional confounding.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: BULK_RNA_SEQ
  sample_count: 19
  publication: PMID:36700853
  notes: >-
    GEO metadata verified on 2026-09-04. Publication: PMID:36700853. No raw-data reanalysis was performed for this review; multiple tissue regions must not be treated as independent donors.
- accession: geo:GSE329156
  title: Modeling Tay-Sachs Disease in Astrocyte-Like Cells Reveals Significant Changes in the Transcriptomic Profile
  description: >-
    RNA-seq study of a Tay-Sachs astrocyte-like cell model. Its six samples describe a cellular transcriptomic experiment; they do not establish human astrocyte state abundance, neuronal injury causality or population prevalence.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: BULK_RNA_SEQ
  sample_count: 6
  notes: GEO metadata verified on 2026-09-04. No associated peer-reviewed publication was identified in the checked record; no raw-data analysis was performed.
- accession: geo:GSE184906
  title: Autophagy and lysosomal dysfunction in Tay Sachs disease are restored by mTOR modulation
  description: >-
    Expression profiling associated with studies of autophagy, mTOR signaling and lysosomal integrity in Tay-Sachs/GM2 patient fibroblasts. Cellular findings and partial L-arginine rescue do not establish a neuronal or clinical therapeutic effect.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: MICROARRAY
  sample_count: 12
  notes: GEO metadata verified on 2026-09-04; the 12 expression samples are not a clinical trial or a 12-patient efficacy cohort.
  publication: PMID:34831346
references:
- reference: PMID:20301397
  title: "HEXA Disorders."
  tags:
  - GeneReviews
  findings: []
diagnosis:
- name: Combined enzyme and molecular diagnosis
  description: >-
    Confirm deficient HexA with preserved or elevated HexB and biallelic pathogenic or likely pathogenic HEXA variants. Sequence HEXA, then consider deletion/duplication testing if zero or one allele is identified; broader genomic testing can resolve atypical presentations. VUS findings alone do not establish diagnosis.
  evidence:
  - reference: PMID:20301397
    reference_title: HEXA Disorders.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: The diagnosis of a HEXA disorder is established in a proband with abnormally low HEX A activity on enzyme testing and biallelic pathogenic variants in HEXA identified by molecular genetic testing.
    explanation: >-
      GeneReviews establishes combined biochemical and molecular diagnosis.
- name: Distinguish pseudodeficiency and substrate-specific B1 alleles
  description: >-
    Pseudodeficiency impairs hydrolysis of artificial substrates while preserving natural GM2 catabolism, producing false-positive biochemical results. B1 alleles can retain artificial-substrate activity but fail to hydrolyze natural GM2, producing false-negative results in some assays. Molecular testing resolves discordant biochemical and clinical findings.
  evidence:
  - reference: PMID:20301397
    reference_title: HEXA Disorders.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Pseudodeficiency refers to an in vitro phenomenon caused by specific HEXA variants that renders the enzyme unable to process the synthetic (but not the natural) GM2 substrates, and leads to false positive enzyme testing results.
    explanation: >-
      Synthetic-substrate pseudodeficiency is not disease-causing GM2 storage.
  - reference: PMID:10571007
    reference_title: Biochemical consequences of mutations causing the GM2 gangliosidoses.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: The few exceptions to this generalization are missense mutations at two codons in HEXA, causing the unique biochemical phenotype known as the B1-variant, and one codon in both the HEXB and GM2A genes.
    explanation: >-
      B1 alleles alter substrate-specific function; detailed assay interpretation was checked in GeneReviews.
animal_models:
- name: Hexa knockout mouse
  species: Mouse
  genotype: Hexa-null
  publication: PMID:7610760
  description: Models biochemical storage with limited clinical fidelity.
  modeled_mechanisms:
  - target: GM2 ganglioside accumulation in neurons
    relationship: PARTIALLY_RECAPITULATES
    fidelity: MODERATE
    model_scale: ORGANISM
    limitations: Murine sialidase bypass restricts storage and disease severity.
    evidence:
    - reference: PMID:7610760
      reference_title: Neuropathology of mice with targeted disruption of Hexa gene, a model of Tay-Sachs disease.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: Storage neurons were absent in the olfactory bulb, cerebellar cortex and spinal anterior horns.
      explanation: >-
        Hexa-null mice reproduce substrate storage but have markedly different regional vulnerability from severe human disease.
- name: Hexa/Neu3 double-knockout mouse
  species: Mouse
  genotype: Hexa-null; Neu3-null
  publication: PMID:32951593
  description: Severe storage, Purkinje loss and inflammatory mouse model. A separate study documented reduced trabecular bone measures; this does not establish human osteoporosis penetrance.
  modeled_mechanisms:
  - target: Neuroinflammation and Astrogliosis
    relationship: PARTIALLY_RECAPITULATES
    fidelity: MODERATE
    model_scale: ORGANISM
    limitations: Additional Neu3 loss alters physiology; it does not fully reproduce every human phenotype.
    evidence:
    - reference: PMID:32951593
      reference_title: GM2 ganglioside accumulation causes neuroinflammation and behavioral alterations in a mouse model of early onset Tay-Sachs disease.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: We found elevated levels of pro-inflammatory cytokine and chemokine transcripts, such as Ccl2, Ccl3, Ccl4, and Cxcl10 and also extensive microglial and astrocyte activation and proliferation, accompanied by peripheral blood mononuclear cell infiltration in the vicinity of neurons and oligodendrocytes.
      explanation: >-
        Hexa/Neu3 double-knockout mice demonstrate the inflammatory branch; this is not direct human causal evidence.
    - reference: PMID:28442549
      reference_title: Neuraminidases 3 and 4 regulate neuronal function by catabolizing brain gangliosides.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: neuraminidase 3 deficiency drastically increased storage of GM2 in the brain tissues of an asymptomatic mouse model of Tay-Sachs disease
      explanation: >-
        Deleting Neu3 exposes severe storage otherwise bypassed through murine GM2 catabolism.
  - target: GM2 ganglioside accumulation in neurons
    relationship: PARTIALLY_RECAPITULATES
    fidelity: MODERATE
    model_scale: ORGANISM
    limitations: >-
      Brain-wide storage is only obtained by also deleting Neu3, a sialidase not mutated in human Tay-Sachs disease, so the genotype is a compensating construct rather than a genocopy; results obtained by manipulating Neu3 in this background test a pathway human patients do not depend on in the same way.
    evidence:
    - reference: PMID:41819452
      reference_title: Human Neuraminidase 3 reduces the severity of Tay-Sachs disease symptoms in a mouse model.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: Hence, Hexa-/-Neu3-/- mice, which mimic the neuropathological and clinical abnormalities observed in patients, were considered the early-onset TSD model.
      explanation: >-
        The authors treat this genotype as their early-onset Tay-Sachs storage model on the strength of brain-wide GM2, astrogliosis, Purkinje cell loss and a motor phenotype. This is a model-level claim about fidelity, not human causal evidence.
    readouts:
    - name: Brain GM2 ganglioside content
      target: GM2 ganglioside accumulation in neurons
      direction: INCREASED
      interpretation: Biochemical measurement of the stored substrate in double-knockout brain tissue.
      evidence:
      - reference: PMID:41819452
        reference_title: Human Neuraminidase 3 reduces the severity of Tay-Sachs disease symptoms in a mouse model.
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: Abnormal GM2 accumulation was revealed in the brains of Hexa-/-Neu3-/- mice using thin-layer chromatography and mass spectrometric analyses.
        explanation: >-
          Thin-layer chromatography and mass spectrometry quantify the accumulated substrate directly, rather than inferring storage from histology.
  evidence:
  - reference: PMID:39514043
    reference_title: Abnormally accumulated GM2 ganglioside contributes to skeletal deformity in Tay-Sachs mice.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Micro-computed tomography and analysis show reduced trabecular bone volume, mineral density, number, and thickness in Hexa-/-Neu3-/- mice.
    explanation: >-
      Five-month double-knockout mouse bone phenotype; direct GM2 effects are not separated from genotype, mobility, growth or systemic factors.
- name: Gly269Ser knock-in/Neu3-null mouse
  species: Mouse
  genotype: Hexa Gly269Ser knock-in; Neu3-null
  publication: PMID:40916664
  description: Allele-specific model with GM2 turnover but unexpectedly severe survival phenotype.
  modeled_mechanisms:
  - target: Residual but insufficient HexA activity in late-onset disease
    relationship: PARTIALLY_RECAPITULATES
    fidelity: LOW
    model_scale: ORGANISM
    limitations: Both knock-in and knockout combinations died by 24 weeks; not a faithful chronic LOTS clinical model.
    evidence:
    - reference: PMID:40916664
      reference_title: Generation of mice with combined Hexa Gly269Ser KI or KO and Neu3 KO alleles to create new models of GM2 gangliosidoses.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: Although survival and behavioural phenotypes did not differ between KO and KI models, the KI model had substantial Hexa mRNA and evidence of GM2 turnover.
      explanation: >-
        G269S/Neu3-null mice retain a biochemical partial-deficiency feature but do not reproduce a chronic human late-onset survival course.
- name: Naturally occurring Jacob sheep Tay-Sachs disease
  species: Sheep
  genotype: HEXA exon-11 splice-disrupting variant
  publication: PMID:20817517
  description: Large-brain storage model with glial/myelin pathology and gene-delivery studies.
  modeled_mechanisms:
  - target: GM2 ganglioside accumulation in neurons
    relationship: PARTIALLY_RECAPITULATES
    fidelity: MODERATE
    model_scale: ORGANISM
    limitations: Species and route/dose differences constrain human translation; up to five years is the maximum reported follow-up.
    evidence:
    - reference: PMID:20817517
      reference_title: Tay-Sachs disease in Jacob sheep.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: A missense mutation was found in the hexa cDNA of the affected sheep caused by a single nucleotide change at the end of exon 11 resulting in skipping of exon 11.
      explanation: >-
        Naturally occurring Jacob sheep disease has a splice-disrupting HEXA variant and deficient HexA.
    - reference: PMID:41026525
      reference_title: Five-year analysis of efficacy and safety of a bidirectional AAV gene therapy in Tay-Sachs sheep.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: The longest survival and best distribution were achieved by multipoint CSF delivery (combined CM, ICV, and LIT) with treated animals that survived up to 5 years of age (untreated animals with TSD die after ~9 months).
      explanation: >-
        Selected treated sheep reached five years; this is neither a median survival estimate nor a human efficacy result.
experimental_models:
- name: GM2-loaded neuronal cultures
  experimental_model_type: PRIMARY_CELL_CULTURE
  description: GM2 loading with PERK inhibition and calcineurin/CHOP knockdown.
  modeled_mechanisms:
  - target: GM2-associated PERK activation
    relationship: PARTIALLY_RECAPITULATES
    fidelity: MODERATE
    model_scale: CELLULAR
    limitations: Experimental GM2 delivery does not reproduce the complete HEXA-genotype-to-ER trafficking route.
    evidence:
    - reference: PMID:30389374
      reference_title: Neurite atrophy and apoptosis mediated by PERK signaling after accumulation of GM2-ganglioside.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: We found that ER GM2 accumulation in cultured neurons induces luminal Ca2+ depletion, which in turn activates PERK (protein kinase RNA [PKR]-like ER kinase), one of three UPR sensors.
      explanation: >-
        Cultured-neuron GM2 loading supports an ER calcium/PERK mechanism; lysosomal-to-ER trafficking and necessity in human Tay-Sachs are unresolved.
    - reference: PMID:30389374
      reference_title: Neurite atrophy and apoptosis mediated by PERK signaling after accumulation of GM2-ganglioside.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: Both processes were effectively modulated by treatment with the selective PERK inhibitor GSK2606414, by CN knockdown, and by CHOP knockdown.
      explanation: >-
        PERK inhibition and calcineurin/CHOP knockdown provide direct cellular perturbation evidence for neurite atrophy/apoptosis.
- name: Patient-derived GM2 skin fibroblasts
  experimental_model_type: PRIMARY_CELL_CULTURE
  description: Tay-Sachs and Sandhoff fibroblast lysosomal, mTOR and autophagic-flux assays.
  modeled_mechanisms:
  - target: Impaired autophagic flux and lysosomal integrity
    relationship: PARTIALLY_RECAPITULATES
    fidelity: MODERATE
    model_scale: CELLULAR
    limitations: Mixed genetic diagnoses and non-neuronal cells; no demonstrated clinical benefit of L-arginine.
    evidence:
    - reference: PMID:34831346
      reference_title: L-Arginine Ameliorates Defective Autophagy in GM2 Gangliosidoses by mTOR Modulation.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: GM2 fibroblasts showed diminished mTOR signalling with reduced basal mTOR activity.
      explanation: >-
        Patient-derived Tay-Sachs and Sandhoff fibroblasts reveal an autophagy/lysosomal phenotype; neuronal in vivo generalization is unproven.
    - reference: PMID:34831346
      reference_title: L-Arginine Ameliorates Defective Autophagy in GM2 Gangliosidoses by mTOR Modulation.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: Pathological autophagosomes with impaired autophagic flux, an abnormality confirmed by electron microscopy and biochemical studies revealing the accelerated release of mature cathepsins and HexA into the cytosol, indicating increased lysosomal permeability.
      explanation: >-
        Patient fibroblast assays document impaired flux and lysosomal leakage, not the full human neurodegenerative sequence.
- name: Sandhoff cerebral organoids with isogenic correction
  experimental_model_type: ORGANOID
  description: HEXB-corrected isogenic organoids compared with patient-derived Sandhoff organoids.
  modeled_mechanisms:
  - target: Prenatal neurodevelopmental perturbation
    relationship: PARTIALLY_RECAPITULATES
    fidelity: LOW
    model_scale: TISSUE
    limitations: Sandhoff genotype, not a Tay-Sachs organoid model; developmental effects do not prove irreversible prenatal damage in all patients.
    evidence:
    - reference: PMID:29358305
      reference_title: Cerebral organoids derived from Sandhoff disease-induced pluripotent stem cells exhibit impaired neurodifferentiation.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: The Sandhoff disease organoids, but not the HEXB-corrected organoids, accumulated GM2 ganglioside and exhibited increased size and cellular proliferation compared with the HEXB-corrected organoids.
      explanation: >-
        Isogenic rescue supports a developmental effect in a related GM2 disorder.
discussions:
- discussion_id: experimental_routes
  kind: KNOWLEDGE_GAP
  prompt: How do lysosomal storage, ER stress, autophagy and inflammation interact in human neurons?
  attaches_to:
  - pathophysiology#GM2-associated PERK activation
  - pathophysiology#Impaired autophagic flux and lysosomal integrity
  - pathophysiology#Neuroinflammation and Astrogliosis
  rationale: >-
    ER stress and autophagy nodes have primary experimental support but are not joined to the neuronal-storage node by invented transport or death edges. GM2 loading does not establish lysosomal-to-ER trafficking, fibroblast abnormalities do not establish neuronal injury, and reduced inflammatory markers do not identify a dominant pathway. PERK/CHOP perturbation is causal in its cellular model, contrary to the report’s blanket statement that downstream links have only temporal evidence.
  evidence:
  - reference: PMID:30389374
    reference_title: Neurite atrophy and apoptosis mediated by PERK signaling after accumulation of GM2-ganglioside.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: We found that ER GM2 accumulation in cultured neurons induces luminal Ca2+ depletion, which in turn activates PERK (protein kinase RNA [PKR]-like ER kinase), one of three UPR sensors.
    explanation: >-
      Cultured-neuron GM2 loading supports an ER calcium/PERK mechanism; lysosomal-to-ER trafficking and necessity in human Tay-Sachs are unresolved.
  - reference: PMID:30389374
    reference_title: Neurite atrophy and apoptosis mediated by PERK signaling after accumulation of GM2-ganglioside.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Both processes were effectively modulated by treatment with the selective PERK inhibitor GSK2606414, by CN knockdown, and by CHOP knockdown.
    explanation: >-
      PERK inhibition and calcineurin/CHOP knockdown provide direct cellular perturbation evidence for neurite atrophy/apoptosis.
  - reference: PMID:34831346
    reference_title: L-Arginine Ameliorates Defective Autophagy in GM2 Gangliosidoses by mTOR Modulation.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Pathological autophagosomes with impaired autophagic flux, an abnormality confirmed by electron microscopy and biochemical studies revealing the accelerated release of mature cathepsins and HexA into the cytosol, indicating increased lysosomal permeability.
    explanation: >-
      Patient fibroblast assays document impaired flux and lysosomal leakage, not the full human neurodegenerative sequence.
  - reference: PMID:40019557
    reference_title: Combined treatment of Ketogenic diet and propagermanium reduces neuroinflammation in Tay-Sachs disease mouse model.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: This study aimed to display the effect of combining the ketogenic diet and propagermanium treatment on chronic neuroinflammation in the Tay-Sachs disease mouse model.
    explanation: >-
      Mouse combination treatment tests inflammatory modulation; it does not establish a human treatment effect or that inflammation is the sole driver.
- discussion_id: selective_vulnerability
  kind: KNOWLEDGE_GAP
  prompt: What determines subtype, circuit and neuronal population vulnerability?
  attaches_to:
  - pathophysiology#Late-onset multifocal neuronal dysfunction
  - phenotypes#Depression
  - phenotypes#Sleep disturbance
  - phenotypes#Axonal polyneuropathy
  - phenotypes#Macrocephaly
  - phenotypes#Abnormal saccadic eye movements
  - phenotypes#Sphincter incontinence
  rationale: >-
    Clinical cohorts identify different cerebellar, motor, peripheral nerve and psychiatric manifestations without resolving all substrate-to-circuit mechanisms. The Czech 1.8–4.1% enzyme range is assay/cohort-specific, not a universal threshold. Peripheral axon loss, sleep and mood findings are retained without speculative circuit arrows. Quantitative saccadic abnormalities localize cerebellar dysfunction, but correlation with ataxia severity does not isolate the substrate-to-circuit sequence. Juvenile sphincter incontinence is clinically documented without a resolved autonomic or motor pathway. The macrocephaly case establishes the finding without separating storage, gliosis and ventricular contributions; these three phenotypes remain explicitly unwired.
  evidence:
  - reference: PMID:31076878
    reference_title: Amyotrophy, cerebellar impairment and psychiatric disease are the main symptoms in a cohort of 14 Czech patients with the late-onset form of Tay-Sachs disease.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Residual enzyme activity was 1.8-4.1% of controls.
    explanation: >-
      Fourteen Czech LOTS cases define a study-specific assay range, not a universal disease threshold.
  - reference: PMID:9073025
    reference_title: 'Progressive cerebellar ataxia, proximal neurogenic weakness and ocular motor disturbances: hexosaminidase A deficiency with late clinical onset in four siblings.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The phenotypical expression was remarkably homogeneous, consisting in a combination of slowly progressive motor neuron disease, ataxia and ocular motor disturbances. None of the patients were demented at this stage of their illness.
    explanation: >-
      Four adult siblings carrying the same compound-heterozygous genotype expressed the same narrow motor-neuron, cerebellar and oculomotor pattern, so the population selectivity is reproducible within one genotype and family. The study reports clinical and imaging phenotype, not regional GM2 load, so it does not establish that cortical neurons are spared.
  - reference: PMID:31964693
    reference_title: Quantitative oculomotor and nonmotor assessments in late-onset GM2 gangliosidosis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Cerebellar oculomotor abnormalities were present in all patients with LOGG, including those with normal clinical oculomotor examinations.
    explanation: >-
      The ten-person mixed late-onset GM2 cohort supports an oculomotor association, not a directly isolated storage-to-circuit mechanism.
  - reference: PMID:17015493
    reference_title: 'The natural history of juvenile or subacute GM2 gangliosidosis: 21 new cases and literature review of 134 previously reported.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: However, dysphagia, sphincter incontinence, and sleep problems occurred earlier in those with the Tay-Sachs variant.
    explanation: >-
      Clinical timing in juvenile Tay-Sachs supports the sphincter phenotype without identifying the responsible neuronal circuit.
  - reference: PMID:7732608
    reference_title: 'Tay-Sachs disease: a case report.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Generalized hypotonia, macrocephaly, hyperacusis and a retinal cherry red spot appearance were present.
    explanation: >-
      An infantile case establishes macrocephaly as a clinical observation without partitioning its anatomical causes.
- discussion_id: developmental_window
  kind: KNOWLEDGE_GAP
  prompt: Do prenatal abnormalities constrain the window for treatment?
  attaches_to:
  - pathophysiology#Prenatal neurodevelopmental perturbation
  rationale: >-
    Human fetal transcriptomics existed before the OpenScientist report: two affected sibling fetuses and two controls, with multiple regional samples. These observations complement Sandhoff organoids but do not prove irreversible prenatal clinical damage or that prenatal treatment is necessary.
  evidence:
  - reference: PMID:36700853
    reference_title: Gene expression changes in Tay-Sachs disease begin early in fetal brain development.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: We find that the transcriptomes are perturbed by 17 week’s gestation, suggesting abnormal neurodevelopment, which has implications for therapeutic intervention for TSD.
    explanation: >-
      Two affected sibling fetuses with a juvenile-associated genotype and two controls were sampled across brain regions; 19 GEO libraries are not 19 independent fetuses.
- discussion_id: biomarker_clinical_dissociation
  kind: KNOWLEDGE_GAP
  prompt: Which biomarkers predict meaningful clinical benefit?
  attaches_to:
  - biochemical#CSF GM2 concentration
  - biochemical#Plasma GM2 34:1 and GM2/GM3 ratio
  - treatments#Venglustat substrate reduction investigation
  rationale: >-
    AMETHIST reduced CSF GM2 without clinical improvement or biomarker-outcome correlation. CSF target engagement does not directly establish clearance of intraneuronal lysosomal GM2, so the human trial alone is not used to assert a treatment-effect edge to neuronal storage. Plasma diagnostic discrimination in a selected cohort is not a therapeutic surrogate. Randomized treatment, timing, tissue exposure and clinical outcome studies are needed.
  evidence:
  - reference: PMID:41108138
    reference_title: 'Venglustat in GM2 gangliosidoses and related disorders: Results of the AMETHIST randomized controlled and basket trials.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Decreased CSF GM2 concentrations did not correlate with clinical endpoints.
    explanation: >-
      Direct trial evidence prevents equating substrate reduction with clinical efficacy.
- discussion_id: cross_disorder_lipid_cascades
  kind: KNOWLEDGE_GAP
  prompt: Which secondary lipid changes contribute specifically to Tay-Sachs pathology?
  attaches_to:
  - pathophysiology#GM2 ganglioside accumulation in neurons
  rationale: >-
    The report’s secondary-lipid cascade discussion relies mainly on Niemann-Pick and mucopolysaccharidosis biochemistry. Secondary GM2 storage in those disorders supports convergence but does not prove that GM2 drives the same cholesterol/glucosylceramide cascade in Tay-Sachs.
  evidence:
  - reference: PMID:32272755
    reference_title: Mechanism of Secondary Ganglioside and Lipid Accumulation in Lysosomal Disease.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: they trigger a secondary accumulation of ganglioside GM2, glucosylceramide and cholesterol in Niemann-Pick disease type A and B, and of GM2 and glucosylceramide in Niemann-Pick disease type C.
    explanation: >-
      Review/reconstitution evidence describes different primary lysosomal disorders.
  - reference: PMID:8896570
    reference_title: Mice lacking both subunits of lysosomal beta-hexosaminidase display gangliosidosis and mucopolysaccharidosis.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: The mucopolysaccharidosis phenotype is not seen in the Tay-Sachs or Sandhoff disease model mice or in the corresponding human patients.
    explanation: >-
      Glycosaminoglycan storage appears only when both hexosaminidase subunits are removed, and is absent from Tay-Sachs model mice and from patients. This is direct evidence against carrying mucopolysaccharidosis storage biochemistry into the Tay-Sachs cascade, which is the caution this gap records.
- discussion_id: visual-loss-localization
  kind: KNOWLEDGE_GAP
  prompt: How much visual impairment arises from retinal versus central visual pathway dysfunction?
  attaches_to:
  - pathophysiology#Retinal ganglion cell lipid storage
  - phenotypes#Blindness
  - phenotypes#Visual Impairment
  rationale: >-
    The retinal-storage source directly explains the cherry-red macula but does not establish the causal partition of visual loss. Clinical visual impairment is retained without forcing a retinal-storage-to-blindness edge from a phenotype-frequency annotation.
  evidence:
  - reference: PMID:19820796
    reference_title: "'Cherry red spot' in a patient with Tay-Sachs disease: case report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The accumulation of lipid in retinal ganglion cells that leads to a chalk-white appearance of the fundus called 'cherry red spot' is the hallmark of Tay-Sachs disease.
    explanation: >-
      This supports the visible macular sign, not attribution of all blindness to retinal storage.
differential_diagnoses:
- name: Sandhoff disease
  description: Related GM2 storage disorder with overlapping infantile, juvenile and adult neurological phenotypes.
  distinguishing_features:
  - Biallelic HEXB variants reduce both HexA and HexB; Tay-Sachs primarily reduces HexA with preserved or increased HexB.
  - Visceral involvement may be more prominent in Sandhoff disease, but enzyme and molecular testing determine the diagnosis.
  evidence:
  - reference: PMID:10571007
    reference_title: Biochemical consequences of mutations causing the GM2 gangliosidoses.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: A deficiency of any one of these proteins leads to storage of the ganglioside, primarily in the lysosomes of neuronal cells, and one of the three forms of GM2-gangliosidosis, Tay-Sachs disease, Sandhoff disease or the AB-variant form.
    explanation: >-
      The review establishes three distinct genetic etiologies converging on GM2 storage.
- name: GM2 activator deficiency
  description: The GM2A-related AB variant can resemble Tay-Sachs despite normal measured HexA and HexB activity.
  distinguishing_features:
  - GM2 activator deficiency impairs presentation of membrane GM2 to HexA; biallelic GM2A variants establish the molecular cause.
  evidence:
  - reference: PMID:8900233
    reference_title: Molecular analysis of a GM2-activator deficiency in two patients with GM2-gangliosidosis AB variant.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Lysosomal degradation of ganglioside GM2 by beta-hexosaminidase A (hex A) requires the presence of the GM2 activator protein (GM2AP) as an essential cofactor.
    explanation: >-
      Normal artificial-substrate enzyme measurements do not exclude GM2A-related disease.
- name: Other disorders with a cherry-red macula
  description: GM1 gangliosidosis, other sphingolipidoses and central retinal artery occlusion can also produce a cherry-red appearance.
  distinguishing_features:
  - A cherry-red spot is not diagnostic in isolation; clinical course, visceral findings, enzyme assays and molecular testing distinguish etiologies.
  evidence:
  - reference: PMID:19820796
    reference_title: "'Cherry red spot' in a patient with Tay-Sachs disease: case report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: It is also seen in others neurometabolic diseases as well as in central retinal artery occlusion.
    explanation: >-
      The Tay-Sachs case report explicitly states that the retinal finding is not specific.
- name: Adult motor neuron and cerebellar disorders
  description: Late-onset Tay-Sachs can resemble spinal muscular atrophy, amyotrophic lateral sclerosis or inherited ataxia.
  distinguishing_features:
  - A mixed pattern of proximal neurogenic weakness, cerebellar signs and psychiatric or cognitive features should prompt HexA and HEXA testing.
  - Marked cerebellar atrophy can occur even when the presenting complaint is weakness or psychiatric illness.
  evidence:
  - reference: PMID:31995250
    reference_title: Natural History of Adult Patients with GM2 Gangliosidosis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The main brain magnetic resonance imaging feature was cerebellar atrophy, even in patients without cerebellar symptoms.
    explanation: >-
      Adult GM2 case series plus literature review supports the heterogeneous pattern; GeneReviews differential diagnosis was also checked.
📚

References & Deep Research

References

1
PMID:20301397
HEXA Disorders.
No top-level findings curated for this source.

Deep Research

1

Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.

Falcon ▸
Tay–Sachs Disease (HEXA-related GM2 gangliosidosis variant B): Disease Characteristics Research Report
Edison Scientific Literature 47 citations 2026-04-25T22:35:19.387623

Tay–Sachs Disease (HEXA-related GM2 gangliosidosis variant B): Disease Characteristics Research Report

Target Disease

  • Disease name: Tay–Sachs disease (TSD) (gonzalezsanchez2025advancesindiagnosis pages 1-2, ibrahim2023biochemicalandmutational pages 1-2)
  • Category: Genetic; lysosomal storage disorder (GM2 gangliosidosis) (gonzalezsanchez2025advancesindiagnosis pages 1-2, ibrahim2023biochemicalandmutational pages 1-2)

1. Disease information

Concise overview (current understanding)

Tay–Sachs disease is an autosomal recessive GM2 gangliosidosis caused by deficiency of lysosomal β-hexosaminidase A (HexA), leading to progressive GM2 ganglioside accumulation in neurons and neurodegeneration (gonzalezsanchez2025advancesindiagnosis pages 1-2, ibrahim2023biochemicalandmutational pages 1-2). Tay–Sachs is classically subdivided into infantile, juvenile, and late-/adult-onset clinical forms that correlate with residual HexA activity (gonzalezsanchez2025advancesindiagnosis pages 1-2, gonzalezsanchez2025advancesindiagnosis pages 2-4).

Direct abstract quotes (examples) - From a fetal-brain transcriptomics study (Feb 2023): the authors state they identified “dramatic changes in the transcriptome, suggesting a perturbation of normal development” and that fetal transcriptomes were “perturbed by 17 week’s gestation, suggesting abnormal neurodevelopment” (han2023geneexpressionchanges pages 1-3).

Key identifiers, synonyms, and alternative names

Identifier system ID/code Preferred label Notes/source
OMIM (disease) 272800 Tay–Sachs disease Retrieved review explicitly lists OMIM 272800 for TSD; described as a rare autosomal recessive GM2 gangliosidosis caused by HEXA-related HexA deficiency (gonzalezsanchez2025advancesindiagnosis pages 1-2, ibrahim2023biochemicalandmutational pages 1-2)
OMIM (gene) 606869 HEXA Retrieved primary study gives HEXA (MIM# 606869) as the causal gene encoding the alpha subunit of β-hexosaminidase A (ibrahim2023biochemicalandmutational pages 1-2)
Orphanet ORPHA:845 Tay–Sachs disease Retrieved review explicitly lists ORPHANET/Orphanet ORPHA845 for TSD (gonzalezsanchez2025advancesindiagnosis pages 1-2)
MeSH not found in retrieved sources Tay–Sachs disease MeSH identifier was not present in the retrieved evidence set used here; disease overview and synonyms supported by retrieved literature (gonzalezsanchez2025advancesindiagnosis pages 1-2, ibrahim2023biochemicalandmutational pages 1-2)
ICD-10 not found in retrieved sources Tay–Sachs disease ICD-10 code not present in the retrieved evidence set used here (gonzalezsanchez2025advancesindiagnosis pages 1-2, ibrahim2023biochemicalandmutational pages 1-2)
ICD-11 not found in retrieved sources Tay–Sachs disease ICD-11 code not present in the retrieved evidence set used here (gonzalezsanchez2025advancesindiagnosis pages 1-2, ibrahim2023biochemicalandmutational pages 1-2)
MONDO not found in retrieved sources Tay–Sachs disease MONDO identifier was not present in the retrieved evidence set used here (gonzalezsanchez2025advancesindiagnosis pages 1-2, ibrahim2023biochemicalandmutational pages 1-2)
Disease class / classification GM2 gangliosidosis variant B Tay–Sachs disease Retrieved sources state TSD is also known as GM2 gangliosidosis variant B and belongs to the GM2 gangliosidoses; inheritance is autosomal recessive (ibrahim2023biochemicalandmutational pages 1-2, picache2022therapeuticstrategiesfor pages 1-2)
Synonym — Tay–Sachs disease Common preferred disease name in all retrieved sources (gonzalezsanchez2025advancesindiagnosis pages 1-2, ibrahim2023biochemicalandmutational pages 1-2, picache2022therapeuticstrategiesfor pages 1-2)
Synonym — GM2 gangliosidosis variant B Explicit synonym in retrieved primary literature (ibrahim2023biochemicalandmutational pages 1-2)
Synonym — Hexosaminidase A deficiency Functional disease descriptor supported by retrieved sources describing HexA deficiency as the defining biochemical defect (gonzalezsanchez2025advancesindiagnosis pages 1-2, picache2022therapeuticstrategiesfor pages 1-2)

Table: This table summarizes key retrieved identifiers and synonyms for Tay–Sachs disease, including disease and gene OMIM entries, Orphanet ID, classification, and supported alternative names. It also flags identifier systems not found in the retrieved evidence so the final report can clearly distinguish confirmed versus missing mappings.

  • Synonyms/related labels used in the literature: GM2 gangliosidosis variant B; hexosaminidase A deficiency (ibrahim2023biochemicalandmutational pages 1-2, gonzalezsanchez2025advancesindiagnosis pages 1-2).
  • MONDO ID: not found in the retrieved evidence set used for this report (artifact-00).

Evidence provenance

Most content here is derived from aggregated disease-level resources/reviews plus primary cohort studies and clinical trial registry records. Examples include a 2023 infantile Tay–Sachs cohort study in Egypt (Orphanet Journal of Rare Diseases) (ibrahim2023biochemicalandmutational pages 1-2), fetal brain transcriptomics (Journal of Inherited Metabolic Disease) (han2023geneexpressionchanges pages 1-3), and ClinicalTrials.gov records (NCT04798235 chunk 1).

2. Etiology

Disease causal factors

  • Primary cause: biallelic pathogenic variants in HEXA (OMIM 606869) resulting in deficient HexA enzyme activity and lysosomal GM2 accumulation (ibrahim2023biochemicalandmutational pages 1-2, gonzalezsanchez2025advancesindiagnosis pages 5-7).
  • Tay–Sachs is one of the GM2 gangliosidoses, which also include Sandhoff disease (HEXB) and AB-variant disease (GM2A) (gonzalezsanchez2025advancesindiagnosis pages 7-9, ashiri2023usinganengineered pages 16-23).

Risk factors

  • Genetic risk: carrier status for pathogenic HEXA variants; risk is elevated in some founder populations. A 2023 cohort paper summarizes carrier frequency being substantially higher in Ashkenazi Jewish populations (reported ~1/25) compared with ~1/250–300 in many other populations (ibrahim2023biochemicalandmutational pages 1-2).
  • Consanguinity: in a 2023 Egyptian infantile cohort, most affected children were born to consanguineous marriages (10/13) (ibrahim2023biochemicalandmutational pages 1-2).

Protective factors

No validated genetic or environmental protective factors were identified in the retrieved evidence set. A biologic “protective” concept is that higher residual HexA activity is associated with later onset and milder disease (i.e., acts as a functional modifier), but this is not a protective variant per se (gonzalezsanchez2025advancesindiagnosis pages 2-4).

Gene–environment interactions

No specific gene–environment interactions were identified in the retrieved evidence set; Tay–Sachs is best characterized as a monogenic disorder with phenotype strongly related to enzyme activity and variant class (gonzalezsanchez2025advancesindiagnosis pages 2-4).

3. Phenotypes

Phenotype spectrum and HPO mapping

Subtype (with typical onset) Key clinical features (plain language) Suggested HPO terms (IDs and labels) Natural history/progression (including survival estimates) Frequency data (if available) Key sources
Infantile Tay–Sachs disease (typically 3–6 months) Initially normal infant, then irritability, mild motor weakness, exaggerated startle/hyperacusis, inability to sit, developmental regression, cherry-red macular spot, visual loss/blindness, feeding difficulty/dysphagia, seizures, later spasticity, dyskinesia, macrocephaly, cognitive decline, vegetative state HP:0001257 Spasticity; HP:0002376 Developmental regression; HP:0001344 Hyperreflexia; HP:0002072 Chorea/dyskinesia-related abnormal involuntary movements; HP:0001250 Seizure; HP:0000518 Cataract not appropriate / use HP:0010729 Cherry red spot of the macula; HP:0000407 Sensorineural hearing impairment / hyperacusis feature not directly matched here; HP:0002015 Dysphagia; HP:0000256 Macrocephaly; HP:0001252 Hypotonia Progressive neurodegeneration begins in the first year; cherry-red spot is typically present by ~6 months; vision loss develops by 12–18 months and many patients are blind by ~30 months; rapid worsening between ~8–10 months; tonic–myoclonic seizures often by ~12 months; later refractory seizures, dysphagia, decerebrate posturing, vegetative state; death usually at 2–5 years despite supportive care “More than two-thirds” require multiple anticonvulsants for seizure control; in one Egyptian cohort all 13/13 biochemically confirmed cases had infantile disease; Ashkenazi carrier frequency reported ~1/25 vs ~1/250–300 in many other populations (gonzalezsanchez2025advancesindiagnosis pages 9-11, ibrahim2023biochemicalandmutational pages 1-2, gonzalezsanchez2025advancesindiagnosis pages 2-4)
Juvenile / subacute Tay–Sachs disease (typically 2–10 years; some sources 3–5 years) Speech difficulty, clumsiness, gait problems, limb weakness, progressive spasticity, seizures, optic atrophy/vision decline; often more variable than infantile disease and may lack an early cherry-red spot HP:0002463 Speech impairment; HP:0002317 Unsteady gait; HP:0003324 Muscle weakness; HP:0001257 Spasticity; HP:0001250 Seizure; HP:0000648 Optic atrophy; HP:0002376 Developmental regression Intermediate course between infantile and adult forms; gradual neurologic deterioration over years with loss of motor function and increasing dependency; death commonly in adolescence or by mid-adolescence Specific phenotype frequencies were not provided in the retrieved juvenile-focused excerpts; review data cited elsewhere note limb weakness and ataxic gait as common, but no robust juvenile percentage table was available in retrieved primary evidence (gonzalezsanchez2025advancesindiagnosis pages 2-4, ibrahim2023biochemicalandmutational pages 1-2, sheth2018identificationofdeletionduplication pages 1-2)
Late-onset / adult Tay–Sachs disease (adolescence to adulthood; often 20s–30s) Slowly progressive muscle weakness, clumsy or ataxic gait, tremor, dysarthria/stuttering or other distinct speech changes, falls, difficulty climbing stairs, fatigue, cerebellar signs, triceps/quadriceps wasting, psychiatric symptoms including psychosis/delusions/impulsivity, mild cognitive or subcortical deficits HP:0001324 Muscle weakness; HP:0002066 Gait ataxia; HP:0001337 Tremor; HP:0001260 Dysarthria; HP:0002521 Cerebellar atrophy; HP:0007018 Falls; HP:0012378 Fatigue; HP:0000709 Psychosis; HP:0000738 Hallucinations/delusions-related psychiatric disturbance; HP:0002354 Memory impairment Chronic, slowly progressive course with prolonged survival; diagnostic delay is common; patients may first present to neuromuscular, movement-disorder, or psychiatric services; loss of ambulation may occur later and lifespan is variable Patient/caregiver burden study: muscle weakness 19/20 (95%), difficulty walking 19/20 (95%), falling 17/20 (85%), climbing stairs 16/20 (80%), “clumsy” gait 12/20 (60%), fatigue 10/20 (50%), coughing fits 5/20 (25%), GI issues 4/20 (20%); psychiatric symptoms may be the initial manifestation in up to half of patients (lyn2020patientandcaregiver pages 1-2, gonzalezsanchez2025advancesindiagnosis pages 4-5, barritt2017lateonsettay–sachsdisease pages 1-2, gonzalezsanchez2025advancesindiagnosis pages 2-4)

Table: This table summarizes Tay–Sachs disease manifestations across infantile, juvenile, and late-onset forms, linking clinical features to suggested HPO terms, natural history, and available frequency data. It is useful for phenotype curation, diagnostic support, and subtype-specific knowledge base entry development.

Quality-of-life impact (late-onset disease)

A qualitative study of late-onset GM2 gangliosidosis (including late-onset Tay–Sachs) quantified commonly reported symptoms and functional impacts. Frequently reported items included muscle weakness (95%), difficulty walking (95%), falling (85%), and difficulty climbing stairs (80%), emphasizing substantial impairment of mobility/independence and downstream psychosocial burden (lyn2020patientandcaregiver pages 1-2).

4. Genetic / molecular information

Causal gene(s)

  • HEXA is the causal gene for Tay–Sachs disease; HEXA encodes the α-subunit of HexA (ibrahim2023biochemicalandmutational pages 1-2, gonzalezsanchez2025advancesindiagnosis pages 7-9).

Pathogenic variants (examples and variant types)

  • A 2023 infantile cohort study (Egypt; publication date Mar 2023; URL https://doi.org/10.1186/s13023-023-02637-1) reported multiple novel likely pathogenic variants and recurrent exon 13 variants, including missense and frameshift changes; mean HexA activity in affected children was severely reduced (ibrahim2023biochemicalandmutational pages 1-2).
  • Exon-level deletions/duplications can cause disease and may be missed by exon sequencing alone; MLPA identified exon 1 deletions/duplications and exon 2–3 deletions in enzymatically confirmed cases (sheth2018identificationofdeletionduplication pages 2-3, sheth2018identificationofdeletionduplication pages 1-2).
  • Late-onset presentations can involve combinations such as frameshift plus the common late-onset variant c.805G>A (p.Gly269Ser) in HEXA (barritt2017lateonsettay–sachsdisease pages 1-2).

Functional consequences

Pathogenic HEXA variants generally produce loss of function by disrupting protein folding, heterodimer assembly, lysosomal trafficking, or catalytic function, ultimately preventing HexA-mediated hydrolysis of GM2 (ashiri2023usinganengineered pages 23-28, gonzalezsanchez2025advancesindiagnosis pages 7-9).

Modifier genes / epigenetics / chromosomal abnormalities

No robust modifier genes, epigenetic drivers, or chromosomal abnormalities specific to Tay–Sachs were identified in the retrieved evidence set.

5. Environmental information

Tay–Sachs is not established as an environmentally triggered disorder; no non-genetic causal environmental factors were identified in the retrieved evidence set.

6. Mechanism / pathophysiology

Core biochemical defect and causal chain

  1. HEXA loss-of-function causes deficient lysosomal HexA activity (gonzalezsanchez2025advancesindiagnosis pages 5-7, gonzalezsanchez2025advancesindiagnosis pages 7-9).
  2. HexA “specifically hydrolyzes the N-acetylgalactosamine residue in GM2 ganglioside,” and deficiency leads to “accumulation of GM2 gangliosides within lysosomes” (gonzalezsanchez2025advancesindiagnosis pages 7-9).
  3. GM2 accumulation contributes to lysosomal dysfunction (including lysosomal disruption) and neurodegeneration, with neuronal loss and gliosis (gonzalezsanchez2025advancesindiagnosis pages 7-9, gonzalezsanchez2025advancesindiagnosis pages 5-7).
  4. Downstream mechanisms include ER stress and apoptosis (neuron death) as well as neuroinflammation characterized by microglial activation and astrogliosis (gonzalezsanchez2025advancesindiagnosis pages 7-9, gonzalezsanchez2025advancesindiagnosis pages 9-11).

Neuroinflammation and glial involvement

A 2025 review states “astrogliosis has been identified as a critical component of GM2 gangliosidosis pathophysiology” and highlights that “astrocyte-microglia crosstalk is essential for amplifying neuroinflammatory responses” (gonzalezsanchez2025advancesindiagnosis pages 9-11). Candidate CSF inflammatory biomarkers for infantile disease include ENA-78, MCP-1, MIP-1α, MIP-1β, and TNFR2 (gonzalezsanchez2025advancesindiagnosis pages 9-11).

Myelin/oligodendrocyte involvement and biomarker data (large animal model)

In a sheep natural-history model (publication date Sep 2021; URL https://doi.org/10.1016/j.ymgme.2021.08.009), disease severity tracked with CSF GM2, MRI/MRS markers, and neuropathology including early oligodendrocyte loss and demyelination signatures (story2021naturalhistoryof pages 5-7). Reported MRS patterns included increased myoinositol (gliosis), increased taurine, increased choline-related markers (demyelination), and decreased NAA (neuronal/axonal integrity) (story2021naturalhistoryof pages 5-7).

Developmental stage mechanisms (human fetal brain)

A 2023 RNA-seq study of human fetal Tay–Sachs brain found transcriptomes “perturbed by 17 week’s gestation” and a “shift in the expression of the sphingolipid metabolic pathway away from production of the HEXA substrate, GM2 ganglioside,” implying compensatory remodeling and that developmental perturbations may precede overt neurodegeneration (han2023geneexpressionchanges pages 1-3).

Suggested ontology terms

  • GO (biological process) suggestions: ganglioside catabolic process; sphingolipid metabolic process; lysosomal organization; response to endoplasmic reticulum stress; apoptotic process; microglial activation; astrocyte activation; neuroinflammatory response; myelination (supported conceptually by mechanistic and pathology evidence) (gonzalezsanchez2025advancesindiagnosis pages 7-9, gonzalezsanchez2025advancesindiagnosis pages 9-11, story2021naturalhistoryof pages 5-7).
  • CL (cell type) suggestions: microglia; astrocyte; oligodendrocyte; radial glial cell; neuron (including cerebellar Purkinje neuron) (gonzalezsanchez2025advancesindiagnosis pages 7-9, gonzalezsanchez2025advancesindiagnosis pages 9-11, story2021naturalhistoryof pages 5-7).

7. Anatomical structures affected

Organ/system level

  • Primary system: central nervous system (progressive neurodegeneration) (gonzalezsanchez2025advancesindiagnosis pages 5-7, gonzalezsanchez2025advancesindiagnosis pages 2-4).
  • Neuroanatomical involvement noted on imaging/pathology includes thalamus and cerebral atrophy patterns in clinical descriptions and animal models (gonzalezsanchez2025advancesindiagnosis pages 5-7, story2021naturalhistoryof pages 5-7).

Tissue/cell level

  • Neuronal lysosomal storage with gliosis (gonzalezsanchez2025advancesindiagnosis pages 5-7, gonzalezsanchez2025advancesindiagnosis pages 9-11).
  • Oligodendrocyte/myelin abnormalities suggested by sheep natural history (story2021naturalhistoryof pages 5-7).

Subcellular level

  • Lysosome is the key compartment for substrate accumulation (gonzalezsanchez2025advancesindiagnosis pages 5-7, gonzalezsanchez2025advancesindiagnosis pages 7-9).

Suggested anatomical ontology terms

  • UBERON suggestions: brain; thalamus; cerebellum; cerebral cortex; white matter; spinal cord (supported by sampling sites and pathology descriptions across sources) (story2021naturalhistoryof pages 5-7, han2023geneexpressionchanges pages 1-3).

8. Temporal development

  • Infantile onset: typically 3–6 months with early sensory hypersensitivity/startle, regression, and rapid progression; seizures often develop by ~12 months in one synthesis (gonzalezsanchez2025advancesindiagnosis pages 9-11).
  • Progression: infantile disease progresses to severe disability, vegetative state, and death commonly in early childhood (2–5 years across sources) (ibrahim2023biochemicalandmutational pages 1-2, gonzalezsanchez2025advancesindiagnosis pages 2-4).
  • Late-onset: chronic progression across years with variable lifespan and often long diagnostic delays; psychiatric symptoms may be initial in up to half of patients in one review (gonzalezsanchez2025advancesindiagnosis pages 4-5).

9. Inheritance and population

  • Inheritance pattern: autosomal recessive (gonzalezsanchez2025advancesindiagnosis pages 1-2, ibrahim2023biochemicalandmutational pages 1-2).
  • Epidemiology (illustrative figures from recent secondary sources): One review reports ~1 in 100,000 live births in the U.S. and carrier frequency ~1 in 250, with much higher incidence in Ashkenazi Jewish populations (~1 in 3,900 without screening; carrier ~1 in 29 in some studies) (gonzalezsanchez2025advancesindiagnosis pages 2-4). A 2023 cohort paper summarizes higher carrier frequency in Ashkenazi Jewish populations (~1 in 25) versus ~1/250–300 in many other populations (ibrahim2023biochemicalandmutational pages 1-2).

10. Diagnostics

Test/approach Specimen What it measures Interpretation pitfalls Typical use case (diagnosis/carrier/prenatal) Notes Key sources
HexA/HexB enzyme activity assay using artificial substrates (e.g., MUG/MUGS with thermal differentiation) Leukocytes, serum, cultured skin fibroblasts, chorionic villi, dried blood spots, other cells/tissues/biological fluids Total hexosaminidase and HexA-specific activity; confirms biochemical deficiency Pseudodeficiency alleles can lower in vitro activity on synthetic substrates without causing disease; carrier detection by enzyme assay alone can be unreliable Primary diagnosis; confirmatory testing; prenatal when performed on fetal material Gold-standard confirmatory specimens in retrieved sources are fibroblasts, chorionic villi, or leukocytes; infantile disease often shows very low/absent activity, juvenile higher residual activity (gonzalezsanchez2025advancesindiagnosis pages 4-5, ashiri2023usinganengineered pages 23-28, gonzalezsanchez2025advancesindiagnosis pages 2-4) (gonzalezsanchez2025advancesindiagnosis pages 4-5, ashiri2023usinganengineered pages 23-28, gonzalezsanchez2025advancesindiagnosis pages 2-4)
Dried blood spot (DBS) HexA assay Dried blood spots Screening/initial biochemical detection of low HexA activity Positive/abnormal DBS requires confirmatory enzyme and molecular testing; not sufficient alone for definitive molecular characterization Early diagnosis; newborn/remote screening workflows; triage to confirmatory testing Reported as practical standard-of-care style primary test in one study; can be paired with sequencing/WES follow-up (bibi2021taysachsdiseasetwo pages 5-8, gonzalezsanchez2025advancesindiagnosis pages 2-4) (bibi2021taysachsdiseasetwo pages 5-8, gonzalezsanchez2025advancesindiagnosis pages 2-4)
Targeted HEXA variant analysis / common-variant panels Blood or genomic DNA Detects recurrent pathogenic alleles and selected adult-onset/pseudodeficiency alleles Limited if patient carries rare/private variants or CNVs; founder-focused panels may miss non-founder mutations Carrier screening; targeted diagnostic follow-up in high-risk populations Retrieved review notes panels including common null alleles plus adult-onset p.Gly269Ser and pseudodeficiency alleles p.Arg247Trp / p.Arg249Trp (gonzalezsanchez2025advancesindiagnosis pages 4-5) (gonzalezsanchez2025advancesindiagnosis pages 4-5)
Sanger sequencing of HEXA coding exons and splice junctions Genomic DNA from blood Single-nucleotide variants and small indels in coding/splice regions Can miss deep intronic/regulatory variants and exon-level deletions/duplications; partial detection only in some cohorts Diagnostic confirmation after low enzyme activity; family testing In the Egyptian infantile cohort, bidirectional Sanger sequencing had ~62% detection (8/13), prompting recommendation for broader NGS/CNV-aware workup when unresolved (ibrahim2023biochemicalandmutational pages 1-2) (ibrahim2023biochemicalandmutational pages 1-2)
Next-generation sequencing (targeted panels/WES; CNV-aware if possible) Genomic DNA Broad detection of HEXA variants, including rare/private pathogenic variants; may support broader differential diagnosis Requires variant interpretation; may still miss some structural/regulatory defects if CNV calling is inadequate Diagnosis of unresolved cases; family studies; carrier workup in diverse populations Recommended when Sanger is negative or only one pathogenic allele is found; WES identified novel homozygous HEXA variants in Pakistani/Moroccan families (bibi2021taysachsdiseasetwo pages 5-8, ibrahim2023biochemicalandmutational pages 1-2) (bibi2021taysachsdiseasetwo pages 5-8, ibrahim2023biochemicalandmutational pages 1-2)
MLPA (deletion/duplication analysis) Genomic DNA from whole blood Exon-level copy-number changes in HEXA Not designed for SNVs/small indels; usually used after sequencing fails to identify both alleles Diagnostic resolution of sequencing-inconclusive cases; family studies Detected homozygous exon 2-3 deletions, exon 1 deletions with a missense variant, and exon 1 duplication with splice variant; specifically recommended when one/both alleles are missing by sequencing (sheth2018identificationofdeletionduplication pages 2-3, sheth2018identificationofdeletionduplication pages 1-2) (sheth2018identificationofdeletionduplication pages 2-3, sheth2018identificationofdeletionduplication pages 1-2)
Prenatal enzyme testing on chorionic villi / chorionic villus sampling (CVS) Chorionic villi (typically 10-12 weeks) Fetal HexA activity and/or fetal genotype Requires correct parental interpretation and awareness of pseudodeficiency alleles; invasive procedure Prenatal diagnosis in at-risk pregnancies Retrieved review explicitly identifies CVS as a prenatal option and chorionic villi as a gold-standard specimen type for enzyme testing (gonzalezsanchez2025advancesindiagnosis pages 4-5, gonzalezsanchez2025advancesindiagnosis pages 2-4) (gonzalezsanchez2025advancesindiagnosis pages 4-5, gonzalezsanchez2025advancesindiagnosis pages 2-4)
Prenatal testing by amniocentesis Amniotic fluid/fetal cells (typically 15-18 weeks) Fetal genotype and/or biochemical testing depending laboratory workflow Same interpretive issues as other prenatal tests; invasive procedure Prenatal diagnosis in at-risk pregnancies Retrieved review gives amniocentesis at 15-18 weeks as an option when parental carrier status/risk is established (gonzalezsanchez2025advancesindiagnosis pages 4-5) (gonzalezsanchez2025advancesindiagnosis pages 4-5)
Carrier screening programs (premarital/preconception/community screening) Blood/DBS/DNA depending program Identifies heterozygous carriers to inform reproductive risk Enzyme-based carrier screening can be confounded by pseudodeficiency; molecular confirmation improves specificity Carrier screening; public health prevention In Ashkenazi Jewish communities, premarital carrier screening was associated with an approximately 95% reduction in Tay-Sachs incidence in retrieved evidence; historical founder frequencies are much higher than general-population rates (gonzalezsanchez2025advancesindiagnosis pages 2-4, ashiri2023usinganengineered pages 23-28) (gonzalezsanchez2025advancesindiagnosis pages 2-4, ashiri2023usinganengineered pages 23-28)
Integrated diagnostic workflow Start with leukocytes/fibroblasts/DBS, then DNA-based testing Combines biochemical confirmation with molecular definition of genotype Overreliance on a single modality can miss carriers, pseudodeficiency, or CNVs Best-practice diagnostic pathway Practical pathway from retrieved evidence: low HexA activity -> sequencing -> del/dup analysis/NGS if unresolved; use prenatal testing when familial pathogenic variants are known (gonzalezsanchez2025advancesindiagnosis pages 4-5, ibrahim2023biochemicalandmutational pages 1-2, sheth2018identificationofdeletionduplication pages 2-3) (gonzalezsanchez2025advancesindiagnosis pages 4-5, ibrahim2023biochemicalandmutational pages 1-2, sheth2018identificationofdeletionduplication pages 2-3)

Table: This table summarizes the main diagnostic and screening approaches for Tay-Sachs disease, including biochemical, molecular, prenatal, and carrier-screening methods. It highlights specimen types, what each test measures, common pitfalls such as pseudodeficiency alleles, and how these methods are used in real-world diagnostic pathways.

Real-world diagnostic implementation notes

  • A practical approach in the retrieved evidence is biochemical confirmation (HexA activity) followed by genotyping and, if needed, del/dup analysis such as MLPA to detect exon-level CNVs (gonzalezsanchez2025advancesindiagnosis pages 4-5, sheth2018identificationofdeletionduplication pages 2-3).
  • The first-in-human gene therapy case report highlights the clinical necessity for confirmed diagnosis and the use of CSF HexA activity as a pharmacodynamic readout in treated infants (flotte2022aavgenetherapy pages 1-6).

11. Outcome / prognosis

  • Infantile Tay–Sachs: poor prognosis with death typically in early childhood despite supportive care; one review summarizes death usually by ~5 years (gonzalezsanchez2025advancesindiagnosis pages 2-4), and a 2023 cohort paper describes death at ~2–4 years for the classical infantile phenotype (ibrahim2023biochemicalandmutational pages 1-2).
  • Seizure burden: one synthesis states “more than two-thirds” require multiple anticonvulsants for seizure control (gonzalezsanchez2025advancesindiagnosis pages 9-11).
  • Late-onset disease: prolonged survival but high functional burden, with frequent falls and mobility limitations (lyn2020patientandcaregiver pages 1-2).

12. Treatment

Modality Example intervention Mechanism/rationale Evidence level (human/animal/in vitro) Key quantitative results Status/real-world use ClinicalTrials.gov IDs if applicable Key sources
In vivo gene therapy AAVrh8-HEXA + AAVrh8-HEXB (expanded-access; AXO-AAV-GM2 platform) Dual-vector replacement of both HexA subunits to restore CNS HexA activity; delivered intrathecally and/or intrathalamically because broad CNS distribution is required Human clinical + supporting animal studies In 2 infantile TSD patients, CSF HexA activity “nearly doubled from baseline and remained stable”; no vector-related AEs reported; one patient treated at 7 months showed MRI stabilization at 3 months but decline by 6 months; one older patient remained seizure-free at 4.5–5 years on same anticonvulsant regimen. Doses included 1×10^14 vg IT (75% cisterna magna, 25% thoracolumbar) and 4.2×10^13 vg combined thalamic+IT (flotte2022aavgenetherapy pages 1-6) First-in-human proof-of-concept; not approved Expanded access under IND 18225; follow-up study NCT06614569 (flotte2022aavgenetherapy pages 1-6, gonzalezsanchez2025advancesindiagnosis pages 15-17)
Interventional clinical trial, gene therapy AXO-AAV-GM2 dose-escalation study Same dual-AAV gene replacement strategy for infantile GM2 gangliosidosis/Tay-Sachs or Sandhoff disease Human clinical trial Phase 1; enrollment 9; trial status reported as TERMINATED in retrieved registry results (no efficacy outcomes in retrieved context) Clinical development program; not approved NCT04669535 (NCT04798235 chunk 1)
Interventional clinical trial, gene therapy TSHA-101 (AAV9 carrying HEXA and HEXB) One-time intrathecal AAV9 delivery of HEXA+HEXB to address HexA deficiency in infantile GM2 gangliosidosis Human clinical trial Active not recruiting; actual enrollment 3; outcomes include CSF/serum HexA activity, CHOP-INTEND, overall survival up to 5 years; quantitative efficacy not yet available in retrieved context Ongoing early-phase clinical development; not approved NCT04798235 (NCT04798235 chunk 1)
Substrate reduction therapy Miglustat Inhibits glycosphingolipid synthesis upstream to reduce GM2 substrate burden Animal + human clinical In mouse models, reduced brain GM2 by up to 50% and prolonged survival; in a 24-month study of 5 juvenile patients, did not halt neurological deterioration (gonzalezsanchez2025advancesindiagnosis pages 14-15) Off-label/experimental in GM2; not FDA-approved for Tay-Sachs NCT00418847; NCT00672022; NCT03822013 (gonzalezsanchez2025advancesindiagnosis pages 14-15, abidi2024metabolismofglycosphingolipids pages 85-90)
Next-generation substrate reduction therapy Nizubaglustat (AZ-3102) Small-molecule substrate reduction approach for GM2 gangliosidosis/NPC disease Human clinical trial Phase 2 recruiting; planned enrollment 21; no efficacy results yet in retrieved context Investigational NCT07399704 (NCT04798235 chunk 1)
Pharmacological chaperone Pyrimethamine Mutation-dependent stabilization/folding rescue of residual HexA, with BBB penetration In vitro + human clinical experience summarized in reviews Induced up to a threefold increase in enzymatic activity in TSD fibroblasts, but neurological benefit in patients has been limited/mutation-dependent (gonzalezsanchez2025advancesindiagnosis pages 14-15) Experimental/off-label; not standard disease-modifying therapy not provided in retrieved context (gonzalezsanchez2025advancesindiagnosis pages 14-15, ou2020anovelgene pages 11-11)
Enzyme replacement therapy Engineered human HexA / rhHexA Supplies exogenous enzyme to degrade stored GM2; major challenge is BBB/CNS delivery Animal + in vitro Engineered HexA degraded GM2 in Hexa-/- mouse-related systems and prevented severe storage in preclinical work; yeast-produced rhHexA reduced lysosomal mass and GM2 levels in patient fibroblasts/neuroglial cells after 72 h treatment (ashiri2023usinganengineered pages 23-28, abidi2024metabolismofglycosphingolipids pages 85-90) Preclinical; no approved ERT for Tay-Sachs not applicable (ashiri2023usinganengineered pages 23-28, abidi2024metabolismofglycosphingolipids pages 85-90, picache2022therapeuticstrategiesfor pages 1-2)
Recombinant enzyme production / cell studies Yeast-produced human recombinant lysosomal β-hexosaminidase A (rhHex-A) Scalable recombinant enzyme for cellular rescue of GM2 storage In vitro In patient and murine cell systems, 100 nM rhHexA for 72 h reduced lysosomal mass and GM2/LAMP1 colocalization; authors concluded rhHex-A “can efficiently degrade GM2 ganglioside and rescue lysosomal accumulation” Preclinical research only not applicable (abidi2024metabolismofglycosphingolipids pages 85-90)
Protein delivery across BBB Dual trojan horse HEXA protein (HEXA linked to BBB-entry motifs) Enzyme delivery strategy to shuttle HEXA across BBB, associate with HEXB, reach lysosomes, and reduce brain GM2 Animal + in vitro In adult LOTS-model mice, IV treatment reduced whole-brain GM2 by ~40% within 6 weeks and improved forelimb grip strength; also lowered GM2 in cultured human Tay-Sachs glial cells (osher2024treatinglateonsettay pages 1-2) Preclinical; not approved not applicable (osher2024treatinglateonsettay pages 1-2)
Broad therapeutic category HSCT / bone marrow transplantation Cross-correction via donor-derived enzyme-producing cells Human case series/reviewed clinical experience Can increase systemic HexA; reported survival prolongation in some cases, but overall insufficient CNS correction and no consistent motor improvement (gonzalezsanchez2025advancesindiagnosis pages 14-15) Not established as effective disease-modifying standard for Tay-Sachs CNS disease not provided in retrieved context (gonzalezsanchez2025advancesindiagnosis pages 14-15, gonzalezsanchez2025advancesindiagnosis pages 15-17)
Emerging pathway-targeted SRT B4GALNT1 / GM2 synthesis inhibition (e.g., lead compound QT163) Directly target GM2 synthesis pathway to reduce GM2 and lyso-GM2 production Preclinical in vitro/drug discovery Lead compound QT163 showed strongest inhibition with reported IC50 0.2 mM; lyso-GM2 proposed as biomarker for diagnosis/treatment monitoring (abidi2024metabolismofglycosphingolipids pages 85-90) Experimental discovery-stage not applicable (abidi2024metabolismofglycosphingolipids pages 85-90)

Table: This table summarizes major therapeutic modalities and clinical-trial programs for Tay-Sachs/GM2 gangliosidosis, including current human gene-therapy studies, substrate-reduction approaches, pharmacological chaperones, and preclinical enzyme/protein-delivery strategies. It is useful for comparing mechanism, evidence maturity, quantitative outcomes, and current development status across the treatment landscape.

Key recent developments (prioritizing 2023–2024 sources)

  • 2024 protein BBB-delivery strategy (late-onset model): a “dual trojan horse” HEXA protein lowered whole-brain GM2 by ~40% within 6 weeks in an adult Tay–Sachs mouse model and improved grip strength (publication date Sep 2024; URL https://doi.org/10.1016/j.omtm.2024.101300) (osher2024treatinglateonsettay pages 1-2).
  • 2023 fetal-stage mechanistic insight: transcriptomic perturbations by 17 weeks’ gestation suggest a potentially earlier window for intervention than clinical onset (publication date Feb 2023; URL https://doi.org/10.1002/jimd.12596) (han2023geneexpressionchanges pages 1-3).

Human gene therapy evidence (first-in-human)

A first-in-human expanded-access experience (Nature Medicine version published Feb 2022; preprint posted Feb 18, 2021; URL https://doi.org/10.1038/s41591-021-01664-4; preprint URL https://doi.org/10.21203/rs.3.rs-195847/v1) reported intrathecal and intrathalamic delivery of AAVrh8-HEXA plus AAVrh8-HEXB in two infantile Tay–Sachs patients, with no vector-related adverse events and increased CSF HexA activity; MRI and seizure outcomes suggested partial/temporary deviation from expected infantile natural history in the younger-treated child (flotte2022aavgenetherapy pages 1-6).

Figure evidence: the treatment-associated HexA activity trajectories and delivery-route imaging are shown in retrieved figure/table regions from the case report (flotte2022aavgenetherapy media 379a08f6, flotte2022aavgenetherapy media 8b29bbe4, flotte2022aavgenetherapy media 4f87ceb4, flotte2022aavgenetherapy media c9927c10).

MAXO term suggestions (examples)

  • Gene therapy (intrathecal/intracerebral AAV delivery) (flotte2022aavgenetherapy pages 1-6, NCT04798235 chunk 1)
  • Enzyme replacement therapy / enzyme supplementation (preclinical) (gonzalezsanchez2025advancesindiagnosis pages 14-15)
  • Substrate reduction therapy (miglustat; investigational agents) (gonzalezsanchez2025advancesindiagnosis pages 14-15, NCT04798235 chunk 1)
  • Hematopoietic stem cell transplantation (selected contexts) (gonzalezsanchez2025advancesindiagnosis pages 14-15)

13. Prevention

  • Primary prevention via carrier screening: in some Ashkenazi communities, premarital carrier screening is associated with an approximately 95% reduction in incidence in a synthesis review (gonzalezsanchez2025advancesindiagnosis pages 2-4).
  • Secondary prevention / early detection: biochemical screening using dried blood spots and molecular confirmation can enable earlier diagnosis; prenatal diagnosis is feasible via CVS (10–12 weeks) or amniocentesis (15–18 weeks) in at-risk pregnancies (gonzalezsanchez2025advancesindiagnosis pages 4-5, bibi2021taysachsdiseasetwo pages 5-8).

14. Other species / natural disease

  • Naturally occurring large-animal model: Jacob sheep with a naturally occurring HEXA missense mutation develop progressive neurologic disease and GM2 accumulation; the model enables biomarker and therapeutic evaluation at a large-brain scale (story2021naturalhistoryof pages 1-2, story2021naturalhistoryof pages 5-7).
  • Additional natural disease has been described in other species (e.g., cats/dogs; wild boar variants mentioned in a compilation), but detailed comparative pathology was not comprehensively extractable from the retrieved evidence set (ashiri2023usinganengineered pages 129-133).

15. Model organisms

  • Mouse models: Hexa knockout mice show GM2 accumulation but may lack classical clinical phenotypes due to alternative GM2 catabolic pathways, limiting phenotypic fidelity for some questions (picache2022therapeuticstrategiesfor pages 6-8, gonzalezsanchez2025advancesindiagnosis pages 11-12).
  • Rabbit genome-edited model: prime editing of a common Tay–Sachs insertion produced late-onset–like neurologic and muscle pathology features (picache2022therapeuticstrategiesfor pages 6-8).
  • Sheep model (natural history): provides staged progression (mild symptoms at ~3 months; moderate at ~6 months; severe with humane endpoint around ~9 months), CSF GM2 biomarker utility, and MRI/MRS correlates (story2021naturalhistoryof pages 1-2, story2021naturalhistoryof pages 5-7).
  • Translational therapy testing: A 5-year AAV gene therapy analysis in Tay–Sachs sheep reported long survival after multipoint CSF delivery, supporting large-animal evaluation of delivery routes, biomarkers, and durability (publication date Sep 2025; URL https://doi.org/10.1172/jci182942) (taghian2025fiveyearanalysisof pages 1-2).

Limitations of this report (evidence availability)

  • ICD-10/ICD-11/MeSH/MONDO identifiers were not present in the retrieved evidence set and therefore are explicitly not populated to avoid hallucination (artifact-00).
  • Several key references in this area exist but were not retrievable within this tool run; consequently, some sections (e.g., global epidemiology by region, comprehensive variant frequency from gnomAD, formal clinical guidelines, and late-2024 Neurology Genetics diagnostic paper) could not be exhaustively covered.

References

  1. (gonzalezsanchez2025advancesindiagnosis pages 1-2): María González-Sánchez, María Jesús Ramírez-Expósito, and José Manuel Martínez-Martos. Advances in diagnosis, pathological mechanisms, clinical impact, and future therapeutic perspectives in tay–sachs disease. Neurology International, 17:98, Jun 2025. URL: https://doi.org/10.3390/neurolint17070098, doi:10.3390/neurolint17070098. This article has 4 citations.

  2. (ibrahim2023biochemicalandmutational pages 1-2): Doaa M. A. Ibrahim, Ola S. M. Ali, Hala Nasr, Ekram Fateen, and Alice AbdelAleem. Biochemical and mutational analyses of hexa in a cohort of egyptian patients with infantile tay-sachs disease. expansion of the mutation spectrum. Orphanet Journal of Rare Diseases, Mar 2023. URL: https://doi.org/10.1186/s13023-023-02637-1, doi:10.1186/s13023-023-02637-1. This article has 13 citations and is from a peer-reviewed journal.

  3. (gonzalezsanchez2025advancesindiagnosis pages 2-4): María González-Sánchez, María Jesús Ramírez-Expósito, and José Manuel Martínez-Martos. Advances in diagnosis, pathological mechanisms, clinical impact, and future therapeutic perspectives in tay–sachs disease. Neurology International, 17:98, Jun 2025. URL: https://doi.org/10.3390/neurolint17070098, doi:10.3390/neurolint17070098. This article has 4 citations.

  4. (han2023geneexpressionchanges pages 1-3): Sangwoo T. Han, Ashley Hirt, Elena‐Raluca Nicoli, Mari Kono, Camilo Toro, Richard L. Proia, and Cynthia J. Tifft. Gene expression changes in tay–sachs disease begin early in fetal brain development. Journal of Inherited Metabolic Disease, 46:687-694, Feb 2023. URL: https://doi.org/10.1002/jimd.12596, doi:10.1002/jimd.12596. This article has 10 citations and is from a peer-reviewed journal.

  5. (picache2022therapeuticstrategiesfor pages 1-2): Jaqueline A. Picache, Wei Zheng, and Catherine Z. Chen. Therapeutic strategies for tay-sachs disease. Frontiers in Pharmacology, Jul 2022. URL: https://doi.org/10.3389/fphar.2022.906647, doi:10.3389/fphar.2022.906647. This article has 40 citations.

  6. (NCT04798235 chunk 1): Dr. Anupam Sehgal. First-in-Human Study of TSHA-101 Gene Therapy for Treatment of Infantile Onset GM2 Gangliosidosis. Dr. Anupam Sehgal. 2021. ClinicalTrials.gov Identifier: NCT04798235

  7. (gonzalezsanchez2025advancesindiagnosis pages 5-7): María González-Sánchez, María Jesús Ramírez-Expósito, and José Manuel Martínez-Martos. Advances in diagnosis, pathological mechanisms, clinical impact, and future therapeutic perspectives in tay–sachs disease. Neurology International, 17:98, Jun 2025. URL: https://doi.org/10.3390/neurolint17070098, doi:10.3390/neurolint17070098. This article has 4 citations.

  8. (gonzalezsanchez2025advancesindiagnosis pages 7-9): María González-Sánchez, María Jesús Ramírez-Expósito, and José Manuel Martínez-Martos. Advances in diagnosis, pathological mechanisms, clinical impact, and future therapeutic perspectives in tay–sachs disease. Neurology International, 17:98, Jun 2025. URL: https://doi.org/10.3390/neurolint17070098, doi:10.3390/neurolint17070098. This article has 4 citations.

  9. (ashiri2023usinganengineered pages 16-23): M Ashiri. Using an engineered human hexosaminidase as an enzyme replacement therapy to treat a mouse model of tay-sachs disease. Unknown journal, 2023.

  10. (gonzalezsanchez2025advancesindiagnosis pages 9-11): María González-Sánchez, María Jesús Ramírez-Expósito, and José Manuel Martínez-Martos. Advances in diagnosis, pathological mechanisms, clinical impact, and future therapeutic perspectives in tay–sachs disease. Neurology International, 17:98, Jun 2025. URL: https://doi.org/10.3390/neurolint17070098, doi:10.3390/neurolint17070098. This article has 4 citations.

  11. (sheth2018identificationofdeletionduplication pages 1-2): Jayesh Sheth, Mehul Mistri, Lakshmi Mahadevan, Sanjeev Mehta, Dhaval Solanki, Mahesh Kamate, and Frenny Sheth. Identification of deletion-duplication in hexa gene in five children with tay-sachs disease from india. BMC Medical Genetics, Jul 2018. URL: https://doi.org/10.1186/s12881-018-0632-7, doi:10.1186/s12881-018-0632-7. This article has 11 citations and is from a peer-reviewed journal.

  12. (lyn2020patientandcaregiver pages 1-2): Nicole Lyn, Ruth Pulikottil-Jacob, Camille Rochmann, Robert Krupnick, Chad Gwaltney, Nick Stephens, Julie Kissell, Gerald F. Cox, Tanya Fischer, and Alaa Hamed. Patient and caregiver perspectives on burden of disease manifestations in late-onset tay-sachs and sandhoff diseases. Orphanet Journal of Rare Diseases, Apr 2020. URL: https://doi.org/10.1186/s13023-020-01354-3, doi:10.1186/s13023-020-01354-3. This article has 19 citations and is from a peer-reviewed journal.

  13. (gonzalezsanchez2025advancesindiagnosis pages 4-5): María González-Sánchez, María Jesús Ramírez-Expósito, and José Manuel Martínez-Martos. Advances in diagnosis, pathological mechanisms, clinical impact, and future therapeutic perspectives in tay–sachs disease. Neurology International, 17:98, Jun 2025. URL: https://doi.org/10.3390/neurolint17070098, doi:10.3390/neurolint17070098. This article has 4 citations.

  14. (barritt2017lateonsettay–sachsdisease pages 1-2): Andrew W Barritt, Stuart J Anderson, P Nigel Leigh, and Basil H Ridha. Late-onset tay–sachs disease. Practical Neurology, 17:396-399, Jul 2017. URL: https://doi.org/10.1136/practneurol-2017-001665, doi:10.1136/practneurol-2017-001665. This article has 38 citations and is from a peer-reviewed journal.

  15. (sheth2018identificationofdeletionduplication pages 2-3): Jayesh Sheth, Mehul Mistri, Lakshmi Mahadevan, Sanjeev Mehta, Dhaval Solanki, Mahesh Kamate, and Frenny Sheth. Identification of deletion-duplication in hexa gene in five children with tay-sachs disease from india. BMC Medical Genetics, Jul 2018. URL: https://doi.org/10.1186/s12881-018-0632-7, doi:10.1186/s12881-018-0632-7. This article has 11 citations and is from a peer-reviewed journal.

  16. (ashiri2023usinganengineered pages 23-28): M Ashiri. Using an engineered human hexosaminidase as an enzyme replacement therapy to treat a mouse model of tay-sachs disease. Unknown journal, 2023.

  17. (story2021naturalhistoryof pages 5-7): Brett Story, Toloo Taghian, Jillian Gallagher, Jey Koehler, Amanda Taylor, Ashley Randle, Kayly Nielsen, Amanda Gross, Annie Maguire, Sara Carl, Siauna Johnson, Deborah Fernau, Elise Diffie, Paul Cuddon, Carly Corado, Sundeep Chandra, Miguel Sena-Esteves, Edwin Kolodny, Xuntian Jiang, Douglas Martin, and Heather Gray-Edwards. Natural history of tay-sachs disease in sheep. Molecular Genetics and Metabolism, 134:164-174, Sep 2021. URL: https://doi.org/10.1016/j.ymgme.2021.08.009, doi:10.1016/j.ymgme.2021.08.009. This article has 13 citations and is from a peer-reviewed journal.

  18. (bibi2021taysachsdiseasetwo pages 5-8): Farah Bibi, Asmat Ullah, Thomas Bourinaris, Stephanie Efthymiou, Yamna Kriouile, Tipu Sultan, Shahzad Haider, Vincenzo Salpietro, Henry Houlden, and Ghazala Kaukab Raja. Tay-sachs disease: two novel rare hexa mutations from pakistan and morocco. Klinische Pädiatrie, 233:226-230, Apr 2021. URL: https://doi.org/10.1055/a-1371-1561, doi:10.1055/a-1371-1561. This article has 17 citations.

  19. (flotte2022aavgenetherapy pages 1-6): Terence R. Flotte, Oguz Cataltepe, Ajit Puri, Ana Rita Batista, Richard Moser, Diane McKenna-Yasek, Catherine Douthwright, Gwladys Gernoux, Meghan Blackwood, Christian Mueller, Phillip W. L. Tai, Xuntian Jiang, Scot Bateman, Spiro G. Spanakis, Julia Parzych, Allison M. Keeler, Aly Abayazeed, Saurabh Rohatgi, Laura Gibson, Robert Finberg, Bruce A. Barton, Zeynep Vardar, Mohammed Salman Shazeeb, Matthew Gounis, Cynthia J. Tifft, Florian S. Eichler, Robert H. Brown, Douglas R. Martin, Heather L. Gray-Edwards, and Miguel Sena-Esteves. Aav gene therapy for tay-sachs disease. Nature Medicine, 28:251-259, Feb 2022. URL: https://doi.org/10.1038/s41591-021-01664-4, doi:10.1038/s41591-021-01664-4. This article has 155 citations and is from a highest quality peer-reviewed journal.

  20. (gonzalezsanchez2025advancesindiagnosis pages 15-17): María González-Sánchez, María Jesús Ramírez-Expósito, and José Manuel Martínez-Martos. Advances in diagnosis, pathological mechanisms, clinical impact, and future therapeutic perspectives in tay–sachs disease. Neurology International, 17:98, Jun 2025. URL: https://doi.org/10.3390/neurolint17070098, doi:10.3390/neurolint17070098. This article has 4 citations.

  21. (gonzalezsanchez2025advancesindiagnosis pages 14-15): María González-Sánchez, María Jesús Ramírez-Expósito, and José Manuel Martínez-Martos. Advances in diagnosis, pathological mechanisms, clinical impact, and future therapeutic perspectives in tay–sachs disease. Neurology International, 17:98, Jun 2025. URL: https://doi.org/10.3390/neurolint17070098, doi:10.3390/neurolint17070098. This article has 4 citations.

  22. (abidi2024metabolismofglycosphingolipids pages 85-90): I Abidi. Metabolism of glycosphingolipids and targeting gm2 synthesis pathway to develop substrate reduction approach in tay-sachs and sandhoff disorders. Unknown journal, 2024.

  23. (ou2020anovelgene pages 11-11): Li Ou, Michael J. Przybilla, Alexandru-Flaviu Tăbăran, Paula Overn, M. Gerard O’Sullivan, Xuntian Jiang, Rohini Sidhu, Pamela J. Kell, Daniel S. Ory, and Chester B. Whitley. A novel gene editing system to treat both tay–sachs and sandhoff diseases. Gene Therapy, 27:226-236, Jan 2020. URL: https://doi.org/10.1038/s41434-019-0120-5, doi:10.1038/s41434-019-0120-5. This article has 70 citations and is from a peer-reviewed journal.

  24. (osher2024treatinglateonsettay pages 1-2): Esther Osher, Yossi Anis, Ruth Singer-Shapiro, Nataly Urshanski, Tamar Unger, Shira Albeck, Oren Bogin, Gary Weisinger, Fortune Kohen, Avi Valevski, Aviva Fattal-Valevski, Liora Sagi, Michal Weitman, Yulia Shenberger, Nadav Sagiv, Ruth Navon, Meir Wilchek, and Naftali Stern. Treating late-onset tay sachs disease: brain delivery with a dual trojan horse protein. Molecular Therapy - Methods & Clinical Development, 32:101300, Sep 2024. URL: https://doi.org/10.1016/j.omtm.2024.101300, doi:10.1016/j.omtm.2024.101300. This article has 5 citations.

  25. (flotte2022aavgenetherapy media 379a08f6): Terence R. Flotte, Oguz Cataltepe, Ajit Puri, Ana Rita Batista, Richard Moser, Diane McKenna-Yasek, Catherine Douthwright, Gwladys Gernoux, Meghan Blackwood, Christian Mueller, Phillip W. L. Tai, Xuntian Jiang, Scot Bateman, Spiro G. Spanakis, Julia Parzych, Allison M. Keeler, Aly Abayazeed, Saurabh Rohatgi, Laura Gibson, Robert Finberg, Bruce A. Barton, Zeynep Vardar, Mohammed Salman Shazeeb, Matthew Gounis, Cynthia J. Tifft, Florian S. Eichler, Robert H. Brown, Douglas R. Martin, Heather L. Gray-Edwards, and Miguel Sena-Esteves. Aav gene therapy for tay-sachs disease. Nature Medicine, 28:251-259, Feb 2022. URL: https://doi.org/10.1038/s41591-021-01664-4, doi:10.1038/s41591-021-01664-4. This article has 155 citations and is from a highest quality peer-reviewed journal.

  26. (flotte2022aavgenetherapy media 8b29bbe4): Terence R. Flotte, Oguz Cataltepe, Ajit Puri, Ana Rita Batista, Richard Moser, Diane McKenna-Yasek, Catherine Douthwright, Gwladys Gernoux, Meghan Blackwood, Christian Mueller, Phillip W. L. Tai, Xuntian Jiang, Scot Bateman, Spiro G. Spanakis, Julia Parzych, Allison M. Keeler, Aly Abayazeed, Saurabh Rohatgi, Laura Gibson, Robert Finberg, Bruce A. Barton, Zeynep Vardar, Mohammed Salman Shazeeb, Matthew Gounis, Cynthia J. Tifft, Florian S. Eichler, Robert H. Brown, Douglas R. Martin, Heather L. Gray-Edwards, and Miguel Sena-Esteves. Aav gene therapy for tay-sachs disease. Nature Medicine, 28:251-259, Feb 2022. URL: https://doi.org/10.1038/s41591-021-01664-4, doi:10.1038/s41591-021-01664-4. This article has 155 citations and is from a highest quality peer-reviewed journal.

  27. (flotte2022aavgenetherapy media 4f87ceb4): Terence R. Flotte, Oguz Cataltepe, Ajit Puri, Ana Rita Batista, Richard Moser, Diane McKenna-Yasek, Catherine Douthwright, Gwladys Gernoux, Meghan Blackwood, Christian Mueller, Phillip W. L. Tai, Xuntian Jiang, Scot Bateman, Spiro G. Spanakis, Julia Parzych, Allison M. Keeler, Aly Abayazeed, Saurabh Rohatgi, Laura Gibson, Robert Finberg, Bruce A. Barton, Zeynep Vardar, Mohammed Salman Shazeeb, Matthew Gounis, Cynthia J. Tifft, Florian S. Eichler, Robert H. Brown, Douglas R. Martin, Heather L. Gray-Edwards, and Miguel Sena-Esteves. Aav gene therapy for tay-sachs disease. Nature Medicine, 28:251-259, Feb 2022. URL: https://doi.org/10.1038/s41591-021-01664-4, doi:10.1038/s41591-021-01664-4. This article has 155 citations and is from a highest quality peer-reviewed journal.

  28. (flotte2022aavgenetherapy media c9927c10): Terence R. Flotte, Oguz Cataltepe, Ajit Puri, Ana Rita Batista, Richard Moser, Diane McKenna-Yasek, Catherine Douthwright, Gwladys Gernoux, Meghan Blackwood, Christian Mueller, Phillip W. L. Tai, Xuntian Jiang, Scot Bateman, Spiro G. Spanakis, Julia Parzych, Allison M. Keeler, Aly Abayazeed, Saurabh Rohatgi, Laura Gibson, Robert Finberg, Bruce A. Barton, Zeynep Vardar, Mohammed Salman Shazeeb, Matthew Gounis, Cynthia J. Tifft, Florian S. Eichler, Robert H. Brown, Douglas R. Martin, Heather L. Gray-Edwards, and Miguel Sena-Esteves. Aav gene therapy for tay-sachs disease. Nature Medicine, 28:251-259, Feb 2022. URL: https://doi.org/10.1038/s41591-021-01664-4, doi:10.1038/s41591-021-01664-4. This article has 155 citations and is from a highest quality peer-reviewed journal.

  29. (story2021naturalhistoryof pages 1-2): Brett Story, Toloo Taghian, Jillian Gallagher, Jey Koehler, Amanda Taylor, Ashley Randle, Kayly Nielsen, Amanda Gross, Annie Maguire, Sara Carl, Siauna Johnson, Deborah Fernau, Elise Diffie, Paul Cuddon, Carly Corado, Sundeep Chandra, Miguel Sena-Esteves, Edwin Kolodny, Xuntian Jiang, Douglas Martin, and Heather Gray-Edwards. Natural history of tay-sachs disease in sheep. Molecular Genetics and Metabolism, 134:164-174, Sep 2021. URL: https://doi.org/10.1016/j.ymgme.2021.08.009, doi:10.1016/j.ymgme.2021.08.009. This article has 13 citations and is from a peer-reviewed journal.

  30. (ashiri2023usinganengineered pages 129-133): M Ashiri. Using an engineered human hexosaminidase as an enzyme replacement therapy to treat a mouse model of tay-sachs disease. Unknown journal, 2023.

  31. (picache2022therapeuticstrategiesfor pages 6-8): Jaqueline A. Picache, Wei Zheng, and Catherine Z. Chen. Therapeutic strategies for tay-sachs disease. Frontiers in Pharmacology, Jul 2022. URL: https://doi.org/10.3389/fphar.2022.906647, doi:10.3389/fphar.2022.906647. This article has 40 citations.

  32. (gonzalezsanchez2025advancesindiagnosis pages 11-12): María González-Sánchez, María Jesús Ramírez-Expósito, and José Manuel Martínez-Martos. Advances in diagnosis, pathological mechanisms, clinical impact, and future therapeutic perspectives in tay–sachs disease. Neurology International, 17:98, Jun 2025. URL: https://doi.org/10.3390/neurolint17070098, doi:10.3390/neurolint17070098. This article has 4 citations.

  33. (taghian2025fiveyearanalysisof pages 1-2): Toloo Taghian, Jillian Gallagher, Stephanie Bertrand, William C. Baker, Kalajan Lopez Mercado, Hector R. Benatti, Erin Hall, Yvette Lopez, Abigail McElroy, John T. McCarthy, Sanjana Pulaparthi, Deborah Fernau, Samuel Mather, Sophia Esteves, Elise Diffie, Amanda Gross, Hannah G. Lahey, Xuntian Jiang, Elizabeth Parsley, Rachael Gately, Rachel Prestigiacomo, Siauna Johnson, Amanda Taylor, Lindsey Bierfeldt, Susan Tuominen, Jennifer Koehler, Guangping Gao, Jun Xie, Qin Su, Robert King, Matthew J. Gounis, Vania Anagnostakou, Ajit Puri, Ana Rita Batista, Miguel Sena-Esteves, Douglas R. Martin, and Heather Gray-Edwards. Five-year analysis of efficacy and safety of a bidirectional aav gene therapy in tay-sachs sheep. Journal of Clinical Investigation, Sep 2025. URL: https://doi.org/10.1172/jci182942, doi:10.1172/jci182942. This article has 0 citations and is from a highest quality peer-reviewed journal.